<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">57858</article-id><article-id pub-id-type="doi">10.7554/eLife.57858</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-183333"><name><surname>Zhang</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-183334"><name><surname>Zhang</surname><given-names>Yang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1712-7211</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-183345"><name><surname>Zhou</surname><given-names>Xinyue</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183335"><name><surname>Wright</surname><given-names>Shaela</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183336"><name><surname>Hyle</surname><given-names>Judith</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183337"><name><surname>Zhao</surname><given-names>Lianzhong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183338"><name><surname>An</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183339"><name><surname>Zhao</surname><given-names>Xujie</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183340"><name><surname>Shao</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183344"><name><surname>Xu</surname><given-names>Beisi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0099-858X</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183341"><name><surname>Lee</surname><given-names>Hyeong-Min</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9381-3611</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177171"><name><surname>Chen</surname><given-names>Taosheng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-6420-3809</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183342"><name><surname>Zhou</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-202561"><name><surname>Chen</surname><given-names>Xiang</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-183343"><name><surname>Lu</surname><given-names>Rui</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1593-2612</contrib-id><email>ruilu1@uabmc.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-181818"><name><surname>Li</surname><given-names>Chunliang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5938-5510</contrib-id><email>chunliang.li@stjude.org</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Division of Hematology/Oncology, University of Alabama at Birmingham</institution><addr-line><named-content content-type="city">Birmingham</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham</institution><addr-line><named-content content-type="city">Birmingham</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Tumor Cell Biology, St. Jude Children’s Research Hospital</institution><addr-line><named-content content-type="city">Memphis</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Cancer Biology Program/Comprehensive Cancer Center, St. Jude Children’s Research Hospital</institution><addr-line><named-content content-type="city">Memphis</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital</institution><addr-line><named-content content-type="city">Memphis</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Computational Biology, St. Jude Children’s Research Hospital</institution><addr-line><named-content content-type="city">Memphis</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital</institution><addr-line><named-content content-type="city">Memphis</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Department of Biomedical Engineering School of Engineering, University of Alabama at Birmingham</institution><addr-line><named-content content-type="city">Birmingham</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role>Reviewing Editor</role><aff><institution>Van Andel Institute</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Murphy</surname><given-names>Maureen E</given-names></name><role>Senior Editor</role><aff><institution>The Wistar Institute</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>01</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e57858</elocation-id><history><date date-type="received" iso-8601-date="2020-04-15"><day>15</day><month>04</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-09-30"><day>30</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Zhang et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Zhang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-57858-v2.pdf"/><abstract><p>Aberrant <italic>HOXA9</italic> expression is a hallmark of most aggressive acute leukemias, notably those with KMT2A (MLL) gene rearrangements. <italic>HOXA9</italic> overexpression not only predicts poor diagnosis and outcome but also plays a critical role in leukemia transformation and maintenance. However, our current understanding of <italic>HOXA9</italic> regulation in leukemia is limited, hindering development of therapeutic strategies. Here, we generated the <italic>HOXA9-mCherry</italic> knock-in reporter cell lines to dissect <italic>HOXA9</italic> regulation. By utilizing the reporter and CRISPR/Cas9 screens, we identified transcription factors controlling <italic>HOXA9</italic> expression, including a novel regulator, USF2, whose depletion significantly down-regulated <italic>HOXA9</italic> expression and impaired MLLr leukemia cell proliferation. Ectopic expression of Hoxa9 rescued impaired leukemia cell proliferation upon USF2 loss. Cut and Run analysis revealed the direct occupancy of USF2 at <italic>HOXA9</italic> promoter in MLLr leukemia cells. Collectively, the <italic>HOXA9</italic> reporter facilitated the functional interrogation of the <italic>HOXA9</italic> regulome and has advanced our understanding of the molecular regulation network in <italic>HOXA9</italic>-driven leukemia.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>knock-in</kwd><kwd>CRISPR screen</kwd><kwd>HOXA9</kwd><kwd>transcriptional regulation</kwd><kwd>mll-rearranged leukemia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005968</institution-id><institution>Leukemia Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lu</surname><given-names>Rui</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001558</institution-id><institution>Concern Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lu</surname><given-names>Rui</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>IRG15-59-IRG</award-id><principal-award-recipient><name><surname>Lu</surname><given-names>Rui</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Young Supporters Board of the O’Neal Comprehensive Cancer Center</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lu</surname><given-names>Rui</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30CA021765-37</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Chunliang</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01HL153220</award-id><principal-award-recipient><name><surname>Zhou</surname><given-names>Yang</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The <italic>HOXA9</italic> reporter and genetic screens facilitated the functional interrogation of the <italic>HOXA9</italic> regulome and advanced our understanding of the molecular regulation network in <italic>HOXA9</italic>-driven leukemia.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Dysregulation of the homeobox (HOX)-containing transcription factor <italic>HOXA9</italic> is a prominent feature in most aggressive acute leukemias (<xref ref-type="bibr" rid="bib9">Collins and Hess, 2016a</xref>; <xref ref-type="bibr" rid="bib1">Alharbi et al., 2013</xref>). During normal hematopoiesis, HOXA9 plays a critical role in hematopoietic stem cell expansion and is epigenetically silenced during lineage differentiation (<xref ref-type="bibr" rid="bib1">Alharbi et al., 2013</xref>). In certain leukemia subtypes, this regulatory switch fails and <italic>HOXA9</italic> is maintained at high levels to promote leukemogenesis. However, the mechanisms governing <italic>HOXA9</italic> expression remain to be fully understood. <italic>HOXA9</italic> overexpression is commonly observed in over 70% of human acute myeloid leukemia (AML) cases and ~10% of acute lymphoblastic leukemia (ALL) cases (<xref ref-type="bibr" rid="bib28">Jambon et al., 2019</xref>). Notably, the high expression of <italic>HOXA9</italic> is sharply correlated with poor prognosis and outcome in human leukemia (<xref ref-type="bibr" rid="bib19">Golub et al., 1999</xref>; <xref ref-type="bibr" rid="bib4">Baccelli et al., 2019</xref>). An accumulating body of evidence indicates that <italic>HOXA9</italic> dysregulation is both sufficient and necessary for leukemic transformation (<xref ref-type="bibr" rid="bib9">Collins and Hess, 2016a</xref>; <xref ref-type="bibr" rid="bib1">Alharbi et al., 2013</xref>). Forced expression of <italic>HOXA9</italic> enforces self-renewal, impairs myeloid differentiation of murine marrow progenitors, and ultimately leads to late onset of leukemia transformation (<xref ref-type="bibr" rid="bib5">Bach et al., 2010</xref>), which is accelerated by co-expression with interacting partner protein MEIS1 (<xref ref-type="bibr" rid="bib33">Kroon, 1998</xref>). Conversely, knocking down <italic>HOXA9</italic> expression results in leukemic cell differentiation and apoptosis (<xref ref-type="bibr" rid="bib3">Ayton and Cleary, 2003</xref>; <xref ref-type="bibr" rid="bib81">Zeisig et al., 2004</xref>). Thus, excessive <italic>HOXA9</italic> expression has emerged as a critical mechanism of leukemia transformation in many hematopoietic malignancies.</p><p>Consistent with the broad overexpression pattern of <italic>HOXA9</italic> in many leukemia cases, a wide variety of genetic alterations in leukemia contribute to <italic>HOXA9</italic> dysregulation including <italic>MLL</italic> gene rearrangements (MLLr), <italic>NPM1</italic> mutations, <italic>NUP98</italic>-fusions, <italic>EZH2</italic> loss-of-function mutations, <italic>ASXL1</italic> mutations, <italic>MOZ</italic> fusions and other chromosome alterations (<xref ref-type="bibr" rid="bib9">Collins and Hess, 2016a</xref>; <xref ref-type="bibr" rid="bib28">Jambon et al., 2019</xref>; <xref ref-type="bibr" rid="bib13">De Braekeleer et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Collins and Hess, 2016b</xref>). Additionally, our recent work shows that <italic>DNMT3A</italic> hotspot mutations may also contribute to <italic>HOXA9</italic> overexpression by preventing DNA methylation at its regulatory regions (<xref ref-type="bibr" rid="bib43">Lu et al., 2016</xref>). Given that genomic variation of <italic>HOXA9</italic> including NUP98-HOXA9 fusion and gene amplification accounted for less than 2% of <italic>HOXA9</italic> overexpression in AML cases (<xref ref-type="bibr" rid="bib78">Xu et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Gough et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Nakamura et al., 1996</xref>), uncovering the upstream epigenetic and transcriptional regulators of <italic>HOXA9</italic> in leukemia could advance the design of novel therapeutic interventions. For example, because MLLr proteins recruit the histone methyltransferase DOT1L to the <italic>HOXA</italic> locus promoting hyper-methylation at histone H3 lysine 79 and subsequent high <italic>HOXA9</italic> transcription (<xref ref-type="bibr" rid="bib32">Krivtsov et al., 2008</xref>), selective DOT1L inhibitors have been exploited to inhibit leukemia development and <italic>HOXA9</italic> expression in MLLr leukemias and are now in clinical trials (<xref ref-type="bibr" rid="bib6">Chen et al., 2015</xref>; <xref ref-type="bibr" rid="bib70">Stein and Tallman, 2015</xref>). However, DOT1L inhibitors usually act slowly and their effects remain sub-optimal. To date, most known <italic>HOXA9</italic> regulator proteins are epigenetic modifiers, and little is known about which DNA-binding transcription factors are involved in directly regulating <italic>HOXA9</italic> expression in acute leukemia (<xref ref-type="bibr" rid="bib17">Godfrey et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Daigle et al., 2011</xref>; <xref ref-type="bibr" rid="bib79">Yu et al., 2012</xref>; <xref ref-type="bibr" rid="bib66">Shi et al., 2012</xref>).</p><p>Previous studies have also advocated that the organization of chromatin domains at the <italic>HOXA</italic> gene cluster contributes to high <italic>HOXA9</italic> expression in cancer cells (<xref ref-type="bibr" rid="bib45">Luo et al., 2018</xref>; <xref ref-type="bibr" rid="bib77">Xu et al., 2014</xref>). Specifically, CCCTC-binding factor CTCF may potentiate <italic>HOXA9</italic> expression through direct binding at the conserved motif between <italic>HOXA7</italic> and <italic>HOXA9</italic> (CBS7/9) to establish necessary chromatin looping interaction networks in MLLr AML MOLM13 cells (<xref ref-type="bibr" rid="bib45">Luo et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Luo et al., 2019</xref>). In contrast, Ghasemi et al. reported that <italic>HOXA</italic> gene expression was maintained in the CTCF-binding site deletion mutants derived from AML OCI-AML3 cells, suggesting that transcriptional activity at the <italic>HOXA</italic> locus in NPM1-mutant AML cells does not require long-range CTCF-mediated chromatin interactions (<xref ref-type="bibr" rid="bib16">Ghasemi et al., 2020</xref>). These data also suggest that CTCF may play a cell-type-dependent role on <italic>HOXA9</italic> regulation. However, whether loss of CTCF has a direct effect on <italic>HOXA9</italic> expression remains to be studied. Lastly, although the clinical significance of <italic>HOXA9</italic> has been recognized for more than two decades, it is technically difficult to systematically discover regulators of <italic>HOXA9</italic> in acute leukemia owing to the lack of an endogenous reporter to dictate <italic>HOXA9</italic> expression.</p><p>In this work, we sought to establish an endogenous reporter system enabling real-time monitoring of <italic>HOXA9</italic> expression in conjunction with high-throughput CRISPR/Cas9 screening in a human B-ALL MLLr t(4;11) cell line SEM and a AML MLLr t(6;11) cell line OCI-AML2 equipped with an endogenous <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter allele. The <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter allele authentically recapitulated endogenous transcription of the <italic>HOXA9</italic> gene and did not affect endogenous transcription of other adjacent <italic>HOXA</italic> genes. To gain a global understanding of the transcription factors regulating <italic>HOXA9</italic> expression, we performed a CRISPR/Cas9 loss-of-function screen specifically targeting 1639 human transcription factors. Our screening robustly re-identified expected targets such as <italic>KMT2A</italic>, <italic>DOT1L</italic> and <italic>HOXA9</italic> itself. Surprisingly, the CRISPR screen and global depletion of CTCF via siRNA and degron-associated protein degradation all demonstrated that <italic>HOXA9</italic> does not downregulate upon CTCF loss. More importantly, we identified novel functional regulators of <italic>HOXA9</italic> including Upstream Transcription Factor 2 (USF2). USF2 depletion selectively downregulated <italic>HOXA9</italic> expression in MLLr leukemia cells and impaired cell growth, which could be rescued by ectopic expression of <italic>HOXA9</italic> and its partner MEIS1. Thus, our <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter lines are robust tools for discovery of novel <italic>HOXA9</italic> regulators.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Establishment and characterization of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter human MLLr leukemia cell line</title><p>As shown by many previous studies, <italic>HOXA9</italic> overexpression was observed in refractory MLL-rearranged ALL and AML patients (<xref ref-type="bibr" rid="bib22">Gu et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Haferlach et al., 2010</xref>; <xref ref-type="bibr" rid="bib31">Kohlmann et al., 2008</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–C</xref>). Therefore, we utilized our previously reported high-efficiency knock-in strategy, ‘CHASE knock-in’ (<xref ref-type="bibr" rid="bib27">Hyle et al., 2019</xref>), to deliver the <italic>P2A-mCherry</italic> cassette upstream of the <italic>HOXA9</italic> stop codon in a patient-derived human B-ALL cell line, SEM, which has a typical B-ALL signature along with a t(4;11) translocation and maintains one single allele expression of the <italic>HOXA</italic> gene cluster (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Because the P2A-mediated ribosome skipping disrupts the synthesis of the glycyl-prolyl peptide bond at the C-terminus of the P2A peptide, translation leads to dissociation of the P2A peptide and its immediate downstream mCherry protein (<xref ref-type="bibr" rid="bib30">Kim et al., 2011</xref>). Therefore, the knock-in allele would produce a functional HOXA9 protein under control of the endogenous promoter and intrinsic <italic>cis</italic>-regulatory elements while delivering a separate mCherry protein. In brief, we constructed the knock-in vector containing a <italic>P2A-mCherry</italic> cassette flanked with 5’ and 3’ <italic>HOXA9</italic> homology arms (HAs) of approximately 800-bps, which were cloned from SEM cells. A single guide RNA (sgRNA) and a protospacer adjacent motif (PAM) sequence targeting the genomic sequence 5’ of the <italic>HOXA9</italic> stop codon was inserted into the 5’ end of the 5’ HA and 3’ end of the 3’ HA (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). When the HA/knock-in cassette was co-electroporated with an all-in-one vector expressing wild-type Cas9 and the same <italic>HOXA9</italic> sgRNA, the HA/knock-in cassette was released from the donor vector with two nuclease cleavages and delivered to the target genomic region where double-strand breaks occurred. Successful knock-in cells were enriched by flow cytometry sorting for mCherry (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) and characterized via genotyping PCR and Sanger sequencing (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). To examine the possibility of random integration of the <italic>P2A-mCherry</italic> cassette, fluorescence in situ hybridization (FISH) was performed with a <italic>P2A-mCherry</italic> DNA probe (red) and a FITC-labeled fosmid DNA probe targeting the <italic>HOXA9</italic> locus (green). On-target knock-in cells displayed co-localization of red and green fluorescence without random integration signals in the rest of genome (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A–D</xref>). The bulk knock-in population from SEM cells, hereafter called <italic>HOXA9<sup>P2A-mCherry</sup></italic>, was used as a reporter cell line for the entire study. Similarly, a <italic>HOXA9<sup>P2A-mCherry</sup></italic> allele was delivered to a human MLLr AML cell line OCI-AML2 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>). Many knock-in studies reported the exogenous DNA fragment may affect normal endogenous gene expression in a complex chromatin niche (<xref ref-type="bibr" rid="bib41">Liu et al., 2019</xref>; <xref ref-type="bibr" rid="bib84">Zu et al., 2013</xref>). Therefore, to test whether the inserted <italic>P2A-mCherry</italic> segment would affect the gene expression pattern of <italic>HOXA9</italic> and its neighboring <italic>HOXA</italic> cluster genes, Q-PCR analysis was conducted on both wild-type (WT) and <italic>HOXA9<sup>P2A-mCherry</sup></italic> knock-in (KI) cells. RNA-seq data collected from SEM cells in our previous studies suggested that <italic>HOXA7</italic>, <italic>HOXA9</italic> and <italic>HOXA10</italic> were the only highly expressed <italic>HOXA</italic> genes in MLLr leukemia SEM cells (<xref ref-type="bibr" rid="bib27">Hyle et al., 2019</xref>; <xref ref-type="fig" rid="fig1">Figure 1E</xref>), and that these patterns were indistinguishable between WT and KI populations, indicating the <italic>P2A-mCherry</italic> knock-in did not alter the gene expression landscape at the <italic>HOXA</italic> cluster (<xref ref-type="fig" rid="fig1">Figure 1F</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Establishment and characterization of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter human MLLr leukemia cell line.</title><p>(<bold>A</bold>) Schematic diagram of the knock-in design and genotyping PCR primer design for the <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter allele. (<bold>B</bold>) Flow cytometry analysis of <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter cells. Wild-type SEM cells were used as negative controls. (<bold>C</bold>) Genotyping PCR products from the 5′ and 3′ knock-in boundaries were sequenced to verify the seamless knock-in of the <italic>mCherry</italic> reporter gene to the endogenous locus. (<bold>D</bold>) Fluorescence in situ hybridization of the <italic>P2A-mCherry</italic> knock-in cassette in <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter cells. The <italic>P2A-mCherry</italic> DNA was labeled with a red-dUTP by nick translation, and a <italic>HOXA9 BAC</italic> clone was labeled with a green-dUTP. The cells were then stained with 4,6-diamidino-2-phenylindole (DAPI) to visualize the nuclei. A representative metaphase cell image is shown for the pattern of hybridization (pairing of red and green signals). (<bold>E</bold>) RNA-seq data of all <italic>HOXA</italic> cluster genes were illustrated as log<sub>2</sub> (normalized numbers of FPKM) from two replicate samples of SEM cells. <italic>HOXA7</italic>, <italic>HOXA9</italic>, and <italic>HOXA10</italic> were highlighted by color code. (<bold>F</bold>) Q-PCR analysis confirmed the unaffected <italic>HOXA</italic> cluster gene transcription between <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter (KI) and WT SEM cells. Data shown are means ± SEM from replicate independent experiments. *p&lt;0.05 of two-tailed Student’s <italic>t</italic> test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title><italic>HOXA9</italic> expression profiling in leukemia.</title><p>(<bold>A</bold>) <italic>HOXA9</italic> expression in different leukemia lineages (GSE13159). (<bold>B</bold>) Kaplan-Meier survival curve indicated the poor outcome associated with high HOXA9 expression (GSE13159). (<bold>C</bold>) <italic>HOXA9</italic> expression was revealed by leukemia subtypes in MILE leukemia study cohort (bloodspot). (<bold>D</bold>) <italic>HOXA9</italic> mRNA level was assessed by Q-PCR in MLLr and non-MLLr leukemia cell lines.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Cytogenetic characterization <italic>HOXA9</italic> knock-in allele in MLLr SEM and OCI-AML2 cells.</title><p>(<bold>A</bold>) The genomic <italic>HOXA9</italic> location was highlighted in human chromosome 7. (<bold>B</bold>) Karyotype analysis of parental MLLr SEM cells indicating the mono-allelic deletion of partial segment in chromosome 7 containing the <italic>HOXA</italic> cluster (red arrow). Black arrows indicated other chromosome alterations including t4,11 translocation and trisomy 8. (<bold>C</bold>) Chromosome analysis of spectral karyotyping (SKY) was conducted by using a commercially prepared SKY probe from Applied Spectral Imaging (Carlsbad, CA) on HOXA9 reporter cells. Translocation between chr4 and chr11, trisomy eight and micro-deletion of chr7 was confirmed. (<bold>D</bold>) FISH analysis confirming the co-localization of <italic>HOXA9</italic> and mCherry in targeted SEM cells at interphase (left) and metaphase (right). The <italic>P2A-mCherry</italic> DNA was labeled with a red-dUTP by nick translation, and an <italic>HOXA9 BAC</italic> clone was labeled with a green-dUTP. The cells were then stained with 4,6-diamidino-2-phenylindole (DAPI) to visualize the nuclei. A representative cell image is shown for the pattern of hybridization (pairing of red and green signals). SEM has one copy of the HOXA cluster. (<bold>E</bold>) FISH analysis confirming the co-localization of <italic>HOXA9</italic> and mCherry in targeted OCI-AML2 cells at interphase (left) and metaphase (right). The <italic>P2A-mCherry</italic> DNA was labeled with a red-dUTP by nick translation, and an <italic>HOXA9 BAC</italic> clone was labeled with a green-dUTP. The cells were then stained with 4,6-diamidino-2-phenylindole (DAPI) to visualize the nuclei. A representative cell image is shown for the pattern of hybridization (pairing of red and green signals). OCI-AML2 has two copies of the HOXA cluster.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig1-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>The <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter allele recapitulates endogenous transcription of <italic>HOXA9</italic> in MLLr cells</title><p>To evaluate whether the <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter allele would faithfully respond to the transcriptional regulation of the cellular <italic>HOXA9</italic> promoter, we genetically perturbed or pharmaceutically inhibited <italic>HOXA9</italic>’s upstream regulators. Previous studies have shown that <italic>DOT1L</italic> and <italic>ENL</italic> positively regulate <italic>HOXA9</italic> expression in MLLr leukemia via direct occupancy on <italic>HOXA9</italic>’s promoter (<xref ref-type="bibr" rid="bib81">Zeisig et al., 2004</xref>; <xref ref-type="bibr" rid="bib6">Chen et al., 2015</xref>). Therefore, two sgRNAs targeting the coding region of <italic>DOT1L</italic> (sgDOT1L) and <italic>ENL</italic> (sgENL) were infected into the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells expressing Cas9. Flow cytometry and Q-PCR analysis each revealed that <italic>mCherry</italic> and <italic>HOXA9</italic> expression were both downregulated by sgRNAs targeting <italic>DOT1L</italic> or <italic>ENL</italic> (<xref ref-type="fig" rid="fig2">Figure 2A–D</xref>), and that the mCherry expression correlated well with the expression of <italic>HOXA9</italic> (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Additionally, a DOT1L-selective inhibitor, SGC0946 (<xref ref-type="bibr" rid="bib79">Yu et al., 2012</xref>), was supplemented at different dosages for 6 days to the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells in culture resulting in a dosage-dependent reduction of mCherry fluorescence intensity measured by fluorescence imaging (<xref ref-type="fig" rid="fig2">Figure 2F–G</xref>) and flow cytometry (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). Again, Q-PCR analysis of the DMSO- and SGC0946-treated cells showed that mRNA expression of <italic>mCherry</italic> was significantly correlated with that of <italic>HOXA9</italic> (Pearson’s <italic>r</italic> = 0.90, p&lt;0.001) (<xref ref-type="fig" rid="fig2">Figure 2I</xref>). Similarly, the <italic>HOXA9<sup>P2A-mCherry</sup></italic> knock-in OCI-AML2 reporter line was also comprehensively characterized (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–G</xref>). Taken together, these data confirm that the newly established <italic>HOXA9<sup>P2A-mCherry</sup></italic> alleles were authentically controlled by the endogenous <italic>HOXA9</italic> promoter and its local chromatin niche.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter allele recapitulates endogenous transcription of <italic>HOXA9</italic> in MLLr SEM cells.</title><p>(<bold>A</bold>) Flow cytometry analysis of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells targeted with luciferase-sgRNA (sgLuc) and DOT1L-sgRNA (sgDOT1L). (<bold>B</bold>) Q-PCR analysis of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells targeted with sgLuc and sgDOT1L by using specific primers targeting the mRNA sequences of <italic>mCherry</italic> and <italic>HOXA9</italic>. Three biological replicates were performed. Data shown are means ± SEM from replicate independent experiments. The p-value was calculated by performing a two-tailed <italic>t</italic>-test. (<bold>C</bold>) Flow cytometry analysis of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells targeted with luciferase-sgRNA (sgLuc) and ENL-sgRNA (sgENL). (<bold>D</bold>) Q-PCR analysis of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells targeted with sgLuc and sgENL by using specific primers targeting the mRNA sequence of <italic>mCherry</italic> and <italic>HOXA9</italic>. Three biological replicates were performed. The p-value was calculated by performing a two-tailed <italic>t</italic>-test. (<bold>E</bold>) The correlation of transcription reduction in <italic>mCherry</italic> and <italic>HOXA9</italic> in response to CRISPR–mediated targeting was calculated by Pearson’s correlation test. (<bold>F</bold>) Fluorescence imaging was performed on the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells treated with various dosages of DOT1L inhibitor SGC0946 for six days. Representative images were shown for comparison between 0.3 nM and 10 µM dosages. For each dosage treatment, four replicates were conducted (scale bar 50 μm). (<bold>G</bold>) Fluorescence curve was generated according to mCherry intensity in response to dosage-dependent treatment of drug for 6 days. About 20,000 cells were split in each of the 384-well at the starting time point. (<bold>H</bold>) Flow cytometry analysis of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells treated with DMSO and various dosages of the DOT1L inhibitor SGC0946. (<bold>I</bold>) Q-PCR analysis of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells with or without the 6-day treatment of the DOT1L inhibitor SGC0946 by using specific primers targeting the mRNA sequences of <italic>mCherry</italic> and <italic>HOXA9</italic>. The correlation of transcription reduction in <italic>mCherry</italic> and <italic>HOXA9</italic> in response to inhibitor–mediated transcription repression was calculated by performing Pearson’s correlation test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>The <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter allele recapitulates endogenous transcription of <italic>HOXA9</italic> in MLLr OCI-AML2 cells.</title><p>(<bold>A</bold>) Flow cytometry analysis of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells compared with parental wildtype cells. (<bold>B</bold>) Genotyping PCR was conducted to confirm the successful knock-in. (<bold>C</bold>) Flow cytometry analysis of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells targeted with luciferase-sgRNA (sgLuc), DOT1L-sgRNA (sgDOT1L) and ENL-sgRNA (sgENL). (<bold>D</bold>) The correlation of transcription reduction in <italic>mCherry</italic> and <italic>HOXA9</italic> in response to CRISPR–mediated targeting was calculated by Pearson’s correlation test. (<bold>E</bold>) Q-PCR analysis of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells targeted with sgLuc, sgDOT1L and sgENL by using specific primers targeting the mRNA sequences of <italic>mCherry</italic> and <italic>HOXA9</italic>. Three biological replicates were performed. Data shown are means ± SEM from replicate independent experiments. The p-value was calculated by performing a two-tailed <italic>t</italic>-test. (<bold>F</bold>) Flow cytometry analysis of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells treated with DMSO and various dosages of the DOT1L inhibitor SGC0946. (<bold>G</bold>) Fluorescence imaging was performed on the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells treated with various dosages of DOT1L inhibitor SGC0946 for six days. Representative images were shown for comparison between 3, 10, and 20 nM dosages. For each dosage treatment, four replicates were conducted (scale bar 50 μm).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig2-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Pooled CRISPR/Cas9 screening identified a novel transcription factor, USF2, that regulates <italic>HOXA9</italic> expression</title><p>Although a few regulators of <italic>HOXA9</italic> in MLLr leukemia have been previously identified (<xref ref-type="bibr" rid="bib81">Zeisig et al., 2004</xref>; <xref ref-type="bibr" rid="bib10">Collins and Hess, 2016b</xref>; <xref ref-type="bibr" rid="bib8">Collins et al., 2014</xref>; <xref ref-type="bibr" rid="bib38">Li et al., 2013a</xref>; <xref ref-type="bibr" rid="bib71">Sun et al., 2013</xref>; <xref ref-type="bibr" rid="bib39">Li et al., 2013b</xref>; <xref ref-type="bibr" rid="bib55">Ogawara et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">de Bock et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Lynch et al., 2019</xref>), to date a comprehensive CRISPR/Cas9 screen to unbiasedly identify novel upstream regulatory factors of <italic>HOXA9</italic> has not been feasible owing to the lack of a reliable reporter cell line. Therefore, we combined the <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter line and an in-house CRISPR-Cas9 sgRNA library targeting 1639 human transcription factors to identify novel regulatory effectors (<xref ref-type="bibr" rid="bib35">Lambert et al., 2018</xref>). In this library, seven sgRNAs spanning multiple coding exons were designed per transcription factor, seven sgRNAs targeting DOT1L were included as a positive control, and an additional 100 non-targeting sgRNAs were included as negative controls. Two paralleled screens were performed on the same <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter line stably expressing Cas9 and the lentiviral sgRNA library at a low M.O.I. (less than 0.3). Cells were selected with antibiotics, enriched, and fractionated by flow cytometric sorting for the top 10% (mCherry<sup>High</sup>) and bottom 10% (mCherry<sup>Low</sup>) mCherry populations, followed by genomic DNA extraction, PCR, and deep sequencing to identify differentially represented sgRNAs (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The differentially represented sgRNAs were calculated by DEseq2 analysis and combined for MAGeCK testing at the gene level (<xref ref-type="bibr" rid="bib40">Li et al., 2014</xref>). The positive control genes <italic>HOXA9</italic> and <italic>DOT1L</italic> were identified among the top hits between mCherry<sup>High</sup> and mCherry<sup>Low</sup> populations, suggesting that the screening was successful (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). To mitigate the possibility that key upstream regulators of HOXA9 could be missed due to a survival disadvantage, we conducted an independent CRISPR/Cas9 TF screen in <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter SEM cells with ectopically expressed <italic>HOXA9</italic> together with its functional partner MEIS1. In this regard, exogenously expressed <italic>HOXA9</italic> could rescue the potential cell loss due to decreased <italic>HOXA9</italic> expression in SEM cells, while the level of endogenous <italic>HOXA9</italic> is still monitored by the mCherry reporter. As a result, our CRISPR screening using the <italic>HOXA9/MEIS1</italic> pre-rescued reporter line has identified more well-known regulators of HOXA9, which are also considered survival essential genes. Among the top 10 hits from this screen, DOT1L and HOXA9 were enriched. KMT2A, the translocation partner of MLL-AF4 in SEM cells, was identified in the HOXA9-MEIS1 rescue TF screen but not the original screen without ectopic expression of HOXA9. Notably, the MYST acetyltransferase HBO1 (also known as KAT7 or MYST2) and several members of the HBO1 protein complex, which were recently shown as critical regulators of leukemia stem cell maintenance, were also identified among the top hits (<xref ref-type="bibr" rid="bib50">MacPherson et al., 2020</xref>; <xref ref-type="bibr" rid="bib2">Au et al., 2020</xref>). Most importantly, USF2 was enriched among the top hits in both screens (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), suggesting USF2 is likely a positive regulator with less survival essentiality compared with KMT2A. Consistent with the significant enrichment of these three candidates at the gene level, DEseq2 analysis (<xref ref-type="bibr" rid="bib42">Love et al., 2014</xref>) and sgRNA enrichment plotting both suggested that most of the sgRNAs against these genes were differentially represented (<xref ref-type="fig" rid="fig3">Figure 3C–F</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–F</xref>). Importantly, all the non-targeting control sgRNAs were similarly distributed across mCherry<sup>High</sup> and mCherry<sup>Low</sup> populations, indicating that the sorting-based screen did not bias the enrichment.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Pooled CRISPR/Cas9 screening identified a novel transcription factor, USF2, regulating <italic>HOXA9.</italic></title><p>(<bold>A</bold>) Schematic diagram of a working model of loss-of-function CRISPR screening targeting 1639 human transcription factors. (<bold>B</bold>) The enrichment score of seven sgRNAs against each transcription factor was combined by the MAGeCK algorithm. Positive regulators of HOXA9 were compared between parental reporter strain and HOXA9-MEIS1 overexpressed screens. Overlapped top hits including <italic>HOXA9</italic>, <italic>USF2</italic> and <italic>DOT1L</italic> were highlighted. (<bold>C</bold>) The overall distribution of all sgRNAs from the parental SEM HOXA9 reporter screening was shown based on the p-value and the DEseq2 score calculated by Log<sub>2</sub>[Fold Change (mCherry<sup>High</sup>/mCherry<sup>Low</sup>)]. NT, <italic>HOXA9</italic>, <italic>USF2</italic> and <italic>KMT2A</italic> sgRNAs were highlighted by different color code. (<bold>D</bold>) The ratio for all sgRNAs targeting <italic>HOXA9</italic>, <italic>USF2</italic>, and <italic>KMT2A</italic>, are shown between mCherry<sup>High</sup> and mCherry<sup>Low</sup> sorted population. NT sgRNAs were overlaid on a gray gradient depicting the overall distribution. NT: 100 sgRNAs. Transcription factors: seven sgRNAs/each. RRA score of each gene was collected from MAGeCK analysis. (<bold>E</bold>) The overall distribution of all sgRNAs from the HOXA9-MEIS1 overexpressing SEM HOXA9 reporter screening was shown based on the p-value and the DEseq2 score calculated by Log<sub>2</sub>[Fold Change (mCherry<sup>High</sup>/mCherry<sup>Low</sup>)]. NT, <italic>HOXA9</italic>, <italic>USF2</italic> and <italic>KMT2A</italic> sgRNAs were highlighted by different color code. (<bold>F</bold>) The ratio for all sgRNAs targeting <italic>HOXA9</italic>, <italic>USF2</italic>, and <italic>KMT2A</italic>, are shown between mCherry<sup>High</sup> and mCherry<sup>Low</sup> sorted population. NT sgRNAs were overlaid on a gray gradient depicting the overall distribution. NT: 100 sgRNAs. Transcription factors: seven sgRNAs/each. RRA score of each gene was collected from MAGeCK analysis.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>CRISPR screen and data analysis by MAGeCK.</title><p>(<bold>A</bold>) Gene ranking of the top 10 positive and negative candidate regulators of <italic>HOXA9</italic> enriched from parental SEM reporter screening by MAGeCK algorithm. (<bold>B</bold>) Normalized sgRNA count distribution of each of seven sgRNAs against <italic>HOXA9</italic>. (<bold>C</bold>) Normalized sgRNA count distribution of each of seven sgRNAs against <italic>USF2</italic>. (<bold>D</bold>) Gene ranking of the top 10 positive and negative candidate regulators of <italic>HOXA9</italic> enriched from HOXA9-MEIS1 overexpressing SEM reporter screening by MAGeCK algorithm. (<bold>E</bold>) Normalized sgRNA count distribution of each of seven sgRNAs against <italic>HOXA9</italic>. (<bold>F</bold>) Normalized sgRNA count distribution of each of seven sgRNAs against <italic>USF2</italic>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>CTCF is dispensable for maintaining <italic>HOXA9</italic> expression in MLLr SEM cells.</title><p>(<bold>A</bold>) Flow diagram of auxin-inducible degradation model to acutely deplete endogenous CTCF protein. Dox, doxycycline; IAA: auxin. (<bold>B</bold>) Immunoblotting analysis of CTCF<sup>AID</sup> and MYC in three bi-allelic knock-in clones 27, 35, and 42 with or without auxin (IAA) treatment. GAPDH was used as a loading control. (<bold>C</bold>) CTCF Cut and Run tracks shown at the selective viewpoint of the <italic>HOXA9</italic> locus where significant reduction of CTCF binding at CBS7/9 occurs following 48 hr IAA treatment in clones 27, 35, and 42. Publicly available ChIP-seq tracks of CTCF, AFF1 and H3K27ac were included to indicate the open chromatin status of the locus. (<bold>D</bold>) RNA-seq profiles of <italic>HOXA7</italic>, <italic>HOXA9</italic>, and <italic>HOXA10</italic> in CTCF-depleted SEM cells. (<bold>E</bold>) Quantification of <italic>HOXA7</italic> and <italic>HOXA9</italic> levels in three knock-in clones of CTCF depleted SEM cells using RNA-seq data. (<bold>F</bold>) Q-PCR analysis of <italic>HOXA9</italic> was conducted to monitor the transcriptional response to CTCF depletion for 24, 48 hr and washout from three biological replicates; clones 27, 35, and 42 (N = 3). Data shown are means ± SEM from three independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, two-tailed Student’s <italic>t</italic> test. (<bold>G</bold>) Q-PCR analysis of <italic>HOXA9</italic> was conducted to monitor the transcriptional response to CTCF depletion for 24, 48 hr and washout from three biological replicates; clones 27, 35, and 42 (N = 3). Data shown are means ± SEM from three independent experiments. *p&lt;0.05, two-tailed Student’s <italic>t</italic> test. (<bold>H</bold>) SEM cells were electroporated with CTCF-siRNA and NT-siRNA. Q-PCR was conducted 24 hr post-electroporation to monitor <italic>CTCF</italic> expression. Data shown are means ± SEM from two independent experiments. **p&lt;0.01, two-tailed Student’s <italic>t</italic> test. (<bold>I</bold>) SEM cells were electroporated with CTCF-siRNA and NT-siRNA. Q-PCR analysis was conducted 24 hr post-electroporation to monitor <italic>HOXA7</italic> expression. Data shown are means ± SEM from two independent experiments. *p&lt;0.05, two-tailed Student’s <italic>t</italic> test. (<bold>J</bold>) SEM cells were electroporated with CTCF-siRNA and NT-siRNA. Q-PCR was conducted 24 hr post-electroporation to monitor <italic>HOXA9</italic> expression. Data shown are means ± SEM from two independent experiments. *p&lt;0.05, two-tailed Student’s <italic>t</italic> test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>CTCF regulates <italic>HOXA9</italic> expression in human colorectal cancer HCT116 cells.</title><p>(<bold>A</bold>) ChIP-seq tracks from publicly available ENCODE dataset demonstrated the enriched transcription factor occupancy at CBS7/9 in HCT116 cells RNA-seq profiles of <italic>HOXA7</italic>, <italic>HOXA9</italic>, and <italic>HOXA10</italic> in CTCF depleted SEM cells. (<bold>B</bold>) Q-PCR analysis of <italic>CTCF</italic> in HCT116 cells transfected with CTCF-siRNAs and NT-siRNAs for 48 hr. Data are means ± SEM from two independent experiments. ***p&lt;0.001, Student’s <italic>t</italic> test. (<bold>C</bold>) Immunoblotting confirmed the siRNA-mediated inhibition of CTCF at protein level. (<bold>D</bold>) Q-PCR analysis of <italic>HOXA7</italic> in HCT116 cells transfected with CTCF-siRNAs and NT-siRNAs for 48 hr. Data are means ± SEM from two independent experiments. **p&lt;0.01, Student’s <italic>t</italic> test. (<bold>E</bold>) Q-PCR analysis of <italic>HOXA9</italic> in HCT116 cells transfected with CTCF-siRNAs and NT-siRNAs for 48 hr. Data are means ± SEM from two independent experiments. *p&lt;0.05, Student’s <italic>t</italic> test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig3-figsupp3-v2.tif"/></fig></fig-group><p>Interestingly, the most-characterized looping factors, CTCF and YY1, were not enriched in the <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter screen (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). CTCF was reported to be essential for <italic>HOXA9</italic> expression by occupying the boundary sequence between <italic>HOXA7</italic> and <italic>HOXA9</italic> (CBS7/9) in MLLr AML cell line MOLM13 (<xref ref-type="bibr" rid="bib45">Luo et al., 2018</xref>). CRISPR-mediated deletion of the core sequence CTCF-binding motif in CBS7/9 significantly decreased <italic>HOXA9</italic> expression and tumor progression (<xref ref-type="bibr" rid="bib45">Luo et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Luo et al., 2019</xref>). Given that CTCF is generally essential for cell survival, it is possible that cells targeted by CTCF sgRNAs in the <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter and TF screen quickly dropped out of the population and were unable to be enriched as a regulator of <italic>HOXA9</italic>. To mitigate the challenge, we utilized a previously described auxin-inducible degron (AID) cellular system (<xref ref-type="bibr" rid="bib27">Hyle et al., 2019</xref>; <xref ref-type="bibr" rid="bib51">Morawska and Ulrich, 2013</xref>; <xref ref-type="bibr" rid="bib53">Natsume et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Nora et al., 2017</xref>) to acutely deplete the CTCF protein in SEM cells and evaluate the immediate transcriptional response of <italic>HOXA9</italic> (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). Upon acute depletion of CTCF via auxin (IAA) treatment in three CTCF<sup>AID</sup> bi-allelic knock-in clones, the protein expression of a previously identified vulnerable gene as positive control, <italic>MYC</italic>, was significantly inhibited (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>). Moreover, a Cut and Run assay using CTCF antibody for chromatin immunoprecipitation confirmed loss of CTCF occupancy throughout the <italic>HOXA9</italic> locus, including CBS7/9 (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>). However, RNA-seq data (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2D–E</xref>) and Q-PCR analysis (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2F–G</xref>) collected from these three clones further confirmed the observation that loss of CTCF occupancy did not correlate with a decrease in <italic>HOXA7</italic> or <italic>HOXA9</italic> expression at the mRNA level. Instead, long-term depletion of CTCF by auxin for 48 hr slightly increased the transcription of <italic>HOXA7</italic> and <italic>HOXA9</italic>. Upon washout of auxin from culture medium for an additional 48 hr, both <italic>HOXA7</italic> and <italic>HOXA9</italic> expression were restored to levels indistinguishable from those of the parental untreated cells (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2D–G</xref>). Additionally, siRNA-mediated knock-down of CTCF in SEM cells did not change the transcription level of <italic>HOXA7</italic> or <italic>HOXA9</italic> (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2H–J</xref>). However, suppressing CTCF in human colorectal cancer cell line HCT116 notably reduced <italic>HOXA7</italic> and <italic>HOXA9</italic> expression (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A–E</xref>), consistent with the finding in MLLr AML cell line MOLM13 (<xref ref-type="bibr" rid="bib45">Luo et al., 2018</xref>). Collectively, these data further confirmed the results of our CRISPR screening that CTCF is not a key regulator of <italic>HOXA9</italic> in MLLr B-ALL SEM and likely plays a role in regulating <italic>HOXA9</italic> transcription in a cell-type-specific manner.</p></sec><sec id="s2-4"><title>USF2 is required to maintain <italic>HOXA9</italic> expression in MLLr leukemia</title><p>Aside from the positive controls confirmed from the CRISPR/Cas9 transcription factor screen in <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells, the top-ranked candidate among positive regulators was USF2. To further validate the CRISPR screen result and investigate the regulatory effect of USF2 on <italic>HOXA9</italic> expression, we individually delivered four lentiviral sgRNAs targeting <italic>USF2</italic> exons 1, 2, 7, and 9 into the <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter line stably expressing Cas9. Similar to the results seen in sgENL targeted cells, <italic>USF2</italic> knock-down significantly decreased the mCherry fluorescence in a time-dependent manner compared to that of luciferase sgRNA-targeted control (sgLuc) (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Q-PCR and immunoblotting analysis further confirmed the concordant downregulation of both <italic>HOXA9</italic> and <italic>mCherry</italic> (<xref ref-type="fig" rid="fig4">Figure 4B–C</xref>). Collectively, these data suggest that USF2 positively controls <italic>HOXA9</italic> expression in the MLLr B-ALL SEM cell line. USF2 was reported to generally bind to a symmetrical DNA sequence (E-box motif) (5’CACGTG3’) in a variety of cellular promoters (<xref ref-type="bibr" rid="bib26">Henrion et al., 1995</xref>). Publicly available ChIP-seq data collected from human ES cells suggested that USF2 can directly bind to the conserved E-box element at both <italic>HOXA7</italic> and <italic>HOXA9</italic> promoters (<xref ref-type="bibr" rid="bib7">Cheng et al., 2014</xref>). A Cut and Run assay was performed in control sgLuc and sgUSF2 targeted SEM cells to study genome-wide USF2 occupancy. In control SEM cells, USF2 bound to <italic>HOXA1</italic>, <italic>HOXA-AS3</italic>, <italic>HOXA7</italic>, and <italic>HOXA9</italic> in <italic>HOXA</italic> cluster. Upon USF2 depletion, binding occupancy at these regions was significantly reduced (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), further supporting the specificity of the USF2 binding identified by the Cut and Run assay. Taken together, these data suggest that USF2 could regulate <italic>HOXA9</italic> expression as well as other <italic>HOXA</italic> genes through interactions with its regulatory elements at the <italic>HOXA</italic> cluster gene loci.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>USF2 is required to maintain <italic>HOXA9</italic> expression in MLLr leukemia.</title><p>(<bold>A</bold>) Flow cytometry analysis was performed at day 8 on the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells targeted with lentiviral Cas9 and four sgRNAs against <italic>USF2</italic>. The sgENL-targeted cells were used as positive controls while sgLuc targeted cells were used as negative controls. (<bold>B</bold>) Q-PCR analysis was conducted on the USF2-targeted cells to monitor the reduction of <italic>HOXA9</italic>. The sgENL targeted cells were used as positive controls while sgLuc-targeted cells were used as negative controls. Data shown are means ± SEM from three independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, two-tailed Student’s <italic>t</italic> test. (<bold>C</bold>) Immunoblotting of USF2 in USF2 sgRNAs targeted cells. '*' denoted non-specific bands. (<bold>D</bold>) USF2 occupancy changes in sgLuc and sgUSF2-targeted SEM cells were characterized in <italic>HOXA9</italic> locus (A1, <italic>HOXA1</italic>; AS3, <italic>HOXA-AS3</italic>; A7, <italic>HOXA7</italic>; A9, <italic>HOXA9</italic>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Time-course knock-down of <italic>USF2</italic> and consequent <italic>HOXA9</italic> expression analysis.</title><p>Flow cytometry analysis was performed at day 0, 4, 6, 8, and 11 on the <italic>HOXA9<sup>P2A-mCherry</sup></italic> cells targeted with lentiviral Cas9 and four sgRNAs against <italic>USF2</italic>. The sgLuc- and sgRosa26-targeted cells were included as negative controls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>USF2 is an essential gene in MLLr B-ALL by controlling <italic>HOXA9</italic> expression</title><p>To unbiasedly evaluate the survival dependency of USF2 in SEM cells, we conducted a dropout CRISPR/Cas9 screen by targeting 1639 transcription factors. SEM cells infected with the pooled library of sgRNAs were collected at day 0 and day 12 to sequence for sgRNA distribution (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In accordance with prior genome-wide CRISPR screens and functional studies in B-ALL, many survival dependent genes were identified in the top 50 genes in our screen including <italic>PAX5</italic>, <italic>DOT1L</italic>, <italic>ZFP64</italic>, <italic>YY1</italic>, <italic>MEF2C</italic>, <italic>MYC</italic>, and <italic>KMT2A</italic> (<xref ref-type="bibr" rid="bib22">Gu et al., 2019</xref>; <xref ref-type="bibr" rid="bib27">Hyle et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Pridans et al., 2008</xref>; <xref ref-type="bibr" rid="bib44">Lu et al., 2018</xref>). USF2 was ranked as the top 24th essential gene in MLLr SEM cells (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Taken together, these findings suggest that the USF2/HOXA9 axis might play a role in supporting MLLr B-ALL cell proliferation. To evaluate the importance of the USF2/HOXA9 axis in MLLr B-ALL progression, we sought to investigate the knockout phenotype of USF2 in MLLr B-ALL cells. A competition-based proliferation assay was performed by infecting SEM<sup>Cas9</sup> cells with a lentiviral-mCherry-sgRNAs against the <italic>HOXA9</italic> promoter at ~50% targeting efficiency (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). The proportion of mCherry<sup>+</sup> cells were monitored over a 12-day time course (days 3, 6, 9, and 12) to investigate the proliferation disadvantage of <italic>HOXA9</italic> knock-down cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Next, the same assay was performed by infecting SEM<sup>Cas9</sup> cells with three individual lentiviral-mCherry-sgRNAs against USF2 (sgRNA-2,–3 and 5) at ~50% infection efficiency. As a result, the proliferation-arrested phenotype was observed in all three sgRNA targeted cells but not in cells targeted with sgLuc (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Importantly, in SEM cells constitutively expressing ectopic retroviral mouse Hoxa9 (SEM<sup>HOXA9</sup>), USF2 knock-down had little effect on cell growth (<xref ref-type="fig" rid="fig5">Figure 5F</xref>), suggesting that HOXA9 is a functional and essential downstream gene of USF2 in USF2-mediated leukemia propagation.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>USF1 and USF2 synergistically regulate <italic>HOXA9</italic> expression in MLLr leukemia.</title><p>(<bold>A</bold>) Flow diagram of dropout CRISPR screening procedure. (<bold>B</bold>) Gene ranking of all transcription factors from dropout screening was illustrated. The enrichment score of seven sgRNAs against each transcription factor was combined by the MAGeCK algorithm. (<bold>C</bold>) Q-PCR was conducted to monitor <italic>HOXA9</italic> expression upon CRISPR targeting on its promoter. (<bold>D</bold>) Competitive proliferation assay was conducted by infecting SEM<sup>Cas9</sup> cells with Lentiviral-mCherry-sgRNAs against <italic>HOXA9</italic> promoter at about 50% efficiency. The mCherry% was quantified every three days by flow cytometry to evaluate the growth disadvantage. (<bold>E</bold>) Competitive proliferation assay was conducted by infecting SEM<sup>Cas9</sup> cells with Lentiviral-mCherry-sgRNAs against luciferase (sgLuc) and USF2 (sgUSF2#2, 2#3 and 2#5) at about 50% efficiency. The mCherry% was quantified every 3 days by flow cytometry to evaluate the growth disadvantage. (<bold>F</bold>) Rescued competitive proliferation assay was conducted by infecting SEM cells overexpressing ectopic Hoxa9 with Lentiviral-mCherry-sgRNAs against luciferase (sgLuc) and USF2 (sgUSF2#2, 2#3 and 2#5) at about 50% efficiency. The mCherry% was quantified every 3 days by flow cytometry to evaluate the growth disadvantage. (<bold>G</bold>) Q-PCR analysis was conducted on the sgUSF2, sgUSF1 and sgUSF1/2-targeted SEM cells to monitor the reduction of <italic>HOXA9</italic>. Data shown are means ± SEM from three independent experiments. **p&lt;0.01, two-tailed Student’s <italic>t</italic> test. (<bold>H</bold>) Competitive proliferation assay was conducted by infecting SEM<sup>Cas9</sup> cells with Lentiviral-mCherry-sgLuc, sgUSF1, sgUSF2, and sgUSF1/2 (DKO) at about 50% efficiency. The mCherry% was quantified at days 3, 7, 11, 15, 19, and 23 by flow cytometry to evaluate the growth disadvantage. A guide RNA targeting the survival essential gene RPS19 was included as a positive control for Cas9 activity. Guide RNAs targeting Luciferase gene (sgLuc) and the human ROSA26 gene (sgROSA26) were included as a negative control. (<bold>I</bold>) Q-PCR analysis was conducted on the sgUSF2, sgUSF1 and sgUSF1/2 targeted OCI-AML2 cells to monitor the reduction of <italic>HOXA9</italic>. Data shown are means ± SEM from three independent experiments. *p&lt;0.05, **p&lt;0.01, two-tailed Student’s <italic>t</italic> test. (<bold>J</bold>) Competitive proliferation assay was conducted by infecting OCI-AML2<sup>Cas9</sup> cells with Lentiviral-mCherry-sgLuc, sgUSF1, sgUSF2, and sgUSF1/2 (DKO) at about 50% efficiency. The mCherry% was quantified at days 3, 7, 11, 15, 19, and 23 by flow cytometry to evaluate the growth disadvantage. A guide RNA targeting the survival essential gene RPS19 was included as a positive control for Cas9 activity. Guide RNAs targeting Luciferase gene (sgLuc) and the human ROSA26 gene (sgROSA26) were included as negative controls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>USF2 depletion in MLLr leukemia cells.</title><p>(<bold>A</bold>) Flow cytometry analysis was performed on the <italic>HOXA9<sup>P2A-mCherry</sup></italic> SEM cells targeted with lentiviral Cas9 and sgRNAs against <italic>USF1</italic>, <italic>USF2</italic>, and <italic>USF1/2</italic> (DKO). (<bold>B</bold>) Q-PCR was performed to validate the transcriptional regulation of <italic>HOXA9</italic> upon USF2 targeting by two sgRNAs (sgUSF2#2 and sgUSF2#3) in OCI-AML2 cells. Immunoblotting confirmed the complete depletion of USF2. (<bold>C</bold>) Q-PCR was performed to validate the transcriptional regulation of <italic>HOXA9</italic> upon USF2 targeting by two sgRNAs (sgUSF2#2 and sgUSF2#3) in NOMO-1 cells. Immunoblotting confirmed the complete depletion of USF2. (<bold>D</bold>) Immunoblotting confirmed the complete depletion of USF1 in SEM cells upon USF1 targeting by a sgRNA. (<bold>E</bold>) Immunoblotting confirmed the complete depletion of USF1 in OCI-AML2 cells upon USF1 targeting by a sgRNA. (<bold>F</bold>) Immunoblotting confirmed the complete depletion of USF2 in MOLM13 cells USF2 targeting by two sgRNAs (sgUSF2#2 and sgUSF2#3). (<bold>G</bold>) Competitive proliferation assay was conducted by infecting MOLM13<sup>Cas9</sup> cells with Lentiviral-mCherry-sgRNAs against luciferase (sgLuc) and USF2 (sgUSF2#2, 2#3 and 2#5) at about 50% efficiency. The mCherry% was quantified at days 0, 3, 7, 11, 15, 19, and 23 by flow cytometry to evaluate the growth disadvantage. A guide RNA targeting the survival essential gene RPS19 was included as a positive control for Cas9 activity. Guide RNAs targeting Luciferase gene (sgLuc) and the human ROSA26 gene (sgROSA26) were included as negative controls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>USF2 depletion in non-MLLr leukemia cells.</title><p>(<bold>A</bold>) Q-PCR was performed to validate the transcriptional impact of <italic>HOXA9</italic> upon USF2 targeting by two sgRNAs (sgUSF2#2 and sgUSF2#3) in OCI-AML3 cells. Immunoblotting confirmed the complete depletion of USF2. (<bold>B</bold>) Immunoblotting confirmed the complete depletion of USF2 in OCI-AML3 cells upon USF2 targeting by a sgRNA. (<bold>C</bold>) Q-PCR was performed to validate the transcriptional impact of <italic>HOXA9</italic> upon USF2 targeting by two sgRNAs (sgUSF2#2 and sgUSF2#3) in U937 cells. Immunoblotting confirmed the complete depletion of USF2. (<bold>D</bold>) Immunoblotting confirmed the complete depletion of USF2 in U937 cells upon USF2 targeting by a sgRNA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Transcriptional correlation between <italic>USF2</italic> and <italic>HOXA9</italic> in patient cohorts.</title><p>(<bold>A</bold>) Pearson’s correlation of transcriptional levels of <italic>HOXA9</italic> and top 10 positive regulators identified from TF screen in a cohort of 1988 B-ALL patients (<xref ref-type="bibr" rid="bib22">Gu et al., 2019</xref>). (<bold>B</bold>) Pearson’s correlation of transcriptional levels of <italic>HOXA9</italic> and <italic>USF2</italic> in a cohort of 1988 B-ALL patients (<xref ref-type="bibr" rid="bib22">Gu et al., 2019</xref>). (<bold>C</bold>) Pearson’s correlation of transcriptional levels of <italic>HOXA9</italic> and <italic>USF2</italic> in a cohort of 136 MLLr B-ALL patients (<xref ref-type="bibr" rid="bib22">Gu et al., 2019</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57858-fig5-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>USF1 and USF2 synergistically regulate <italic>HOXA9</italic> expression in MLLr leukemia</title><p>Previously, other studies identified the USF2 homolog protein USF1 shares a similar protein structure with USF2 (49, 53). USF1 and USF2 bind to the same type of E-box elements and are also able to form homo- or heterodimers (<xref ref-type="bibr" rid="bib34">Kumari and Usdin, 2001</xref>; <xref ref-type="bibr" rid="bib76">Wang and Sul, 1995</xref>; <xref ref-type="bibr" rid="bib58">Prasad and Singh, 2008</xref>; <xref ref-type="bibr" rid="bib69">Spohrer et al., 2017</xref>) suggesting that these two proteins may function in synergy to regulate <italic>HOXA9</italic>. Interestingly, in our HOXA9-reporter-based CRISPR screen, USF1 was also among the top 50 positive regulator genes identified (49th) (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). To test whether USF1 and USF2 have redundant roles in regulating <italic>HOXA9</italic> expression, we co-delivered sgRNAs against USF2 (sgUSF2) and USF1 (sgUSF1) to the SEM <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter line stably expressing Cas9. Notably, both the flow cytometry and Q-PCR analysis confirmed a significant decrease in <italic>HOXA9</italic> expression with double inactivation of USF1 and USF2 compared with inactivation of USF2 alone (<xref ref-type="fig" rid="fig5">Figure 5G</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), which was also supported by a synergetic effect in the competitive proliferation assay (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). To further evaluate whether USF2 and USF1 could regulate HOXA9 expression in other MLLr leukemias, sgUSF2 and sgUSF1 alone or in combination were delivered into the human MLLr AML cell line OCI-AML2 which carried the MLL-AF6 translocation. Similar to observations in SEM cells, USF1 or USF2 CRISPR targeting resulted in notably suppressed <italic>HOXA9</italic> expression (<xref ref-type="fig" rid="fig5">Figure 5I</xref>). In addition, USF1 and USF2 synergistically regulate <italic>HOXA9</italic> expression and leukemia survival in OCI-AML2 (<xref ref-type="fig" rid="fig5">Figure 5J</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B-E</xref>). In NOMO-1 MLLr AML cells, USF2 downregulation also notably decreased expression of <italic>HOXA9</italic> (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>) comparable to levels observed in SEM cells. Interestingly, in human MLLr AML cell line MOLM13, individual knockout of USF1 or USF2 did not affect <italic>HOXA9</italic> expression nor cell survival. However, USF1 and USF2 double-knockout cells demonstrated suppressed <italic>HOXA9</italic> expression and reduced survival (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F-G</xref>). Taken together, the data suggests that loss of one <italic>USF</italic> family member gene may lead to varying degrees of compensatory regulation of <italic>HOXA9</italic> by the untargeted <italic>USF</italic> gene, whereas loss of both <italic>USF</italic> genes results in a more robust abrogation of <italic>HOXA9</italic> expression.</p><p>To examine if USF2 regulation of <italic>HOXA9</italic> expression was unique to MLLr leukemias, we used two sgRNAs, sgUSF2#2 and sgUSF2#3, to knockdown USF2 expression in two human non-MLLr leukemia cell lines, OCI-AML3 and U937, which both express <italic>HOXA9</italic>. Upon complete USF2 depletion, <italic>HOXA9</italic> expression remained unchanged, suggesting the USF2/HOXA9 axis may function in a MLLr-dependent manner (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A-D</xref>). Lastly, a transcriptome analysis from the to-date largest human B-ALL transcriptome cohort (N = 1988 patients) (<xref ref-type="bibr" rid="bib22">Gu et al., 2019</xref>) identified <italic>USF2</italic> expression to be significantly correlated with <italic>HOXA9</italic> in MLLr-subtype patients (N = 136 patients) (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A-D</xref>) highlighting that the USF2 and <italic>HOXA9</italic> regulation axis could have clinical relevance for patients in this specific subtype.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p><italic>HOX</italic> genes are a cluster of genes strictly regulated in development by various transcription and epigenetic modulators. Dysregulation of <italic>HOX</italic> genes has been frequently linked to human diseases, particularly cancer. Here, we focus on <italic>HOXA9</italic>, the aberrant expression of which is one of the most significant features in the most aggressive human leukemias. The <italic>HOXA9<sup>P2A-mCherry</sup></italic> knock-in MLLr cell line derived in this study fully recapitulated transcriptional regulation of the endogenous gene. Previously, Godmin, et al. derived two mouse strains by delivering the in-frame GFP cassette to two different murine <italic>Hox</italic> genes, <italic>Hoxa1</italic> and <italic>Hoxc13</italic>, to visualize the proteins during mouse embryogenesis (<xref ref-type="bibr" rid="bib18">Godwin et al., 1998</xref>). Although this previous study certainly added to the repertoire of research tools available to investigate <italic>HOXA</italic>-related gene expression and gene function, our <italic>HOXA9</italic> reporter cell line provides a unique intrinsic cellular model with which to study transcriptional regulation of human <italic>HOXA9</italic> directly. Additionally, the CHASE-knock-in protocol developed to generate the <italic>HOXA9</italic> reporter is user-friendly, highly efficient, robust to reproduce and could be easily adapted to a wide variety of HOXA9-driven human leukemia cell models and other HOXA9-expressing cancer types.</p><p>In mammalian cells, each chromosome is hierarchically organized into hundreds of megabase-sized TADs (<xref ref-type="bibr" rid="bib15">ENCODE Project Consortium, 2012</xref>; <xref ref-type="bibr" rid="bib29">Ji et al., 2016</xref>; <xref ref-type="bibr" rid="bib62">Rowley et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Rowley and Corces, 2018</xref>), each of which is insulated by the boundary elements. Within the TAD scaffold, promoter/enhancer physical contacts intricately regulate gene expression (<xref ref-type="bibr" rid="bib57">Pombo and Dillon, 2015</xref>). Intra-TAD chromatin interactions can be facilitated by a pair of CTCF-binding sites engaged in contact with each other when they are in a convergent linear orientation (<xref ref-type="bibr" rid="bib61">Rao et al., 2014</xref>; <xref ref-type="bibr" rid="bib73">Vietri Rudan et al., 2015</xref>). The <italic>HOXA9</italic> cluster is located on the TAD boundary, providing an opportunity to interact with neighboring genomic elements. However, because of the low resolution of publicly available Hi-C data and the lack of DpnI restriction enzyme sites within the <italic>HOXA</italic> gene cluster that are necessary to generate high-quality 3C libraries, the impact of chromatin interaction regulation of <italic>HOXA9</italic> remains unclear. Using a chromosome conformation capture-based PCR assay and CRISPR-mediated deletion of a minimal CTCF-binding motif between <italic>HOXA7</italic> and <italic>HOXA9</italic> (CBS7/9), Luo and colleagues proposed that the CTCF boundary was crucial for higher order chromatin organization by showing the depletion of CBS7/9 disrupted chromatin interactions and significantly reduced <italic>HOXA9</italic> transcription in MLLr AML MOLM13 cells with t(9;11) (<xref ref-type="bibr" rid="bib45">Luo et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Luo et al., 2019</xref>). In our study, the loss-of-function results from auxin-inducible degradation of CTCF, siRNA-mediated CTCF knock-down, and the unbiased transcription factor screening suggested that CTCF is not required to maintain <italic>HOXA9</italic> expression in SEM cells with MLLr with t(4;11). We speculate that the discrepancy could be due to the following reasons. Although both cell lines carried the MLLr translocation as a driver oncogenic mutation, MOLM13 and SEM were classified as AML and B-ALL, respectively. Besides the lineage difference, SEM cells are also less sensitive to many well-known pharmaceutical inhibitors including JQ1 and DOT1L inhibitor. Therefore, we hypothesized that other as yet to be identified looping factors might be involved in the transcriptional regulation of the <italic>HOXA9</italic> locus in MLLr SEM cells, and that CTCF regulates HOXA9 expression in a cell-type-specific context.</p><p>By performing unbiased CRISPR screens designed to target 1639 known human transcription factors in a <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter cell line, we identified USF2 as a novel regulator of <italic>HOXA9</italic>. In addition, two known <italic>HOXA9</italic> regulators, <italic>HOXA9</italic> and <italic>DOT1L,</italic> were identified among the top hits supporting the reliable sensitivity of both the reporter system and the CRISPR screening strategy. USF2 is a ubiquitously expressed basic helix-loop-helix-leucine-zip transcription factor that generally recognizes E-box DNA motifs (<xref ref-type="bibr" rid="bib26">Henrion et al., 1995</xref>; <xref ref-type="bibr" rid="bib21">Groenen et al., 1996</xref>; <xref ref-type="bibr" rid="bib47">Luo and Sawadogo, 1996</xref>). USF1 and USF2 usually form homo- or heterodimers to modulate gene expression (<xref ref-type="bibr" rid="bib34">Kumari and Usdin, 2001</xref>). Interestingly, USF1 was also enriched in our CRISPR screening. Moreover, the function of USF2 in controlling leukemia progression has not been reported. Although our study identified the regulatory function of USF1/USF2 on <italic>HOXA9</italic> maintenance and leukemia cell survival in MLLr B-ALL and AML cell lines, other HOXA9-independent functions of USF1/2 cannot be excluded and requires further studies.</p><p>In summary, we revealed that candidate transcription factors identified from the CRISPR/Cas9 screen including USF2 and USF1, regulate <italic>HOXA9</italic> thereby providing a more comprehensive understanding about how the <italic>HOXA9</italic> locus is regulated in human cancer cells. Given the well-recognized role of <italic>HOXA9</italic> in hematopoietic malignancies, we anticipate the <italic>HOXA9</italic> reporter cells will advance many lines of investigation including drug screening and the identification of concordant epigenetic modifiers/transcription factors that are required for activation and maintenance of <italic>HOXA9</italic> expression in leukemia progression. Collectively, these efforts would clarify the molecular mechanisms underlying aberrant <italic>HOXA9</italic> activation in leukemias, thus providing the foundation to develop clinically relevant therapies to target the expression and/or function of <italic>HOXA9</italic> in leukemia patients.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or <break/>resource</th><th valign="top">Designation</th><th valign="top">Source or <break/>reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">SEM</td><td valign="top">DSMZ</td><td valign="top">ACC546</td><td valign="top">CVCL_0095</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">NOMO-1</td><td valign="top">DSMZ</td><td valign="top">ACC542</td><td valign="top">CVCL_1609</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">OCI-AML2</td><td valign="top">DSMZ</td><td valign="top">ACC99</td><td valign="top">CVCL_1619</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">OCI-AML3</td><td valign="top">DSMZ</td><td valign="top">ACC582</td><td valign="top">CVCL_1844</td></tr><tr><td valign="top">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td valign="top">MOLM13</td><td valign="top">DSMZ</td><td valign="top">ACC554</td><td valign="top">CVCL_2119</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">U937</td><td valign="top">ATCC</td><td valign="top">CRL-1593.2</td><td valign="top">CVCL_0007</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">293T</td><td valign="top">ATCC</td><td valign="top">CRL-3216</td><td valign="top">CVCL_0063</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">SEM-HOXA9<sup>P2A-mCherry</sup></td><td valign="top">This eLife study</td><td valign="top">Reporter derived from SEM cells via knock-in</td><td valign="top">Cell line is available upon request to Dr. Chunliang Li</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">OCI-AML2-HOXA9<sup>P2A-mCherry</sup></td><td valign="top">This eLife study</td><td valign="top">Reporter derived from OCI-AML2 cells via knock-in</td><td valign="top">Cell line is available upon request to Dr. Chunliang Li</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-USF2 (Rabbit polyclonal)</td><td valign="top">Novus</td><td valign="top">NBP1-92649</td><td valign="top">IP, IB (1:2,000) <break/>AB_11007053</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-USF1</td><td valign="top">Proteintech</td><td valign="top">22327–1-AP</td><td valign="top">IB (1: 2,000) AB_2060867</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-CTCF (Rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">ab70303</td><td valign="top">IB (1:1,000) <break/>AB_1209546</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-MYC (Rabbit polyclonal)</td><td valign="top">Cell Signaling Technology</td><td valign="top">9402</td><td valign="top">IB (1:1000) <break/>AB_2151827</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-GAPDH</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">AM4300</td><td valign="top">IB (1:10,000) AB_437392</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Vinculin</td><td valign="top">Proteintech</td><td valign="top">26520–1-AP</td><td valign="top">IB (1:2,000) AB_2868558</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">U6-Forward sequencing primer</td><td valign="top">This paper</td><td valign="top">sgRNA sequencing primer</td><td valign="top">5’GAGGGCCTATTTCCCATGAT3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">sgRNA sequence</td><td valign="top">This paper</td><td valign="top">sgRNA targeting HOXA9 on C-terminus</td><td valign="top">5’AAAGACGAGTGATGCCATTT3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA9 5’HA cloning primer F</td><td valign="top">This paper</td><td valign="top">HOXA9 knockin reporter cloning</td><td valign="top">5’GGCCGATTCCTTCCACTTCT3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA9 5’HA cloning primer R</td><td valign="top">This paper</td><td valign="top">HOXA9 knockin reporter cloning</td><td valign="top">5’TCACTCGTCTTTTGCTCGGT3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA9 3’HA cloning primer F</td><td valign="top">This paper</td><td valign="top">HOXA9 knockin reporter cloning</td><td valign="top">5’ACCGAGCAAAAGACGAGTGA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA9 3’HA cloning primer R</td><td valign="top">This paper</td><td valign="top">HOXA9 knockin reporter cloning</td><td valign="top">5’CACTGTTCGTCTGGTGCAAA3’.</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Infusion cloning F</td><td valign="top">This paper</td><td valign="top">HOXA9 knockin reporter cloning</td><td valign="top">5’AAGACCGAGCAAAAGACGAGGGATCCGGCGCAACAAACTT3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Infusion cloning R</td><td valign="top">This paper</td><td valign="top">HOXA9 knockin reporter cloning</td><td valign="top">5’AATAAGCCCAAATGGCATCACTTGTACAGCTCGTCCATGC3‘</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Infusion cloning of mCherry F</td><td valign="top">This paper</td><td valign="top">HOXA9 knockin reporter cloning</td><td valign="top">5’AAAGACGAGTGATGCCATTTGGGATGAGGCTGCGGGCGAC3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Infusion cloning of mCherry R</td><td valign="top">This paper</td><td valign="top">HOXA9 knockin reporter cloning</td><td valign="top">5’AAAGACGAGTGATGCCATTTGGGTATATATACAATAGACAAGACAGGAC3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">DOT1L-sgRNA</td><td valign="top">This paper</td><td valign="top">sgRNA sequence</td><td valign="top">5’TCAGCTTCGAGAGCATGCAG3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">ENL-sgRNA</td><td valign="top">This paper</td><td valign="top">sgRNA sequence</td><td valign="top">5’TCACCTGGACGGTGCACTGG3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">USF2-sgRNA#2</td><td valign="top">This paper</td><td valign="top">sgRNA sequence</td><td valign="top">5’AGAAGAGCCCAGCACAACGA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">USF2-sgRNA#3</td><td valign="top">This paper</td><td valign="top">sgRNA sequence</td><td valign="top">5’TGTTTTCCGCAGTGGAGCGG3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">USF2-sgRNA#4</td><td valign="top">This paper</td><td valign="top">sgRNA sequence</td><td valign="top">5’CCGGGGATCTTACCTGGCGG3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">USF2-sgRNA#5</td><td valign="top">This paper</td><td valign="top">sgRNA sequence</td><td valign="top">5’CAGCCACGACAAGGGACCCG3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">USF1-sgRNA</td><td valign="top">This paper</td><td valign="top">sgRNA sequence</td><td valign="top">5’CTATACTTACTTCCCCAGCA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Luciferase-sgRNA</td><td valign="top">This paper</td><td valign="top">sgRNA sequence</td><td valign="top">5’CCCGGCGCCATTCTATCCGC3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">ROSA26-sgRNA</td><td valign="top">This paper</td><td valign="top">sgRNA sequence</td><td valign="top">5’ACCTACCACACTAGCCCGA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">RPS19-sgRNA</td><td valign="top">This paper</td><td valign="top">sgRNA sequence</td><td valign="top">5’GTAGAACCAGTTCTCATCGT3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA9-promoter sgRNA</td><td valign="top">This paper</td><td valign="top">sgRNA sequence</td><td valign="top">5’GATTTCATGTAACAACTTGG3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">CTCF-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’TTTGTCTGTTCTAAGTGTGGGAAA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">CTCF-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’TTAGAGCGCATCTTTCTTTTTCTT3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">GAPDH-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’AGGGCTGCTTTTAACTCTGGT3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">GAPDH-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’CCCCACTTGATTTTGGAGGGA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">ACTB-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">GAGCACAGAGCCTCGCCTTT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">ACTB-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">GAGCGCGGCGATATCATCA</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA1-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’CCAGCCACCAAGAAGCCTGT3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA1-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’CCAGTTCCGTGAGCTGCTTG3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA2-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’ACAGCGAAGGGAAATGTAAAAGC3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA2-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’GGGCCCCAGAGACGCTAA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA3-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’TGCAAAAAGCGACCTACTACGA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA3-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’CGTCGGCGCCCAAAG3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA4-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’CGTGGTGTACCCCTGGATGA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA4-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’AAGACCTGCTGCCGGGTGTA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA5-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’TCTACCCCTGGATGCGCAAG3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA5-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’AATCCTCCTTCTGCGGGTCA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA6-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’TGGATGCAGCGGATGAACTC3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA6-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’CCGTGTCAGGTAGCGGTTGA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA7-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’TCTGCAGTGACCTCGCCAAA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA7-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’AGCGTCTGGTAGCGCGTGTA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA9-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’AAAAACAACCCAGCGAAGGC3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA9-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’ACCGCTTTTTCCGAGTGGAG3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA10-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’CCTTCCGAGAGCAGCAAAGC3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA10-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’CAGCGCTTCTTCCGACCACT3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA11-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’ACAGGCTTTCGACCAGTTTTTC3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA11-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’CCTTCTCGGCGCTCTTGTC3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA13-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’ACTCTGCCCGACGTGGTCTC3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HOXA13-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’TTCGTGGCGTATTCCCGTTC3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mCherry-F</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’CACTACGACGCTGAGGTCAA3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mCherry-R</td><td valign="top">This study</td><td valign="top">Q-PCR primer</td><td valign="top">5’TAGTCCTCGTTGTGGGAGGT3’</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">siRNA: nontargeting control</td><td valign="top">Thermo Fisher</td><td valign="top">siRNA oligo</td><td valign="top">Silencer Select</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">siRNA: CTCF</td><td valign="top">Thermo Fisher</td><td valign="top">siRNA oligo</td><td valign="top">Silencer Select</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">DNA oligo pool</td><td valign="top">CustomArray</td><td valign="top"/><td valign="top">sgRNA synthesis</td></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">In-Fusion HD Cloning</td><td valign="top">Clontech</td><td valign="top">638909</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Polybrene</td><td valign="top">EMD Millipore</td><td valign="top">TR-1003-G</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">DAPI</td><td valign="top">Sigma</td><td valign="top">D9542-10MG</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Lonza nucleofector Kit</td><td valign="top">Lonza</td><td valign="top">VCA-1003</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Q5 High-Fidelity DNA Polymerase</td><td valign="top">New England Biolabs</td><td valign="top">M0491L</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">CloneAMP HiFI PCR Premix</td><td valign="top">Clontech</td><td valign="top">639298</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Quick-DNA Miniprep Kit</td><td valign="top">Zymo</td><td valign="top">D3025</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">NEB Next UltraII DNA Library Prep Kit</td><td valign="top">NEB</td><td valign="top">E7645S</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">ZymoPURE II Plasmid Midiprep Kit</td><td valign="top">Zymo</td><td valign="top">D4201</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">TRIzol</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">15596026</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">High-Capacity cDNA Reverse Transcription Kit</td><td valign="top">Applied Biosystems</td><td valign="top">4374966</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">FAST SYBR Green Master Mix</td><td valign="top">Applied Biosystems</td><td valign="top">4385612</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pSpCas9(BB)−2A-GFP</td><td valign="top">Addgene</td><td valign="top">48138</td><td valign="top">PX458</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">TOPO-cloning vector</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">450641</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">Lenti-Cas9-Blast plasmid</td><td valign="top">Addgene</td><td valign="top">83480</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">Lenti-Guide-Puro plasmid</td><td valign="top">Addgene</td><td valign="top">52963</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">LRCherry2.1</td><td valign="top">Addgene</td><td valign="top">108099</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">LRNeo-2.1 vector</td><td valign="top">This study</td><td valign="top"/><td valign="top">Subclone from LRCherry2.1</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">Lenti-Guide-Puro-IRES-CFP plasmid</td><td valign="top">This study</td><td valign="top"/><td valign="top">Subclone from Lenti-Guide-Puro</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">HOXA9-MEIS1 OE</td><td valign="top">This study</td><td valign="top"/><td valign="top">Subclone from mouse cDNA</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">mHoxa9 OE</td><td valign="top">This study</td><td valign="top"/><td valign="top">Subclone from mouse cDNA</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Puromycin</td><td valign="top">InvivoGen</td><td valign="top">ant-pr-1</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Neomycin</td><td valign="top">GeminiBio</td><td valign="top">400–121P</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Blasticidine</td><td valign="top">Gibco</td><td valign="top">A1113903</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">SGC0946</td><td valign="top">MedChemExpress</td><td valign="top">HY-15650</td><td valign="top">DOT1L inhibitor</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Fluorescene Imaging</td><td valign="top">Perkin Elmer</td><td valign="top"/><td valign="top">Columbus Image Data Storage and Analysis system</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">MAGeCK</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/">https://sourceforge.net/</ext-link> p/mageck/wiki/Home/</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/25476604">25476604</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">MACS2</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://github.com/macs3-project/MACS">https://github.com/macs3-project/MACS</ext-link>; <xref ref-type="bibr" rid="bib82">Zhang et al., 2008</xref></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Cutadapt</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://cutadapt.readthedocs.io/en/v1.9.1/installation.html">https://cutadapt.readthedocs.io/en/v1.9.1/installation.html</ext-link></td><td valign="top">1.9.1</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">BWA</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://github.com/lh3/bwa/releases">https://github.com/lh3/bwa/releases</ext-link>; <xref ref-type="bibr" rid="bib37">Li, 2013</xref></td><td valign="top">0.7.17-r1188</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Samtools</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.htslib.org/">http://www.htslib.org/</ext-link></td><td valign="top">Htslib 1.6</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">IGV</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/software/igv/">http://software.broadinstitute.org/software/igv/</ext-link></td><td valign="top">IGV2.3.97</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">ChIPseeker</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://guangchuangyu.github.io/software/ChIPseeker/">https://guangchuangyu.github.io/software/ChIPseeker/</ext-link>; <xref ref-type="bibr" rid="bib80">Yu et al., 2015</xref></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">TRANSFAC</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://gene-regulation.com/pub/databases.html">http://gene-regulation.com/pub/databases.html</ext-link></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">JASPAR</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://jaspar.genereg.net/">http://jaspar.genereg.net/</ext-link></td><td valign="top">8th release (<bold>2020</bold>)</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">FIMO</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://meme-suite.org/doc/fimo.html">http://meme-suite.org/doc/fimo.html</ext-link></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">DESeq2</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/DESeq2.html">https://bioconductor.org/packages/release/bioc/html/DESeq2.html</ext-link></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">GraphPad Prism</td><td valign="top">version 8.0</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Flowjo</td><td valign="top">version 10.0</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Bowtie</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://bowtie-bio.sourceforge.net/index.shtml">http://bowtie-bio.sourceforge.net/index.shtml</ext-link></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">BamCoverage</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://deeptools.readthedocs.io/en/develop/content/tools/bamCoverage.html">https://deeptools.readthedocs.io/en/develop/content/tools/bamCoverage.html</ext-link></td><td valign="top"/><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture</title><p>SEM cells (ACC-546, DSMZ), OCI-AML2 (ACC-99, DSMZ), Cas9-expressing OCI-AML3 (originally from ACC-582, a kind gift from Dr. Christopher Vakoc) and MOLM13 (ACC-554, DSMZ) were maintained in RPMI-1640 medium (Lonza) containing 10% fetal bovine serum (FBS) (HyClone), and 1% penicillin/streptomycin (Thermo Fisher Scientific) at 37°C, 5% CO<sub>2</sub> atmosphere and 95% humidity. Basal medium for culturing 293 T cells is DMEM (HyClone). All passages of cells used in this study were mycoplasma-free. Cell identity was confirmed by STR analysis.</p></sec><sec id="s4-2"><title>Vector construction</title><p>A pair of oligomers containing a 20 bp sgRNA (5’-<named-content content-type="sequence">AAAGACGAGTGATGCCATTT</named-content>-3’) sequence targeting the surrounding genomic segment of <italic>HOXA9</italic> stop codon was synthesized (Thermo Fisher Scientific) and cloned into the all-in-one vector, pSpCas9(BB)−2A-GFP (Addgene #48138) between <italic>BsmBI</italic> sites. Correct clones were screened and confirmed by Sanger sequencing with the U6-Forward sequencing primer (5’-<named-content content-type="sequence">GAGGGCCTATTTCCCATGAT</named-content>-3’). To construct a CHASE-knock-in donor vector delivering a <italic>P2A-mCherry</italic> DNA segment to the endogenous <italic>HOXA9</italic> locus, a two-step cloning protocol was used. The ~800 bp 5′ and 3’ homology arm (HA) flanking the endogenous sgRNA target was amplified from SEM cells. The 5’ HA PCR primer sequences are 5’-<named-content content-type="sequence">GGCCGATTCCTTCCACTTCT</named-content>-3’ and 5’-<named-content content-type="sequence">TCACTCGTCTTTTGCTCGGT</named-content>-3’, and the 3’ HA PCR primer sequences are 5’-<named-content content-type="sequence">ACCGAGCAAAAGACGAGTGA</named-content>-3’ and 5’-<named-content content-type="sequence">CACTGTTCGTCTGGTGCAAA</named-content>-3’. The <italic>P2A-mCherry</italic> DNA fragment was amplified from p16<sup>INK4A</sup>-P2A-mCherry knock-in donor vector (<xref ref-type="bibr" rid="bib83">Zhang et al., 2019</xref>) using a pair of primers containing overlapping sequences of 5’ HA or 3’ HA for in-fusion cloning (forward primer: 5’-<named-content content-type="sequence">AAGACCGAGCAAAAGACGAGGGATCCGGCGCAACAAACTT</named-content>-3’; reverse primer: 5’- <named-content content-type="sequence">AATAAGCCCAAATGGCATCACTTGTACAGCTCGTCCATGC</named-content>-3‘). The 5’ HA-P2A-mCherry-3’ HA in-fusion cloning product was further supplemented with 23 bp target sgRNA and PAM sequences at both 5’ and 3’ ends through PCR amplification using primers 5’-<named-content content-type="sequence">AAAGACGAGTGATGCCATTTGGGATGAGGCTGCGGGCGAC</named-content>-3’ and 5’-<named-content content-type="sequence">AAAGACGAGTGATGCCATTTGGGTATATATACAATAGACAAGACAGGAC</named-content>-3’. The cloning PCR reactions were performed using Q5 High-Fidelity DNA Polymerase (New England Biolabs # M0491L), and the cycling parameters were as follows for all cloning: 98°C for 30 s, followed by 98°C for 15 s, 72°C for 20 s, and 72°C for 30 s per kb for 40 cycles. The final PCR product was conducted into TOPO cloning vector (Thermo Fisher Scientific #450641). Sanger sequencing was performed to ensure that the knock-in DNA was cloned in-frame with the HAs. The Lenti-Cas9-Blast plasmid (Addgene #83480) and the Lenti-Guide-Puro plasmid (Addgene #52963) were purchased from Addgene. For candidate validation of CRISPR screen, sgRNA sequences against <italic>DOT1L</italic> (5’-<named-content content-type="sequence">TCAGCTTCGAGAGCATGCAG</named-content>-3’), <italic>ENL</italic> (5’-<named-content content-type="sequence">TCACCTGGACGGTGCACTGG</named-content>-3’), <italic>USF2</italic> (#2: 5’-<named-content content-type="sequence">AGAAGAGCCCAGCACAACGA</named-content>-3’, #3: 5’-<named-content content-type="sequence">TGTTTTCCGCAGTGGAGCGG</named-content>-3’, #4: 5’-<named-content content-type="sequence">CCGGGGATCTTACCTGGCGG</named-content>-3’, and #5: 5’-<named-content content-type="sequence">CAGCCACGACAAGGGACCCG</named-content>-3’) were cloned into an in-house-made Lenti-Guide-Puro-IRES-CFP vector. The sgRNA sequence against <italic>USF1</italic> (3#, 5’-<named-content content-type="sequence">CTATACTTACTTCCCCAGCA</named-content>-3’) was cloned into an in-house-made LRNeo-2.1 vector in which the mCherry-expressing cassette of LRCherry2.1 (Addgene #108099) was replaced by Neomycin. For competitive proliferation assay, sgRNAs against Luciferase (Luc)(5’-<named-content content-type="sequence">CCCGGCGCCATTCTATCCGC</named-content>-3’) and USF2 (#2, #3 and #5 as above) were cloned into mCherry-expressing LRCherry2.1 (Addgene #108099) vector.</p></sec><sec id="s4-3"><title>Generation of a <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter allele</title><p>SEM and OCI-AML2 were electroporated by using the Nucleofector-2b device (Lonza) with the V-kit and program X-001. For <italic>HOXA9<sup>P2A-mCherry</sup></italic> knock-in delivery, 2.5 μg of the donor plasmid and 2.5 μg of the CRISPR/Cas9-HOXA9-C-terminus-sgRNA all-in-one plasmid were used for 5 million SEM cells. Twenty-four hours after transfection, cells were sorted for the GFP fluorescent marker linked to Cas9 expression vector to enrich the transfected cell population. After the sorted cells recovered in culture for up to 3 weeks, a second sort was performed to select cells for successful knock-in by sorting for cells expressing the knock-in mCherry fluorescent marker. Two weeks later, a third sort was repeated based on the selection mCherry-expressing cells.</p></sec><sec id="s4-4"><title>Characterization of successful knock-in events by PCR and Sanger sequencing</title><p>DNA from single-cell-derived bacterial or cell colonies was extracted with a Quick-DNA Miniprep Kit (Zymo #D3025). Combinatorial primer sets designed to recognize the 5′ and 3′ knock-in boundaries were used with the following PCR cycling conditions: 98°C for two mins, followed by 40 cycles of 98°C for 30 s and 68°C for 60 s. The sequences for genotyping primers are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. After electrophoresis, the bands that were at the expected size were cut out, purified, and sequenced with two specific primers (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p></sec><sec id="s4-5"><title>CRISPR library construction and screening</title><p>A set of ~11,000 sgRNA oligos that target 1639 human transcription factors were designed for array-based oligonucleotide synthesis (CustomArray). Unique binding of each sgRNA was verified by sequence blast against the whole human genome. In the sgRNA pooled library, seven gRNAs against each of the 1639 human transcription factors were obtained from validated sgRNA libraries published previously (<xref ref-type="bibr" rid="bib75">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib14">Doench et al., 2016</xref>; <xref ref-type="bibr" rid="bib64">Sanjana et al., 2014</xref>; <xref ref-type="bibr" rid="bib49">Ma et al., 2015</xref>; <xref ref-type="bibr" rid="bib72">Tzelepis et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Hart et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Hart et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">Smith et al., 2008</xref>; <xref ref-type="bibr" rid="bib56">Park et al., 2017</xref>). The synthesized oligo pool was amplified by PCR and cloned into LentiGuide-Puro backbone (#52963) by in-fusion assembly (Clontech #638909). The <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter cell line was overexpressed with lentiviral Cas9 followed by infection of pooled sgRNA library at low M.O.I (~0.3). Infected cells were selected by blasticidine and puromycin and later sorted for mCherry<sup>High</sup> and mCherry<sup>Low</sup> populations between days 10–12. The sgRNA sequences were recovered by genomic PCR analysis and deep sequencing using MiSeq for single-end 150 bp read length (Illumina). The primer sequences used for cloning and sequencing are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. The sgRNA sequences are described in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. High-titer lentivirus stocks were generated in 293 T cells as previously described (<xref ref-type="bibr" rid="bib74">Vo et al., 2017</xref>).</p></sec><sec id="s4-6"><title>Data analysis of CRISPR screening</title><p>The raw FASTQ data were de-barcoded and mapped to the original reference sgRNA library. The differentially enriched sgRNAs were defined by comparing normalized counts between sorted cells in the top 10% and those in the bottom 10% of mCherry-expressing bulk populations. Two independent replicate screenings were performed with the <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter cell line stably expressing Cas9. Normalized counts for each sgRNA were extracted and used to identify differentially enriched sgRNA by DESeq2 (<xref ref-type="bibr" rid="bib42">Love et al., 2014</xref>). The combined analysis of seven sgRNAs against each human transcription factor was conducted by using the MAGeCK algorithm (<xref ref-type="bibr" rid="bib40">Li et al., 2014</xref>). Detailed screening results were included in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p></sec><sec id="s4-7"><title>Fluorescence imaging and analysis</title><p>0.1% of DMSO (vehicle control) or 10 doses of SGC0946 with a half log scale (0.3 nM-10 μM) were first dispensed into 384-well plates (in quadruplicate, four wells per dose). Suspension-cultured SEM cells were immediately plated into the 384-well plate (20,000 cells / well). Six days after drug treatment, the cells were fixed with 4% paraformaldehyde for 10 mins at room temperature, followed by Hoechst staining for 15 mins at room temperature. Fluorescence images (Hoechst and mCherry) were taken by a CellVoyager 8000 high content imager (Yokogawa). The acquired images were processed by using the Columbus Image Data Storage and Analysis system (Perkin Elmer) to count the number of positive cells and measure fluorescent intensity. To determine the changes of mCherry intensity in SEM expressing <italic>HOXA9<sup>P2A-mCherry</sup></italic>, we measured average mCherry intensity of four fields per well and normalized to vehicle (0.1% DMSO) treated control. Wild-type SEMs with no fluorescence were included as negative controls.</p></sec><sec id="s4-8"><title>Cut and Run assay</title><p>Cut and Run assay was conducted following the protocol described previously (<xref ref-type="bibr" rid="bib67">Skene and Henikoff, 2017</xref>). In brief, three million cells were collected for each sample. The USF2 antibody (NBP1-92649, Novus) was used at a 1:100 dilution. Library construction was performed using the NEBNext UltraII DNA Library Prep Kit from NEB (E7645S). Indexed samples were run using the Illumina Next-seq 300-cycle kit. Cut and Run raw reads were mapped to genome hg19. by bowtie 2.3.4 with default parameter. The mapping file were converse to. bw file by bamCoverage (<xref ref-type="bibr" rid="bib36">Langmead and Salzberg, 2012</xref>; <xref ref-type="bibr" rid="bib60">Ramírez et al., 2014</xref>).</p></sec><sec id="s4-9"><title>Flow cytometry</title><p>Suspension-cultured SEM and OCI-AML2 cells were collected by centrifugation at 800X<italic>g</italic>, filtered through a 70 µm filter, and analyzed for mCherry on a BD FACS Aria III flow cytometer with a negative control. The 4,6-diamidino-2-phenylindole (DAPI) staining was conducted prior to sorting to exclude dead cells.</p></sec><sec id="s4-10"><title>Inhibitor treatment</title><p>SEM and OCI-AML2 cells were seeded at a density of 1 × 10<sup>5</sup> cells/mL in medium supplemented with DMSO vehicle or different doses (from 0.5 µM to 15 μM) of the DOT1L inhibitor SGC0946 (MedChemExpress #HY-15650). Medium was replaced every three days, and fresh inhibitor was added. At day-6 post-treatment, cells were collected for flow cytometry analysis and RNA extraction.</p></sec><sec id="s4-11"><title>Fluorescence in situ hybridization</title><p>An ~800 bp purified <italic>P2A-mCherry</italic> DNA fragment was labeled with a red-dUTP (AF594, Molecular Probes) by nick translation, and a <italic>HOXA9</italic> BAC clone (CH17-412I12/7p15.2) was labeled with a green-dUTP (AF488, Molecular Probes). Both of labeled probes were combined with sheared human DNA and independently hybridized to fix the interphase and metaphase nuclei derived from each sample by using routine cytogenetic methods in a solution containing 50% formamide, 10% dextran sulfate, and 2XSSC. The cells were then stained with DAPI and analyzed.</p></sec><sec id="s4-12"><title>Quantitative real-time PCR</title><p>Total RNA was collected by using TRIzol (Thermo Fisher Scientific #15596026) or <ext-link ext-link-type="uri" xlink:href="https://www.zymoresearch.com/collections/direct-zol-rna-kits/products/direct-zol-rna-miniprep-kits">Direct-zol RNA Miniprep</ext-link> Kit (Zymo #R2052). Reverse transcription was performed by using a High-Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems #4374966). Real-time PCR was performed by using FAST SYBR Green Master Mix (Applied Biosystems #4385612) in accordance with the manufacturer’s instructions. Relative gene expression was determined by using the ΔΔ-CT method (<xref ref-type="bibr" rid="bib65">Schmittgen and Livak, 2008</xref>). All Q-PCR primers used in this study are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-13"><title>Competitive proliferation assay</title><p>For evaluating the impact of USF2 sgRNAs on leukemia expansion, cell cultures were lentivirally transduced with individual USF2 sgRNAs in mCherry expressing vector, followed by measurement of the mCherry-positive percentage at various days post-infection using flow cytometry. The rate of mCherry-positive percentage was normalized to that of Day 3 and declined over time, which was used to infer a defect in cell accumulation conferred by a given sgRNA targeting USF2 relative to the uninfected cells in the same culture.</p></sec><sec id="s4-14"><title>Immunoblotting</title><p>Cells lysate was prepared by using RIPA buffer followed with SDS-PAGE (Thermo Fisher Scientific) and transferred to a PVDF membrane according to the manufacturer’s protocols (Bio-Rad) at constant 100 V for 1 hr. After blocking incubation with 5% non-fat milk in TBS-T (10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween-20) for 1 hr at room temperature, the membrane was incubated with antibodies against GAPDH (Thermo Fisher Scientific, AM4300, 1:10,000), MYC (Cell Signaling Technology, #9402, 1:1,000), USF2 (Novus, NBP1-92649, 1:2,000), USF1 (Proteintech, 22327–1-AP, 1:2,000), GAPDH (Thermo Fisher Scientific, AM4300, 1:10,000), Vinculin (Proteintech, 26520–1-AP, 1:2,000) and CTCF (abcam, ab70303, 1:1,000) at 4°C for 12 hr with gentle shaking. Membranes were washed three times for 30 min and incubated with a 1:2000 dilution of horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies for 2 hr at room temperature. Blots were washed with TBS-T three times for 30 min and developed with the ECL system (Amersham Biosciences) according to the manufacturer’s protocol.</p></sec><sec id="s4-15"><title>Statistics</title><p>All values are shown as the mean ± SEM. Statistical analyses were performed with GraphPad Prism software, version 8.0. p-Values were calculated by performing a two-tailed <italic>t</italic>-test.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We gratefully acknowledge the staffs of the Hartwell Sequencing, Cytogenetics, Flow Cytometry and Cell Sorting Shared Resource facility within the Comprehensive Cancer Center of St. Jude Children’s Research Hospital. We thank Li and Lu laboratory members for critical comments and discussion. We thank Dr. Cherise Guess for helping with scientific editing.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Software, Formal analysis, Validation, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Validation, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Methodology</p></fn><fn fn-type="con" id="con9"><p>Methodology</p></fn><fn fn-type="con" id="con10"><p>Software, Formal analysis</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Supervision, Methodology</p></fn><fn fn-type="con" id="con13"><p>Methodology</p></fn><fn fn-type="con" id="con14"><p>Software</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Oligo information used in this paper.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57858-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Raw count information related to CRISPR screen.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-57858-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-57858-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All plasmids created in this study will be deposited to Addgene. Raw data collected from Cut&amp;Run were deposited at NCBI GEO (GSE140664). Raw data collected from CRISPR screening were included in Supplementary File 2. Publicly available dataset used in this study were cited accordingly including Figures 1E and S5D: GSE120781; Figure 1-supplement 1A-C: GSE13159; Figure 3-supplement 2C: GSE126619, GSE74812, GSE89485; Figure 3-supplement 3A: ENCODE (HCT116); Figure 5-supplement 3A-C: European Genome-phenome Archive (EGA) under accession number EGAS00001003266, EGAS00001000654, EGAS00001001952, EGAS00001001923, EGAS00001002217 and EGAS00001000447.</p><p>The following dataset was generated:</p><p><element-citation id="dataset12" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Functional Interrogation of HOXA9 Regulome in Leukemia via Endogenous Reporter-based CRISPR/Cas9 screen.</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140664">GSE140664</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Hyle</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wright</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Easton</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Acute deletion of CTCF disrupted enhancer-promoter regulation of MYC in human cancer cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120781">GSE120781</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Kohlmann</surname><given-names>A</given-names></name><name><surname>Kipps</surname><given-names>TJ</given-names></name><name><surname>Rassenti</surname><given-names>LZ</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Shurtleff</surname><given-names>SA</given-names></name><name><surname>Mills</surname><given-names>KI</given-names></name><name><surname>Gilkes</surname><given-names>AF</given-names></name><name><surname>Hofmann</surname><given-names>W-K</given-names></name><name><surname>Basso</surname><given-names>G</given-names></name><name><surname>Dell'orto</surname><given-names>MC</given-names></name><name><surname>Foà</surname><given-names>R</given-names></name><name><surname>Chiaretti</surname><given-names>S</given-names></name><name><surname>Vos</surname><given-names>JD</given-names></name><name><surname>Rauhut</surname><given-names>S</given-names></name><name><surname>Papenhausen</surname><given-names>PR</given-names></name><name><surname>Hernández</surname><given-names>JM</given-names></name><name><surname>Lumbreras</surname><given-names>E</given-names></name><name><surname>Yeoh</surname><given-names>AE</given-names></name><name><surname>Koay</surname><given-names>ES</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>W-M</given-names></name><name><surname>Williams</surname><given-names>PM</given-names></name><name><surname>Wieczorek</surname><given-names>L</given-names></name><name><surname>Haferlach</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><data-title>Microarray Innovations in LEukemia (MILE) study: Stage 1 data</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13159">GSE13159</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Hyle</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wright</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>easton</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Acute deletion of CTCF disrupted enhancer-promoter regulation of MYC in human cancer cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126619">GSE126619</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Kerry</surname><given-names>J</given-names></name><name><surname>Milne</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>MLL-rearranged acute lymphoblastic leukemias upregulate BCL-2 through H3K79 methylation and are highly sensitive to the BCL-2 specific antagonist ABT-199</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74812">GSE74812</pub-id></element-citation></p><p><element-citation id="dataset5" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>ER</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Therapeutic targeting MLL degradation pathways in MLL-rearranged leukemia</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89485">GSE89485</pub-id></element-citation></p><p><element-citation id="dataset6" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Churchman</surname><given-names>ML</given-names></name><name><surname>Roberts</surname><given-names>KG</given-names></name><name><surname>Moore</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Nakitandwe</surname><given-names>J</given-names></name><name><surname>Hagiwara</surname><given-names>K</given-names></name><name><surname>Pelletier</surname><given-names>S</given-names></name><name><surname>Gingras</surname><given-names>S</given-names></name><name><surname>Berns</surname><given-names>H</given-names></name><name><surname>Payne-Turner</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Iacobucci</surname><given-names>I</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Pounds</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Newman</surname><given-names>S</given-names></name><name><surname>Devidas</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Reshmi</surname><given-names>SC</given-names></name><name><surname>Gastier-Foster</surname><given-names>J</given-names></name><name><surname>Raetz</surname><given-names>EA</given-names></name><name><surname>Borowitz</surname><given-names>MJ</given-names></name><name><surname>Wood</surname><given-names>BL</given-names></name><name><surname>Carroll</surname><given-names>WL</given-names></name><name><surname>Zweidler-McKay</surname><given-names>PA</given-names></name><name><surname>Rabin</surname><given-names>KR</given-names></name><name><surname>Mattano</surname><given-names>LA</given-names></name><name><surname>Maloney</surname><given-names>KW</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Spinelli</surname><given-names>O</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Rowe</surname><given-names>JM</given-names></name><name><surname>Luger</surname><given-names>S</given-names></name><name><surname>Litzow</surname><given-names>MR</given-names></name><name><surname>Tallman</surname><given-names>MS</given-names></name><name><surname>Racevskis</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><name><surname>Kohlschmidt</surname><given-names>J</given-names></name><name><surname>Mrózek</surname><given-names>K</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><name><surname>Stock</surname><given-names>W</given-names></name><name><surname>Kornblau</surname><given-names>S</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Konopleva</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>Jeha</surname><given-names>S</given-names></name><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Paietta</surname><given-names>E</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Relling</surname><given-names>MV</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>ML</given-names></name><name><surname>Hunger</surname><given-names>SP</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>PAX5-driven Subtypes of B-cell Acute Lymphoblastic Leukemia</data-title><source>European Genome-phenome Archive</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ega/studies/EGAS00001003266?order=type&amp;sort=asc">EGAS00001003266</pub-id></element-citation></p><p><element-citation id="dataset7" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Churchman</surname><given-names>ML</given-names></name><name><surname>Roberts</surname><given-names>KG</given-names></name><name><surname>Moore</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Nakitandwe</surname><given-names>J</given-names></name><name><surname>Hagiwara</surname><given-names>K</given-names></name><name><surname>Pelletier</surname><given-names>S</given-names></name><name><surname>Gingras</surname><given-names>S</given-names></name><name><surname>Berns</surname><given-names>H</given-names></name><name><surname>Payne-Turner</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Iacobucci</surname><given-names>I</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Pounds</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Newman</surname><given-names>S</given-names></name><name><surname>Devidas</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Reshmi</surname><given-names>SC</given-names></name><name><surname>Gastier-Foster</surname><given-names>J</given-names></name><name><surname>Raetz</surname><given-names>EA</given-names></name><name><surname>Borowitz</surname><given-names>MJ</given-names></name><name><surname>Wood</surname><given-names>BL</given-names></name><name><surname>Carroll</surname><given-names>WL</given-names></name><name><surname>Zweidler-McKay</surname><given-names>PA</given-names></name><name><surname>Rabin</surname><given-names>KR</given-names></name><name><surname>Mattano</surname><given-names>LA</given-names></name><name><surname>Maloney</surname><given-names>KW</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Spinelli</surname><given-names>O</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Rowe</surname><given-names>JM</given-names></name><name><surname>Luger</surname><given-names>S</given-names></name><name><surname>Litzow</surname><given-names>MR</given-names></name><name><surname>Tallman</surname><given-names>MS</given-names></name><name><surname>Racevskis</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><name><surname>Kohlschmidt</surname><given-names>J</given-names></name><name><surname>Mrózek</surname><given-names>K</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><name><surname>Stock</surname><given-names>W</given-names></name><name><surname>Kornblau</surname><given-names>S</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Konopleva</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>Jeha</surname><given-names>S</given-names></name><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Paietta</surname><given-names>E</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Relling</surname><given-names>MV</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>ML</given-names></name><name><surname>Hunger</surname><given-names>SP</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>PAX5-driven Subtypes of B-cell Acute Lymphoblastic Leukemia</data-title><source>European Genome-phenome Archive</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ega/studies/EGAS00001000654">EGAS00001000654</pub-id></element-citation></p><p><element-citation id="dataset8" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Churchman</surname><given-names>ML</given-names></name><name><surname>Roberts</surname><given-names>KG</given-names></name><name><surname>Moore</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Nakitandwe</surname><given-names>J</given-names></name><name><surname>Hagiwara</surname><given-names>K</given-names></name><name><surname>Pelletier</surname><given-names>S</given-names></name><name><surname>Gingras</surname><given-names>S</given-names></name><name><surname>Berns</surname><given-names>H</given-names></name><name><surname>Payne-Turner</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Iacobucci</surname><given-names>I</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Pounds</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Newman</surname><given-names>S</given-names></name><name><surname>Devidas</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Reshmi</surname><given-names>SC</given-names></name><name><surname>Gastier-Foster</surname><given-names>J</given-names></name><name><surname>Raetz</surname><given-names>EA</given-names></name><name><surname>Borowitz</surname><given-names>MJ</given-names></name><name><surname>Wood</surname><given-names>BL</given-names></name><name><surname>Carroll</surname><given-names>WL</given-names></name><name><surname>Zweidler-McKay</surname><given-names>PA</given-names></name><name><surname>Rabin</surname><given-names>KR</given-names></name><name><surname>Mattano</surname><given-names>LA</given-names></name><name><surname>Maloney</surname><given-names>KW</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Spinelli</surname><given-names>O</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Rowe</surname><given-names>JM</given-names></name><name><surname>Luger</surname><given-names>S</given-names></name><name><surname>Litzow</surname><given-names>MR</given-names></name><name><surname>Tallman</surname><given-names>MS</given-names></name><name><surname>Racevskis</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><name><surname>Kohlschmidt</surname><given-names>J</given-names></name><name><surname>Mrózek</surname><given-names>K</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><name><surname>Stock</surname><given-names>W</given-names></name><name><surname>Kornblau</surname><given-names>S</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Konopleva</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>Jeha</surname><given-names>S</given-names></name><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Paietta</surname><given-names>E</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Relling</surname><given-names>MV</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>ML</given-names></name><name><surname>Hunger</surname><given-names>SP</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>PAX5-driven Subtypes of B-cell Acute Lymphoblastic Leukemia</data-title><source>European Genome-phenome Archive</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ega/studies/EGAS00001001952">EGAS00001001952</pub-id></element-citation></p><p><element-citation id="dataset9" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Churchman</surname><given-names>ML</given-names></name><name><surname>Roberts</surname><given-names>KG</given-names></name><name><surname>Moore</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Nakitandwe</surname><given-names>J</given-names></name><name><surname>Hagiwara</surname><given-names>K</given-names></name><name><surname>Pelletier</surname><given-names>S</given-names></name><name><surname>Gingras</surname><given-names>S</given-names></name><name><surname>Berns</surname><given-names>H</given-names></name><name><surname>Payne-Turner</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Iacobucci</surname><given-names>I</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Pounds</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Newman</surname><given-names>S</given-names></name><name><surname>Devidas</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Reshmi</surname><given-names>SC</given-names></name><name><surname>Gastier-Foster</surname><given-names>J</given-names></name><name><surname>Raetz</surname><given-names>EA</given-names></name><name><surname>Borowitz</surname><given-names>MJ</given-names></name><name><surname>Wood</surname><given-names>BL</given-names></name><name><surname>Carroll</surname><given-names>WL</given-names></name><name><surname>Zweidler-McKay</surname><given-names>PA</given-names></name><name><surname>Rabin</surname><given-names>KR</given-names></name><name><surname>Mattano</surname><given-names>LA</given-names></name><name><surname>Maloney</surname><given-names>KW</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Spinelli</surname><given-names>O</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Rowe</surname><given-names>JM</given-names></name><name><surname>Luger</surname><given-names>S</given-names></name><name><surname>Litzow</surname><given-names>MR</given-names></name><name><surname>Tallman</surname><given-names>MS</given-names></name><name><surname>Racevskis</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><name><surname>Kohlschmidt</surname><given-names>J</given-names></name><name><surname>Mrózek</surname><given-names>K</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><name><surname>Stock</surname><given-names>W</given-names></name><name><surname>Kornblau</surname><given-names>S</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Konopleva</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>Jeha</surname><given-names>S</given-names></name><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Paietta</surname><given-names>E</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Relling</surname><given-names>MV</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>ML</given-names></name><name><surname>Hunger</surname><given-names>SP</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>PAX5-driven Subtypes of B-cell Acute Lymphoblastic Leukemia</data-title><source>European Genome-phenome Archive</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ega/studies/EGAS00001001923">EGAS00001001923</pub-id></element-citation></p><p><element-citation id="dataset10" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Churchman</surname><given-names>ML</given-names></name><name><surname>Roberts</surname><given-names>KG</given-names></name><name><surname>Moore</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Nakitandwe</surname><given-names>J</given-names></name><name><surname>Hagiwara</surname><given-names>K</given-names></name><name><surname>Pelletier</surname><given-names>S</given-names></name><name><surname>Gingras</surname><given-names>S</given-names></name><name><surname>Berns</surname><given-names>H</given-names></name><name><surname>Payne-Turner</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Iacobucci</surname><given-names>I</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Pounds</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Newman</surname><given-names>S</given-names></name><name><surname>Devidas</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Reshmi</surname><given-names>SC</given-names></name><name><surname>Gastier-Foster</surname><given-names>J</given-names></name><name><surname>Raetz</surname><given-names>EA</given-names></name><name><surname>Borowitz</surname><given-names>MJ</given-names></name><name><surname>Wood</surname><given-names>BL</given-names></name><name><surname>Carroll</surname><given-names>WL</given-names></name><name><surname>Zweidler-McKay</surname><given-names>PA</given-names></name><name><surname>Rabin</surname><given-names>KR</given-names></name><name><surname>Mattano</surname><given-names>LA</given-names></name><name><surname>Maloney</surname><given-names>KW</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Spinelli</surname><given-names>O</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Rowe</surname><given-names>JM</given-names></name><name><surname>Luger</surname><given-names>S</given-names></name><name><surname>Litzow</surname><given-names>MR</given-names></name><name><surname>Tallman</surname><given-names>MS</given-names></name><name><surname>Racevskis</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><name><surname>Kohlschmidt</surname><given-names>J</given-names></name><name><surname>Mrózek</surname><given-names>K</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><name><surname>Stock</surname><given-names>W</given-names></name><name><surname>Kornblau</surname><given-names>S</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Konopleva</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>Jeha</surname><given-names>S</given-names></name><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Paietta</surname><given-names>E</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Relling</surname><given-names>MV</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>ML</given-names></name><name><surname>Hunger</surname><given-names>SP</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>PAX5-driven Subtypes of B-cell Acute Lymphoblastic Leukemia</data-title><source>European Genome-phenome Archive</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ega/studies/EGAS00001002217">EGAS00001002217</pub-id></element-citation></p><p><element-citation id="dataset11" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Churchman</surname><given-names>ML</given-names></name><name><surname>Roberts</surname><given-names>KG</given-names></name><name><surname>Moore</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Nakitandwe</surname><given-names>J</given-names></name><name><surname>Hagiwara</surname><given-names>K</given-names></name><name><surname>Pelletier</surname><given-names>S</given-names></name><name><surname>Gingras</surname><given-names>S</given-names></name><name><surname>Berns</surname><given-names>H</given-names></name><name><surname>Payne-Turner</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Iacobucci</surname><given-names>I</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Pounds</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Newman</surname><given-names>S</given-names></name><name><surname>Devidas</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Reshmi</surname><given-names>SC</given-names></name><name><surname>Gastier-Foster</surname><given-names>J</given-names></name><name><surname>Raetz</surname><given-names>EA</given-names></name><name><surname>Borowitz</surname><given-names>MJ</given-names></name><name><surname>Wood</surname><given-names>BL</given-names></name><name><surname>Carroll</surname><given-names>WL</given-names></name><name><surname>Zweidler-McKay</surname><given-names>PA</given-names></name><name><surname>Rabin</surname><given-names>KR</given-names></name><name><surname>Mattano</surname><given-names>LA</given-names></name><name><surname>Maloney</surname><given-names>KW</given-names></name><name><surname>Rambaldi</surname><given-names>A</given-names></name><name><surname>Spinelli</surname><given-names>O</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Rowe</surname><given-names>JM</given-names></name><name><surname>Luger</surname><given-names>S</given-names></name><name><surname>Litzow</surname><given-names>MR</given-names></name><name><surname>Tallman</surname><given-names>MS</given-names></name><name><surname>Racevskis</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><name><surname>Kohlschmidt</surname><given-names>J</given-names></name><name><surname>Mrózek</surname><given-names>K</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><name><surname>Stock</surname><given-names>W</given-names></name><name><surname>Kornblau</surname><given-names>S</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Konopleva</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>Jeha</surname><given-names>S</given-names></name><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Paietta</surname><given-names>E</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Relling</surname><given-names>MV</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>ML</given-names></name><name><surname>Hunger</surname><given-names>SP</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>PAX5-driven Subtypes of B-cell Acute Lymphoblastic Leukemia</data-title><source>European Genome-phenome Archive</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ega/studies/EGAS00001000447">EGAS00001000447</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alharbi</surname> <given-names>RA</given-names></name><name><surname>Pettengell</surname> <given-names>R</given-names></name><name><surname>Pandha</surname> <given-names>HS</given-names></name><name><surname>Morgan</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The role of HOX genes in normal hematopoiesis and acute leukemia</article-title><source>Leukemia</source><volume>27</volume><fpage>1000</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1038/leu.2012.356</pub-id><pub-id pub-id-type="pmid">23212154</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au</surname> <given-names>YZ</given-names></name><name><surname>Gu</surname> <given-names>M</given-names></name><name><surname>De Braekeleer</surname> <given-names>E</given-names></name><name><surname>Gozdecka</surname> <given-names>M</given-names></name><name><surname>Aspris</surname> <given-names>D</given-names></name><name><surname>Tarumoto</surname> <given-names>Y</given-names></name><name><surname>Cooper</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Ong</surname> <given-names>SH</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Tzelepis</surname> <given-names>K</given-names></name><name><surname>Huntly</surname> <given-names>BJP</given-names></name><name><surname>Vassiliou</surname> <given-names>G</given-names></name><name><surname>Yusa</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements</article-title><source>Leukemia</source><volume>374</volume><elocation-id>1001-z</elocation-id><pub-id pub-id-type="doi">10.1038/s41375-020-1001-z</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayton</surname> <given-names>PM</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9</article-title><source>Genes &amp; Development</source><volume>17</volume><fpage>2298</fpage><lpage>2307</lpage><pub-id pub-id-type="doi">10.1101/gad.1111603</pub-id><pub-id pub-id-type="pmid">12952893</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baccelli</surname> <given-names>I</given-names></name><name><surname>Gareau</surname> <given-names>Y</given-names></name><name><surname>Lehnertz</surname> <given-names>B</given-names></name><name><surname>Gingras</surname> <given-names>S</given-names></name><name><surname>Spinella</surname> <given-names>J-F</given-names></name><name><surname>Corneau</surname> <given-names>S</given-names></name><name><surname>Mayotte</surname> <given-names>N</given-names></name><name><surname>Girard</surname> <given-names>S</given-names></name><name><surname>Frechette</surname> <given-names>M</given-names></name><name><surname>Blouin-Chagnon</surname> <given-names>V</given-names></name><name><surname>Leveillé</surname> <given-names>K</given-names></name><name><surname>Boivin</surname> <given-names>I</given-names></name><name><surname>MacRae</surname> <given-names>T</given-names></name><name><surname>Krosl</surname> <given-names>J</given-names></name><name><surname>Thiollier</surname> <given-names>C</given-names></name><name><surname>Lavallée</surname> <given-names>V-P</given-names></name><name><surname>Kanshin</surname> <given-names>E</given-names></name><name><surname>Bertomeu</surname> <given-names>T</given-names></name><name><surname>Coulombe-Huntington</surname> <given-names>J</given-names></name><name><surname>St-Denis</surname> <given-names>C</given-names></name><name><surname>Bordeleau</surname> <given-names>M-E</given-names></name><name><surname>Boucher</surname> <given-names>G</given-names></name><name><surname>Roux</surname> <given-names>PP</given-names></name><name><surname>Lemieux</surname> <given-names>S</given-names></name><name><surname>Tyers</surname> <given-names>M</given-names></name><name><surname>Thibault</surname> <given-names>P</given-names></name><name><surname>Hébert</surname> <given-names>J</given-names></name><name><surname>Marinier</surname> <given-names>A</given-names></name><name><surname>Sauvageau</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia</article-title><source>Cancer Cell</source><volume>36</volume><fpage>84</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.06.003</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname> <given-names>C</given-names></name><name><surname>Buhl</surname> <given-names>S</given-names></name><name><surname>Mueller</surname> <given-names>D</given-names></name><name><surname>García-Cuéllar</surname> <given-names>MP</given-names></name><name><surname>Maethner</surname> <given-names>E</given-names></name><name><surname>Slany</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Leukemogenic transformation by HOXA cluster genes</article-title><source>Blood</source><volume>115</volume><fpage>2910</fpage><lpage>2918</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-04-216606</pub-id><pub-id pub-id-type="pmid">20130239</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>CW</given-names></name><name><surname>Koche</surname> <given-names>RP</given-names></name><name><surname>Sinha</surname> <given-names>AU</given-names></name><name><surname>Deshpande</surname> <given-names>AJ</given-names></name><name><surname>Zhu</surname> <given-names>N</given-names></name><name><surname>Eng</surname> <given-names>R</given-names></name><name><surname>Doench</surname> <given-names>JG</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Chu</surname> <given-names>SH</given-names></name><name><surname>Qi</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Delaney</surname> <given-names>C</given-names></name><name><surname>Bernt</surname> <given-names>KM</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia</article-title><source>Nature Medicine</source><volume>21</volume><fpage>335</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/nm.3832</pub-id><pub-id pub-id-type="pmid">25822366</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>Y</given-names></name><name><surname>Ma</surname> <given-names>Z</given-names></name><name><surname>Kim</surname> <given-names>BH</given-names></name><name><surname>Wu</surname> <given-names>W</given-names></name><name><surname>Cayting</surname> <given-names>P</given-names></name><name><surname>Boyle</surname> <given-names>AP</given-names></name><name><surname>Sundaram</surname> <given-names>V</given-names></name><name><surname>Xing</surname> <given-names>X</given-names></name><name><surname>Dogan</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Euskirchen</surname> <given-names>G</given-names></name><name><surname>Lin</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Visel</surname> <given-names>A</given-names></name><name><surname>Kawli</surname> <given-names>T</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Patacsil</surname> <given-names>D</given-names></name><name><surname>Keller</surname> <given-names>CA</given-names></name><name><surname>Giardine</surname> <given-names>B</given-names></name><name><surname>Kundaje</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Pennacchio</surname> <given-names>LA</given-names></name><name><surname>Weng</surname> <given-names>Z</given-names></name><name><surname>Hardison</surname> <given-names>RC</given-names></name><name><surname>Snyder</surname> <given-names>MP</given-names></name><collab>mouse ENCODE Consortium</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Principles of regulatory information conservation between mouse and human</article-title><source>Nature</source><volume>515</volume><fpage>371</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/nature13985</pub-id><pub-id pub-id-type="pmid">25409826</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Miao</surname> <given-names>H</given-names></name><name><surname>Bronstein</surname> <given-names>J</given-names></name><name><surname>Nawer</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>T</given-names></name><name><surname>Figueroa</surname> <given-names>M</given-names></name><name><surname>Muntean</surname> <given-names>AG</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis</article-title><source>PNAS</source><volume>111</volume><fpage>9899</fpage><lpage>9904</lpage><pub-id pub-id-type="doi">10.1073/pnas.1402238111</pub-id><pub-id pub-id-type="pmid">24958854</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname> <given-names>CT</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets</article-title><source>Oncogene</source><volume>35</volume><fpage>1090</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.174</pub-id><pub-id pub-id-type="pmid">26028034</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname> <given-names>CT</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Deregulation of the HOXA9/MEIS1 Axis in acute leukemia</article-title><source>Current Opinion in Hematology</source><volume>23</volume><fpage>354</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1097/MOH.0000000000000245</pub-id><pub-id pub-id-type="pmid">27258906</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daigle</surname> <given-names>SR</given-names></name><name><surname>Olhava</surname> <given-names>EJ</given-names></name><name><surname>Therkelsen</surname> <given-names>CA</given-names></name><name><surname>Majer</surname> <given-names>CR</given-names></name><name><surname>Sneeringer</surname> <given-names>CJ</given-names></name><name><surname>Song</surname> <given-names>J</given-names></name><name><surname>Johnston</surname> <given-names>LD</given-names></name><name><surname>Scott</surname> <given-names>MP</given-names></name><name><surname>Smith</surname> <given-names>JJ</given-names></name><name><surname>Xiao</surname> <given-names>Y</given-names></name><name><surname>Jin</surname> <given-names>L</given-names></name><name><surname>Kuntz</surname> <given-names>KW</given-names></name><name><surname>Chesworth</surname> <given-names>R</given-names></name><name><surname>Moyer</surname> <given-names>MP</given-names></name><name><surname>Bernt</surname> <given-names>KM</given-names></name><name><surname>Tseng</surname> <given-names>JC</given-names></name><name><surname>Kung</surname> <given-names>AL</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name><name><surname>Copeland</surname> <given-names>RA</given-names></name><name><surname>Richon</surname> <given-names>VM</given-names></name><name><surname>Pollock</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor</article-title><source>Cancer Cell</source><volume>20</volume><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.06.009</pub-id><pub-id pub-id-type="pmid">21741596</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bock</surname> <given-names>CE</given-names></name><name><surname>Demeyer</surname> <given-names>S</given-names></name><name><surname>Degryse</surname> <given-names>S</given-names></name><name><surname>Verbeke</surname> <given-names>D</given-names></name><name><surname>Sweron</surname> <given-names>B</given-names></name><name><surname>Gielen</surname> <given-names>O</given-names></name><name><surname>Vandepoel</surname> <given-names>R</given-names></name><name><surname>Vicente</surname> <given-names>C</given-names></name><name><surname>Vanden Bempt</surname> <given-names>M</given-names></name><name><surname>Dagklis</surname> <given-names>A</given-names></name><name><surname>Geerdens</surname> <given-names>E</given-names></name><name><surname>Bornschein</surname> <given-names>S</given-names></name><name><surname>Gijsbers</surname> <given-names>R</given-names></name><name><surname>Soulier</surname> <given-names>J</given-names></name><name><surname>Meijerink</surname> <given-names>JP</given-names></name><name><surname>Heinäniemi</surname> <given-names>M</given-names></name><name><surname>Teppo</surname> <given-names>S</given-names></name><name><surname>Bouvy-Liivrand</surname> <given-names>M</given-names></name><name><surname>Lohi</surname> <given-names>O</given-names></name><name><surname>Radaelli</surname> <given-names>E</given-names></name><name><surname>Cools</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>HOXA9 cooperates with activated JAK/STAT signaling to drive leukemia development</article-title><source>Cancer Discovery</source><volume>8</volume><fpage>616</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0583</pub-id><pub-id pub-id-type="pmid">29496663</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Braekeleer</surname> <given-names>E</given-names></name><name><surname>Douet-Guilbert</surname> <given-names>N</given-names></name><name><surname>Basinko</surname> <given-names>A</given-names></name><name><surname>Le Bris</surname> <given-names>MJ</given-names></name><name><surname>Morel</surname> <given-names>F</given-names></name><name><surname>De Braekeleer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title><italic>Hox</italic> gene dysregulation in acute myeloid leukemia</article-title><source>Future Oncology</source><volume>10</volume><fpage>475</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.2217/fon.13.195</pub-id><pub-id pub-id-type="pmid">24559452</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doench</surname> <given-names>JG</given-names></name><name><surname>Fusi</surname> <given-names>N</given-names></name><name><surname>Sullender</surname> <given-names>M</given-names></name><name><surname>Hegde</surname> <given-names>M</given-names></name><name><surname>Vaimberg</surname> <given-names>EW</given-names></name><name><surname>Donovan</surname> <given-names>KF</given-names></name><name><surname>Smith</surname> <given-names>I</given-names></name><name><surname>Tothova</surname> <given-names>Z</given-names></name><name><surname>Wilen</surname> <given-names>C</given-names></name><name><surname>Orchard</surname> <given-names>R</given-names></name><name><surname>Virgin</surname> <given-names>HW</given-names></name><name><surname>Listgarten</surname> <given-names>J</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/nbt.3437</pub-id><pub-id pub-id-type="pmid">26780180</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ENCODE Project Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>An integrated encyclopedia of DNA elements in the human genome</article-title><source>Nature</source><volume>489</volume><fpage>57</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/nature11247</pub-id><pub-id pub-id-type="pmid">22955616</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghasemi</surname> <given-names>R</given-names></name><name><surname>Struthers</surname> <given-names>H</given-names></name><name><surname>Wilson</surname> <given-names>ER</given-names></name><name><surname>Spencer</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Contribution of CTCF binding to transcriptional activity at The HOXA locus in NPM1-mutant AML cells</article-title><source>Leukemia</source><volume>29</volume><elocation-id>0856-3</elocation-id><pub-id pub-id-type="doi">10.1038/s41375-020-0856-3</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godfrey</surname> <given-names>L</given-names></name><name><surname>Kerry</surname> <given-names>J</given-names></name><name><surname>Thorne</surname> <given-names>R</given-names></name><name><surname>Repapi</surname> <given-names>E</given-names></name><name><surname>Davies</surname> <given-names>JO</given-names></name><name><surname>Tapia</surname> <given-names>M</given-names></name><name><surname>Ballabio</surname> <given-names>E</given-names></name><name><surname>Hughes</surname> <given-names>JR</given-names></name><name><surname>Geng</surname> <given-names>H</given-names></name><name><surname>Konopleva</surname> <given-names>M</given-names></name><name><surname>Milne</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation</article-title><source>Experimental Hematology</source><volume>47</volume><fpage>64</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2016.11.003</pub-id><pub-id pub-id-type="pmid">27856324</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godwin</surname> <given-names>AR</given-names></name><name><surname>Stadler</surname> <given-names>HS</given-names></name><name><surname>Nakamura</surname> <given-names>K</given-names></name><name><surname>Capecchi</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Detection of targeted GFP-Hox gene fusions during mouse embryogenesis</article-title><source>PNAS</source><volume>95</volume><fpage>13042</fpage><lpage>13047</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.22.13042</pub-id><pub-id pub-id-type="pmid">9789037</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Slonim</surname> <given-names>DK</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Huard</surname> <given-names>C</given-names></name><name><surname>Gaasenbeek</surname> <given-names>M</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name><name><surname>Coller</surname> <given-names>H</given-names></name><name><surname>Loh</surname> <given-names>ML</given-names></name><name><surname>Downing</surname> <given-names>JR</given-names></name><name><surname>Caligiuri</surname> <given-names>MA</given-names></name><name><surname>Bloomfield</surname> <given-names>CD</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Molecular classification of Cancer: class discovery and class prediction by gene expression monitoring</article-title><source>Science</source><volume>286</volume><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1126/science.286.5439.531</pub-id><pub-id pub-id-type="pmid">10521349</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gough</surname> <given-names>SM</given-names></name><name><surname>Slape</surname> <given-names>CI</given-names></name><name><surname>Aplan</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights</article-title><source>Blood</source><volume>118</volume><fpage>6247</fpage><lpage>6257</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-07-328880</pub-id><pub-id pub-id-type="pmid">21948299</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groenen</surname> <given-names>PM</given-names></name><name><surname>Garcia</surname> <given-names>E</given-names></name><name><surname>Debeer</surname> <given-names>P</given-names></name><name><surname>Devriendt</surname> <given-names>K</given-names></name><name><surname>Fryns</surname> <given-names>JP</given-names></name><name><surname>Van de Ven</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Structure, sequence, and chromosome 19 localization of human USF2 and its rearrangement in a patient with multicystic renal dysplasia</article-title><source>Genomics</source><volume>38</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1006/geno.1996.0609</pub-id><pub-id pub-id-type="pmid">8954795</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>Z</given-names></name><name><surname>Churchman</surname> <given-names>ML</given-names></name><name><surname>Roberts</surname> <given-names>KG</given-names></name><name><surname>Moore</surname> <given-names>I</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Nakitandwe</surname> <given-names>J</given-names></name><name><surname>Hagiwara</surname> <given-names>K</given-names></name><name><surname>Pelletier</surname> <given-names>S</given-names></name><name><surname>Gingras</surname> <given-names>S</given-names></name><name><surname>Berns</surname> <given-names>H</given-names></name><name><surname>Payne-Turner</surname> <given-names>D</given-names></name><name><surname>Hill</surname> <given-names>A</given-names></name><name><surname>Iacobucci</surname> <given-names>I</given-names></name><name><surname>Shi</surname> <given-names>L</given-names></name><name><surname>Pounds</surname> <given-names>S</given-names></name><name><surname>Cheng</surname> <given-names>C</given-names></name><name><surname>Pei</surname> <given-names>D</given-names></name><name><surname>Qu</surname> <given-names>C</given-names></name><name><surname>Newman</surname> <given-names>S</given-names></name><name><surname>Devidas</surname> <given-names>M</given-names></name><name><surname>Dai</surname> <given-names>Y</given-names></name><name><surname>Reshmi</surname> <given-names>SC</given-names></name><name><surname>Gastier-Foster</surname> <given-names>J</given-names></name><name><surname>Raetz</surname> <given-names>EA</given-names></name><name><surname>Borowitz</surname> <given-names>MJ</given-names></name><name><surname>Wood</surname> <given-names>BL</given-names></name><name><surname>Carroll</surname> <given-names>WL</given-names></name><name><surname>Zweidler-McKay</surname> <given-names>PA</given-names></name><name><surname>Rabin</surname> <given-names>KR</given-names></name><name><surname>Mattano</surname> <given-names>LA</given-names></name><name><surname>Maloney</surname> <given-names>KW</given-names></name><name><surname>Rambaldi</surname> <given-names>A</given-names></name><name><surname>Spinelli</surname> <given-names>O</given-names></name><name><surname>Radich</surname> <given-names>JP</given-names></name><name><surname>Minden</surname> <given-names>MD</given-names></name><name><surname>Rowe</surname> <given-names>JM</given-names></name><name><surname>Luger</surname> <given-names>S</given-names></name><name><surname>Litzow</surname> <given-names>MR</given-names></name><name><surname>Tallman</surname> <given-names>MS</given-names></name><name><surname>Racevskis</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Bhatia</surname> <given-names>R</given-names></name><name><surname>Kohlschmidt</surname> <given-names>J</given-names></name><name><surname>Mrózek</surname> <given-names>K</given-names></name><name><surname>Bloomfield</surname> <given-names>CD</given-names></name><name><surname>Stock</surname> <given-names>W</given-names></name><name><surname>Kornblau</surname> <given-names>S</given-names></name><name><surname>Kantarjian</surname> <given-names>HM</given-names></name><name><surname>Konopleva</surname> <given-names>M</given-names></name><name><surname>Evans</surname> <given-names>WE</given-names></name><name><surname>Jeha</surname> <given-names>S</given-names></name><name><surname>Pui</surname> <given-names>CH</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Paietta</surname> <given-names>E</given-names></name><name><surname>Downing</surname> <given-names>JR</given-names></name><name><surname>Relling</surname> <given-names>MV</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Loh</surname> <given-names>ML</given-names></name><name><surname>Hunger</surname> <given-names>SP</given-names></name><name><surname>Mullighan</surname> <given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia</article-title><source>Nature Genetics</source><volume>51</volume><fpage>296</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0315-5</pub-id><pub-id pub-id-type="pmid">30643249</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haferlach</surname> <given-names>T</given-names></name><name><surname>Kohlmann</surname> <given-names>A</given-names></name><name><surname>Wieczorek</surname> <given-names>L</given-names></name><name><surname>Basso</surname> <given-names>G</given-names></name><name><surname>Kronnie</surname> <given-names>GT</given-names></name><name><surname>Béné</surname> <given-names>MC</given-names></name><name><surname>De Vos</surname> <given-names>J</given-names></name><name><surname>Hernández</surname> <given-names>JM</given-names></name><name><surname>Hofmann</surname> <given-names>WK</given-names></name><name><surname>Mills</surname> <given-names>KI</given-names></name><name><surname>Gilkes</surname> <given-names>A</given-names></name><name><surname>Chiaretti</surname> <given-names>S</given-names></name><name><surname>Shurtleff</surname> <given-names>SA</given-names></name><name><surname>Kipps</surname> <given-names>TJ</given-names></name><name><surname>Rassenti</surname> <given-names>LZ</given-names></name><name><surname>Yeoh</surname> <given-names>AE</given-names></name><name><surname>Papenhausen</surname> <given-names>PR</given-names></name><name><surname>Liu</surname> <given-names>WM</given-names></name><name><surname>Williams</surname> <given-names>PM</given-names></name><name><surname>Foà</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the international microarray innovations in leukemia study group</article-title><source>Journal of Clinical Oncology</source><volume>28</volume><fpage>2529</fpage><lpage>2537</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.4732</pub-id><pub-id pub-id-type="pmid">20406941</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname> <given-names>T</given-names></name><name><surname>Chandrashekhar</surname> <given-names>M</given-names></name><name><surname>Aregger</surname> <given-names>M</given-names></name><name><surname>Steinhart</surname> <given-names>Z</given-names></name><name><surname>Brown</surname> <given-names>KR</given-names></name><name><surname>MacLeod</surname> <given-names>G</given-names></name><name><surname>Mis</surname> <given-names>M</given-names></name><name><surname>Zimmermann</surname> <given-names>M</given-names></name><name><surname>Fradet-Turcotte</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>S</given-names></name><name><surname>Mero</surname> <given-names>P</given-names></name><name><surname>Dirks</surname> <given-names>P</given-names></name><name><surname>Sidhu</surname> <given-names>S</given-names></name><name><surname>Roth</surname> <given-names>FP</given-names></name><name><surname>Rissland</surname> <given-names>OS</given-names></name><name><surname>Durocher</surname> <given-names>D</given-names></name><name><surname>Angers</surname> <given-names>S</given-names></name><name><surname>Moffat</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>High-Resolution CRISPR screens reveal fitness genes and Genotype-Specific Cancer liabilities</article-title><source>Cell</source><volume>163</volume><fpage>1515</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.11.015</pub-id><pub-id pub-id-type="pmid">26627737</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname> <given-names>T</given-names></name><name><surname>Tong</surname> <given-names>AHY</given-names></name><name><surname>Chan</surname> <given-names>K</given-names></name><name><surname>Van Leeuwen</surname> <given-names>J</given-names></name><name><surname>Seetharaman</surname> <given-names>A</given-names></name><name><surname>Aregger</surname> <given-names>M</given-names></name><name><surname>Chandrashekhar</surname> <given-names>M</given-names></name><name><surname>Hustedt</surname> <given-names>N</given-names></name><name><surname>Seth</surname> <given-names>S</given-names></name><name><surname>Noonan</surname> <given-names>A</given-names></name><name><surname>Habsid</surname> <given-names>A</given-names></name><name><surname>Sizova</surname> <given-names>O</given-names></name><name><surname>Nedyalkova</surname> <given-names>L</given-names></name><name><surname>Climie</surname> <given-names>R</given-names></name><name><surname>Tworzyanski</surname> <given-names>L</given-names></name><name><surname>Lawson</surname> <given-names>K</given-names></name><name><surname>Sartori</surname> <given-names>MA</given-names></name><name><surname>Alibeh</surname> <given-names>S</given-names></name><name><surname>Tieu</surname> <given-names>D</given-names></name><name><surname>Masud</surname> <given-names>S</given-names></name><name><surname>Mero</surname> <given-names>P</given-names></name><name><surname>Weiss</surname> <given-names>A</given-names></name><name><surname>Brown</surname> <given-names>KR</given-names></name><name><surname>Usaj</surname> <given-names>M</given-names></name><name><surname>Billmann</surname> <given-names>M</given-names></name><name><surname>Rahman</surname> <given-names>M</given-names></name><name><surname>Costanzo</surname> <given-names>M</given-names></name><name><surname>Myers</surname> <given-names>CL</given-names></name><name><surname>Andrews</surname> <given-names>BJ</given-names></name><name><surname>Boone</surname> <given-names>C</given-names></name><name><surname>Durocher</surname> <given-names>D</given-names></name><name><surname>Moffat</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Evaluation and design of Genome-Wide CRISPR/SpCas9 knockout screens</article-title><source>G3: Genes, Genomes, Genetics</source><volume>7</volume><fpage>2719</fpage><lpage>2727</lpage><pub-id pub-id-type="doi">10.1534/g3.117.041277</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henrion</surname> <given-names>AA</given-names></name><name><surname>Martinez</surname> <given-names>A</given-names></name><name><surname>Mattei</surname> <given-names>MG</given-names></name><name><surname>Kahn</surname> <given-names>A</given-names></name><name><surname>Raymondjean</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Structure, sequence, and chromosomal location of the gene for USF2 transcription factors in mouse</article-title><source>Genomics</source><volume>25</volume><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/0888-7543(95)80107-W</pub-id><pub-id pub-id-type="pmid">7774954</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyle</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Wright</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Shao</surname> <given-names>Y</given-names></name><name><surname>Easton</surname> <given-names>J</given-names></name><name><surname>Tian</surname> <given-names>L</given-names></name><name><surname>Feng</surname> <given-names>R</given-names></name><name><surname>Xu</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Acute depletion of CTCF directly affects MYC regulation through loss of enhancer-promoter looping</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>6699</fpage><lpage>6713</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz462</pub-id><pub-id pub-id-type="pmid">31127282</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jambon</surname> <given-names>M</given-names></name><name><surname>Depauw</surname> <given-names>S</given-names></name><name><surname>Van Seuningen</surname> <given-names>I</given-names></name><name><surname>David-Cordonnier</surname> <given-names>M-H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Direct and indirect targeting of HOXA9 transcription factor in acute myeloid leukemia</article-title><source>Cancers</source><volume>11</volume><elocation-id>837</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11060837</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname> <given-names>X</given-names></name><name><surname>Dadon</surname> <given-names>DB</given-names></name><name><surname>Powell</surname> <given-names>BE</given-names></name><name><surname>Fan</surname> <given-names>ZP</given-names></name><name><surname>Borges-Rivera</surname> <given-names>D</given-names></name><name><surname>Shachar</surname> <given-names>S</given-names></name><name><surname>Weintraub</surname> <given-names>AS</given-names></name><name><surname>Hnisz</surname> <given-names>D</given-names></name><name><surname>Pegoraro</surname> <given-names>G</given-names></name><name><surname>Lee</surname> <given-names>TI</given-names></name><name><surname>Misteli</surname> <given-names>T</given-names></name><name><surname>Jaenisch</surname> <given-names>R</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>3d chromosome regulatory landscape of human pluripotent cells</article-title><source>Cell Stem Cell</source><volume>18</volume><fpage>262</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.11.007</pub-id><pub-id pub-id-type="pmid">26686465</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Lee</surname> <given-names>SR</given-names></name><name><surname>Li</surname> <given-names>LH</given-names></name><name><surname>Park</surname> <given-names>HJ</given-names></name><name><surname>Park</surname> <given-names>JH</given-names></name><name><surname>Lee</surname> <given-names>KY</given-names></name><name><surname>Kim</surname> <given-names>MK</given-names></name><name><surname>Shin</surname> <given-names>BA</given-names></name><name><surname>Choi</surname> <given-names>SY</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e18556</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018556</pub-id><pub-id pub-id-type="pmid">21602908</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohlmann</surname> <given-names>A</given-names></name><name><surname>Kipps</surname> <given-names>TJ</given-names></name><name><surname>Rassenti</surname> <given-names>LZ</given-names></name><name><surname>Downing</surname> <given-names>JR</given-names></name><name><surname>Shurtleff</surname> <given-names>SA</given-names></name><name><surname>Mills</surname> <given-names>KI</given-names></name><name><surname>Gilkes</surname> <given-names>AF</given-names></name><name><surname>Hofmann</surname> <given-names>WK</given-names></name><name><surname>Basso</surname> <given-names>G</given-names></name><name><surname>Dell'orto</surname> <given-names>MC</given-names></name><name><surname>Foà</surname> <given-names>R</given-names></name><name><surname>Chiaretti</surname> <given-names>S</given-names></name><name><surname>De Vos</surname> <given-names>J</given-names></name><name><surname>Rauhut</surname> <given-names>S</given-names></name><name><surname>Papenhausen</surname> <given-names>PR</given-names></name><name><surname>Hernández</surname> <given-names>JM</given-names></name><name><surname>Lumbreras</surname> <given-names>E</given-names></name><name><surname>Yeoh</surname> <given-names>AE</given-names></name><name><surname>Koay</surname> <given-names>ES</given-names></name><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>WM</given-names></name><name><surname>Williams</surname> <given-names>PM</given-names></name><name><surname>Wieczorek</surname> <given-names>L</given-names></name><name><surname>Haferlach</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the microarray innovations in LEukemia study prephase</article-title><source>British Journal of Haematology</source><volume>142</volume><fpage>802</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2008.07261.x</pub-id><pub-id pub-id-type="pmid">18573112</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krivtsov</surname> <given-names>AV</given-names></name><name><surname>Feng</surname> <given-names>Z</given-names></name><name><surname>Lemieux</surname> <given-names>ME</given-names></name><name><surname>Faber</surname> <given-names>J</given-names></name><name><surname>Vempati</surname> <given-names>S</given-names></name><name><surname>Sinha</surname> <given-names>AU</given-names></name><name><surname>Xia</surname> <given-names>X</given-names></name><name><surname>Jesneck</surname> <given-names>J</given-names></name><name><surname>Bracken</surname> <given-names>AP</given-names></name><name><surname>Silverman</surname> <given-names>LB</given-names></name><name><surname>Kutok</surname> <given-names>JL</given-names></name><name><surname>Kung</surname> <given-names>AL</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>H3K79 methylation profiles define murine and human MLL-AF4 leukemias</article-title><source>Cancer Cell</source><volume>14</volume><fpage>355</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.10.001</pub-id><pub-id pub-id-type="pmid">18977325</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroon</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b</article-title><source>The EMBO Journal</source><volume>17</volume><fpage>3714</fpage><lpage>3725</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.13.3714</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname> <given-names>D</given-names></name><name><surname>Usdin</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Interaction of the transcription factors USF1, USF2, and alpha -Pal/Nrf-1 with the FMR1 promoter implications for fragile X mental retardation syndrome</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>4357</fpage><lpage>4364</lpage><pub-id pub-id-type="doi">10.1074/jbc.M009629200</pub-id><pub-id pub-id-type="pmid">11058604</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname> <given-names>SA</given-names></name><name><surname>Jolma</surname> <given-names>A</given-names></name><name><surname>Campitelli</surname> <given-names>LF</given-names></name><name><surname>Das</surname> <given-names>PK</given-names></name><name><surname>Yin</surname> <given-names>Y</given-names></name><name><surname>Albu</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Taipale</surname> <given-names>J</given-names></name><name><surname>Hughes</surname> <given-names>TR</given-names></name><name><surname>Weirauch</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The human transcription factors</article-title><source>Cell</source><volume>172</volume><fpage>650</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.01.029</pub-id><pub-id pub-id-type="pmid">29425488</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname> <given-names>B</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Aligning sequence reads, clone sequences and assembly contigs with BWA-MEMH</article-title><source>arXiv</source><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/1303.3997">https://arxiv.org/abs/1303.3997</ext-link></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>A</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Gao</surname> <given-names>C</given-names></name><name><surname>Lu</surname> <given-names>J</given-names></name><name><surname>Jeong</surname> <given-names>HW</given-names></name><name><surname>Liu</surname> <given-names>BH</given-names></name><name><surname>Tang</surname> <given-names>P</given-names></name><name><surname>Yao</surname> <given-names>X</given-names></name><name><surname>Neuberg</surname> <given-names>D</given-names></name><name><surname>Huang</surname> <given-names>G</given-names></name><name><surname>Tenen</surname> <given-names>DG</given-names></name><name><surname>Chai</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis</article-title><source>Journal of Clinical Investigation</source><volume>123</volume><fpage>4195</fpage><lpage>4207</lpage><pub-id pub-id-type="doi">10.1172/JCI62891</pub-id><pub-id pub-id-type="pmid">24051379</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Arnovitz</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>P</given-names></name><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Hong</surname> <given-names>GM</given-names></name><name><surname>Kunjamma</surname> <given-names>RB</given-names></name><name><surname>Ren</surname> <given-names>H</given-names></name><name><surname>He</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>CZ</given-names></name><name><surname>Elkahloun</surname> <given-names>AG</given-names></name><name><surname>Valk</surname> <given-names>PJ</given-names></name><name><surname>Döhner</surname> <given-names>K</given-names></name><name><surname>Neilly</surname> <given-names>MB</given-names></name><name><surname>Bullinger</surname> <given-names>L</given-names></name><name><surname>Delwel</surname> <given-names>R</given-names></name><name><surname>Löwenberg</surname> <given-names>B</given-names></name><name><surname>Liu</surname> <given-names>PP</given-names></name><name><surname>Morgan</surname> <given-names>R</given-names></name><name><surname>Rowley</surname> <given-names>JD</given-names></name><name><surname>Yuan</surname> <given-names>CS</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>PBX3 is an important cofactor of HOXA9 in leukemogenesis</article-title><source>Blood</source><volume>121</volume><fpage>1422</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-07-442004</pub-id><pub-id pub-id-type="pmid">23264595</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Xiao</surname> <given-names>T</given-names></name><name><surname>Cong</surname> <given-names>L</given-names></name><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Irizarry</surname> <given-names>RA</given-names></name><name><surname>Liu</surname> <given-names>JS</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>554</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0554-4</pub-id><pub-id pub-id-type="pmid">25476604</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>JY</given-names></name><name><surname>Souroullas</surname> <given-names>GP</given-names></name><name><surname>Diekman</surname> <given-names>BO</given-names></name><name><surname>Krishnamurthy</surname> <given-names>J</given-names></name><name><surname>Hall</surname> <given-names>BM</given-names></name><name><surname>Sorrentino</surname> <given-names>JA</given-names></name><name><surname>Parker</surname> <given-names>JS</given-names></name><name><surname>Sessions</surname> <given-names>GA</given-names></name><name><surname>Gudkov</surname> <given-names>AV</given-names></name><name><surname>Sharpless</surname> <given-names>NE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cells exhibiting strong <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter activation in vivo display features of senescence</article-title><source>PNAS</source><volume>116</volume><fpage>2603</fpage><lpage>2611</lpage><pub-id pub-id-type="doi">10.1073/pnas.1818313116</pub-id><pub-id pub-id-type="pmid">30683717</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Parton</surname> <given-names>T</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Chrysovergis</surname> <given-names>K</given-names></name><name><surname>Rockowitz</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>WY</given-names></name><name><surname>Abdel-Wahab</surname> <given-names>O</given-names></name><name><surname>Wade</surname> <given-names>PA</given-names></name><name><surname>Zheng</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>GG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Epigenetic perturbations by Arg882-Mutated DNMT3A potentiate aberrant stem cell Gene-Expression program and acute leukemia development</article-title><source>Cancer Cell</source><volume>30</volume><fpage>92</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.05.008</pub-id><pub-id pub-id-type="pmid">27344947</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>B</given-names></name><name><surname>Klingbeil</surname> <given-names>O</given-names></name><name><surname>Tarumoto</surname> <given-names>Y</given-names></name><name><surname>Somerville</surname> <given-names>TDD</given-names></name><name><surname>Huang</surname> <given-names>YH</given-names></name><name><surname>Wei</surname> <given-names>Y</given-names></name><name><surname>Wai</surname> <given-names>DC</given-names></name><name><surname>Low</surname> <given-names>JKK</given-names></name><name><surname>Milazzo</surname> <given-names>JP</given-names></name><name><surname>Wu</surname> <given-names>XS</given-names></name><name><surname>Cao</surname> <given-names>Z</given-names></name><name><surname>Yan</surname> <given-names>X</given-names></name><name><surname>Demerdash</surname> <given-names>OE</given-names></name><name><surname>Huang</surname> <given-names>G</given-names></name><name><surname>Mackay</surname> <given-names>JP</given-names></name><name><surname>Kinney</surname> <given-names>JB</given-names></name><name><surname>Shi</surname> <given-names>J</given-names></name><name><surname>Vakoc</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A transcription factor addiction in leukemia imposed by the MLL promoter sequence</article-title><source>Cancer Cell</source><volume>34</volume><fpage>970</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.10.015</pub-id><pub-id pub-id-type="pmid">30503706</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Zha</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Yan</surname> <given-names>B</given-names></name><name><surname>Du</surname> <given-names>Q</given-names></name><name><surname>Yang</surname> <given-names>F</given-names></name><name><surname>Sobh</surname> <given-names>A</given-names></name><name><surname>Vulpe</surname> <given-names>C</given-names></name><name><surname>Drusbosky</surname> <given-names>L</given-names></name><name><surname>Cogle</surname> <given-names>C</given-names></name><name><surname>Chepelev</surname> <given-names>I</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Nimer</surname> <given-names>SD</given-names></name><name><surname>Licht</surname> <given-names>J</given-names></name><name><surname>Qiu</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CTCF boundary remodels chromatin domain and drives aberrant <italic>HOX</italic> gene transcription in acute myeloid leukemia</article-title><source>Blood</source><volume>132</volume><fpage>837</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-11-814319</pub-id><pub-id pub-id-type="pmid">29760161</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>H</given-names></name><name><surname>Zhu</surname> <given-names>G</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Lai</surname> <given-names>Q</given-names></name><name><surname>Yan</surname> <given-names>B</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Fung</surname> <given-names>TK</given-names></name><name><surname>Zeisig</surname> <given-names>BB</given-names></name><name><surname>Cui</surname> <given-names>Y</given-names></name><name><surname>Zha</surname> <given-names>J</given-names></name><name><surname>Cogle</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Yang</surname> <given-names>FC</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>So</surname> <given-names>CWE</given-names></name><name><surname>Qiu</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HOTTIP lncRNA promotes hematopoietic stem cell Self-Renewal leading to AML-like disease in mice</article-title><source>Cancer Cell</source><volume>36</volume><fpage>645</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.10.011</pub-id><pub-id pub-id-type="pmid">31786140</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>X</given-names></name><name><surname>Sawadogo</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Functional domains of the transcription factor USF2: atypical nuclear localization signals and context-dependent transcriptional activation domains</article-title><source>Molecular and Cellular Biology</source><volume>16</volume><fpage>1367</fpage><lpage>1375</lpage><pub-id pub-id-type="doi">10.1128/MCB.16.4.1367</pub-id><pub-id pub-id-type="pmid">8657110</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname> <given-names>JR</given-names></name><name><surname>Salik</surname> <given-names>B</given-names></name><name><surname>Connerty</surname> <given-names>P</given-names></name><name><surname>Vick</surname> <given-names>B</given-names></name><name><surname>Leung</surname> <given-names>H</given-names></name><name><surname>Pijning</surname> <given-names>A</given-names></name><name><surname>Jeremias</surname> <given-names>I</given-names></name><name><surname>Spiekermann</surname> <given-names>K</given-names></name><name><surname>Trahair</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Haber</surname> <given-names>M</given-names></name><name><surname>Norris</surname> <given-names>MD</given-names></name><name><surname>Woo</surname> <given-names>AJ</given-names></name><name><surname>Hogg</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>JY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis</article-title><source>Leukemia</source><volume>33</volume><fpage>1400</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1038/s41375-018-0354-z</pub-id><pub-id pub-id-type="pmid">30622285</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>H</given-names></name><name><surname>Dang</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Jia</surname> <given-names>G</given-names></name><name><surname>Anaya</surname> <given-names>E</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Abraham</surname> <given-names>S</given-names></name><name><surname>Choi</surname> <given-names>JG</given-names></name><name><surname>Shi</surname> <given-names>G</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Manjunath</surname> <given-names>N</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A CRISPR-Based screen identifies genes essential for West-Nile-Virus-Induced cell death</article-title><source>Cell Reports</source><volume>12</volume><fpage>673</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.06.049</pub-id><pub-id pub-id-type="pmid">26190106</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacPherson</surname> <given-names>L</given-names></name><name><surname>Anokye</surname> <given-names>J</given-names></name><name><surname>Yeung</surname> <given-names>MM</given-names></name><name><surname>Lam</surname> <given-names>EYN</given-names></name><name><surname>Chan</surname> <given-names>YC</given-names></name><name><surname>Weng</surname> <given-names>CF</given-names></name><name><surname>Yeh</surname> <given-names>P</given-names></name><name><surname>Knezevic</surname> <given-names>K</given-names></name><name><surname>Butler</surname> <given-names>MS</given-names></name><name><surname>Hoegl</surname> <given-names>A</given-names></name><name><surname>Chan</surname> <given-names>KL</given-names></name><name><surname>Burr</surname> <given-names>ML</given-names></name><name><surname>Gearing</surname> <given-names>LJ</given-names></name><name><surname>Willson</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Choi</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Bilardi</surname> <given-names>RA</given-names></name><name><surname>Falk</surname> <given-names>H</given-names></name><name><surname>Nguyen</surname> <given-names>N</given-names></name><name><surname>Stupple</surname> <given-names>PA</given-names></name><name><surname>Peat</surname> <given-names>TS</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>de Silva</surname> <given-names>M</given-names></name><name><surname>Carrasco-Pozo</surname> <given-names>C</given-names></name><name><surname>Avery</surname> <given-names>VM</given-names></name><name><surname>Khoo</surname> <given-names>PS</given-names></name><name><surname>Dolezal</surname> <given-names>O</given-names></name><name><surname>Dennis</surname> <given-names>ML</given-names></name><name><surname>Nuttall</surname> <given-names>S</given-names></name><name><surname>Surjadi</surname> <given-names>R</given-names></name><name><surname>Newman</surname> <given-names>J</given-names></name><name><surname>Ren</surname> <given-names>B</given-names></name><name><surname>Leaver</surname> <given-names>DJ</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Baell</surname> <given-names>JB</given-names></name><name><surname>Dovey</surname> <given-names>O</given-names></name><name><surname>Vassiliou</surname> <given-names>GS</given-names></name><name><surname>Grebien</surname> <given-names>F</given-names></name><name><surname>Dawson</surname> <given-names>SJ</given-names></name><name><surname>Street</surname> <given-names>IP</given-names></name><name><surname>Monahan</surname> <given-names>BJ</given-names></name><name><surname>Burns</surname> <given-names>CJ</given-names></name><name><surname>Choudhary</surname> <given-names>C</given-names></name><name><surname>Blewitt</surname> <given-names>ME</given-names></name><name><surname>Voss</surname> <given-names>AK</given-names></name><name><surname>Thomas</surname> <given-names>T</given-names></name><name><surname>Dawson</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HBO1 is required for the maintenance of leukaemia stem cells</article-title><source>Nature</source><volume>577</volume><fpage>266</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1835-6</pub-id><pub-id pub-id-type="pmid">31827282</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morawska</surname> <given-names>M</given-names></name><name><surname>Ulrich</surname> <given-names>HD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An expanded tool kit for the auxin-inducible degron system in budding yeast</article-title><source>Yeast</source><volume>30</volume><fpage>341</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1002/yea.2967</pub-id><pub-id pub-id-type="pmid">23836714</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname> <given-names>T</given-names></name><name><surname>Largaespada</surname> <given-names>DA</given-names></name><name><surname>Lee</surname> <given-names>MP</given-names></name><name><surname>Johnson</surname> <given-names>LA</given-names></name><name><surname>Ohyashiki</surname> <given-names>K</given-names></name><name><surname>Toyama</surname> <given-names>K</given-names></name><name><surname>Chen</surname> <given-names>SJ</given-names></name><name><surname>Willman</surname> <given-names>CL</given-names></name><name><surname>Chen</surname> <given-names>IM</given-names></name><name><surname>Feinberg</surname> <given-names>AP</given-names></name><name><surname>Jenkins</surname> <given-names>NA</given-names></name><name><surname>Copeland</surname> <given-names>NG</given-names></name><name><surname>Shaughnessy</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia</article-title><source>Nature Genetics</source><volume>12</volume><fpage>154</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1038/ng0296-154</pub-id><pub-id pub-id-type="pmid">8563753</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natsume</surname> <given-names>T</given-names></name><name><surname>Kiyomitsu</surname> <given-names>T</given-names></name><name><surname>Saga</surname> <given-names>Y</given-names></name><name><surname>Kanemaki</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Rapid protein depletion in human cells by Auxin-Inducible degron tagging with short homology donors</article-title><source>Cell Reports</source><volume>15</volume><fpage>210</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.03.001</pub-id><pub-id pub-id-type="pmid">27052166</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nora</surname> <given-names>EP</given-names></name><name><surname>Goloborodko</surname> <given-names>A</given-names></name><name><surname>Valton</surname> <given-names>AL</given-names></name><name><surname>Gibcus</surname> <given-names>JH</given-names></name><name><surname>Uebersohn</surname> <given-names>A</given-names></name><name><surname>Abdennur</surname> <given-names>N</given-names></name><name><surname>Dekker</surname> <given-names>J</given-names></name><name><surname>Mirny</surname> <given-names>LA</given-names></name><name><surname>Bruneau</surname> <given-names>BG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeted degradation of CTCF decouples local insulation of chromosome domains from genomic compartmentalization</article-title><source>Cell</source><volume>169</volume><fpage>930</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.004</pub-id><pub-id pub-id-type="pmid">28525758</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawara</surname> <given-names>Y</given-names></name><name><surname>Katsumoto</surname> <given-names>T</given-names></name><name><surname>Aikawa</surname> <given-names>Y</given-names></name><name><surname>Shima</surname> <given-names>Y</given-names></name><name><surname>Kagiyama</surname> <given-names>Y</given-names></name><name><surname>Soga</surname> <given-names>T</given-names></name><name><surname>Matsunaga</surname> <given-names>H</given-names></name><name><surname>Seki</surname> <given-names>T</given-names></name><name><surname>Araki</surname> <given-names>K</given-names></name><name><surname>Kitabayashi</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>IDH2 and NPM1 mutations cooperate to activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia</article-title><source>Cancer Research</source><volume>75</volume><fpage>2005</fpage><lpage>2016</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2200</pub-id><pub-id pub-id-type="pmid">25795706</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>RJ</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Koundakjian</surname> <given-names>D</given-names></name><name><surname>Hultquist</surname> <given-names>JF</given-names></name><name><surname>Lamothe-Molina</surname> <given-names>P</given-names></name><name><surname>Monel</surname> <given-names>B</given-names></name><name><surname>Schumann</surname> <given-names>K</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Krupzcak</surname> <given-names>KM</given-names></name><name><surname>Garcia-Beltran</surname> <given-names>W</given-names></name><name><surname>Piechocka-Trocha</surname> <given-names>A</given-names></name><name><surname>Krogan</surname> <given-names>NJ</given-names></name><name><surname>Marson</surname> <given-names>A</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Hacohen</surname> <given-names>N</given-names></name><name><surname>Walker</surname> <given-names>BD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors</article-title><source>Nature Genetics</source><volume>49</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1038/ng.3741</pub-id><pub-id pub-id-type="pmid">27992415</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pombo</surname> <given-names>A</given-names></name><name><surname>Dillon</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Three-dimensional genome architecture: players and mechanisms</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>16</volume><fpage>245</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1038/nrm3965</pub-id><pub-id pub-id-type="pmid">25757416</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname> <given-names>S</given-names></name><name><surname>Singh</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Interaction of USF1/USF2 and alpha-Pal/Nrf1 to Fmr-1 promoter increases in mouse brain during aging</article-title><source>Biochemical and Biophysical Research Communications</source><volume>376</volume><fpage>347</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.08.155</pub-id><pub-id pub-id-type="pmid">18782566</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pridans</surname> <given-names>C</given-names></name><name><surname>Holmes</surname> <given-names>ML</given-names></name><name><surname>Polli</surname> <given-names>M</given-names></name><name><surname>Wettenhall</surname> <given-names>JM</given-names></name><name><surname>Dakic</surname> <given-names>A</given-names></name><name><surname>Corcoran</surname> <given-names>LM</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name><name><surname>Nutt</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Identification of Pax5 target genes in early B cell differentiation</article-title><source>The Journal of Immunology</source><volume>180</volume><fpage>1719</fpage><lpage>1728</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.3.1719</pub-id><pub-id pub-id-type="pmid">18209069</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramírez</surname> <given-names>F</given-names></name><name><surname>Dündar</surname> <given-names>F</given-names></name><name><surname>Diehl</surname> <given-names>S</given-names></name><name><surname>Grüning</surname> <given-names>BA</given-names></name><name><surname>Manke</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>deepTools: a flexible platform for exploring deep-sequencing data</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>W187</fpage><lpage>W191</lpage><pub-id pub-id-type="doi">10.1093/nar/gku365</pub-id><pub-id pub-id-type="pmid">24799436</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname> <given-names>SS</given-names></name><name><surname>Huntley</surname> <given-names>MH</given-names></name><name><surname>Durand</surname> <given-names>NC</given-names></name><name><surname>Stamenova</surname> <given-names>EK</given-names></name><name><surname>Bochkov</surname> <given-names>ID</given-names></name><name><surname>Robinson</surname> <given-names>JT</given-names></name><name><surname>Sanborn</surname> <given-names>AL</given-names></name><name><surname>Machol</surname> <given-names>I</given-names></name><name><surname>Omer</surname> <given-names>AD</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Aiden</surname> <given-names>EL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A 3D map of the human genome at Kilobase resolution reveals principles of chromatin looping</article-title><source>Cell</source><volume>159</volume><fpage>1665</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.11.021</pub-id><pub-id pub-id-type="pmid">25497547</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowley</surname> <given-names>MJ</given-names></name><name><surname>Nichols</surname> <given-names>MH</given-names></name><name><surname>Lyu</surname> <given-names>X</given-names></name><name><surname>Ando-Kuri</surname> <given-names>M</given-names></name><name><surname>Rivera</surname> <given-names>ISM</given-names></name><name><surname>Hermetz</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Ruan</surname> <given-names>Y</given-names></name><name><surname>Corces</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Evolutionarily conserved principles predict 3D chromatin organization</article-title><source>Molecular Cell</source><volume>67</volume><fpage>837</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.07.022</pub-id><pub-id pub-id-type="pmid">28826674</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowley</surname> <given-names>MJ</given-names></name><name><surname>Corces</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Organizational principles of 3D genome architecture</article-title><source>Nature Reviews Genetics</source><volume>19</volume><fpage>789</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1038/s41576-018-0060-8</pub-id><pub-id pub-id-type="pmid">30367165</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjana</surname> <given-names>NE</given-names></name><name><surname>Shalem</surname> <given-names>O</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Improved vectors and genome-wide libraries for CRISPR screening</article-title><source>Nature Methods</source><volume>11</volume><fpage>783</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3047</pub-id><pub-id pub-id-type="pmid">25075903</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmittgen</surname> <given-names>TD</given-names></name><name><surname>Livak</surname> <given-names>KJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Analyzing real-time PCR data by the comparative C(T) method</article-title><source>Nature Protocols</source><volume>3</volume><fpage>1101</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.73</pub-id><pub-id pub-id-type="pmid">18546601</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>A</given-names></name><name><surname>Murai</surname> <given-names>MJ</given-names></name><name><surname>He</surname> <given-names>S</given-names></name><name><surname>Lund</surname> <given-names>G</given-names></name><name><surname>Hartley</surname> <given-names>T</given-names></name><name><surname>Purohit</surname> <given-names>T</given-names></name><name><surname>Reddy</surname> <given-names>G</given-names></name><name><surname>Chruszcz</surname> <given-names>M</given-names></name><name><surname>Grembecka</surname> <given-names>J</given-names></name><name><surname>Cierpicki</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia</article-title><source>Blood</source><volume>120</volume><fpage>4461</fpage><lpage>4469</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-05-429274</pub-id><pub-id pub-id-type="pmid">22936661</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skene</surname> <given-names>PJ</given-names></name><name><surname>Henikoff</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites</article-title><source>eLife</source><volume>6</volume><elocation-id>e21856</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.21856</pub-id><pub-id pub-id-type="pmid">28079019</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>JR</given-names></name><name><surname>Maguire</surname> <given-names>S</given-names></name><name><surname>Davis</surname> <given-names>LA</given-names></name><name><surname>Alexander</surname> <given-names>M</given-names></name><name><surname>Yang</surname> <given-names>F</given-names></name><name><surname>Chandran</surname> <given-names>S</given-names></name><name><surname>ffrench-Constant</surname> <given-names>C</given-names></name><name><surname>Pedersen</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Robust, persistent transgene expression in human embryonic stem cells is achieved with AAVS1-targeted integration</article-title><source>Stem Cells</source><volume>26</volume><fpage>496</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1634/stemcells.2007-0039</pub-id><pub-id pub-id-type="pmid">18024421</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spohrer</surname> <given-names>S</given-names></name><name><surname>Groß</surname> <given-names>R</given-names></name><name><surname>Nalbach</surname> <given-names>L</given-names></name><name><surname>Schwind</surname> <given-names>L</given-names></name><name><surname>Stumpf</surname> <given-names>H</given-names></name><name><surname>Menger</surname> <given-names>MD</given-names></name><name><surname>Ampofo</surname> <given-names>E</given-names></name><name><surname>Montenarh</surname> <given-names>M</given-names></name><name><surname>Götz</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Functional interplay between the transcription factors USF1 and PDX-1 and protein kinase CK2 in pancreatic β-cells</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>16367</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-16590-0</pub-id><pub-id pub-id-type="pmid">29180680</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname> <given-names>EM</given-names></name><name><surname>Tallman</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L</article-title><source>Current Opinion in Hematology</source><volume>22</volume><fpage>92</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1097/MOH.0000000000000123</pub-id><pub-id pub-id-type="pmid">25635757</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>M</given-names></name><name><surname>Song</surname> <given-names>CX</given-names></name><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Frankenberger</surname> <given-names>CA</given-names></name><name><surname>Sankarasharma</surname> <given-names>D</given-names></name><name><surname>Gomes</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>P</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Chada</surname> <given-names>KK</given-names></name><name><surname>He</surname> <given-names>C</given-names></name><name><surname>Rosner</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>HMGA2/TET1/HOXA9 signaling pathway regulates breast Cancer growth and metastasis</article-title><source>PNAS</source><volume>110</volume><fpage>9920</fpage><lpage>9925</lpage><pub-id pub-id-type="doi">10.1073/pnas.1305172110</pub-id><pub-id pub-id-type="pmid">23716660</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzelepis</surname> <given-names>K</given-names></name><name><surname>Koike-Yusa</surname> <given-names>H</given-names></name><name><surname>De Braekeleer</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Metzakopian</surname> <given-names>E</given-names></name><name><surname>Dovey</surname> <given-names>OM</given-names></name><name><surname>Mupo</surname> <given-names>A</given-names></name><name><surname>Grinkevich</surname> <given-names>V</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Mazan</surname> <given-names>M</given-names></name><name><surname>Gozdecka</surname> <given-names>M</given-names></name><name><surname>Ohnishi</surname> <given-names>S</given-names></name><name><surname>Cooper</surname> <given-names>J</given-names></name><name><surname>Patel</surname> <given-names>M</given-names></name><name><surname>McKerrell</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Domingues</surname> <given-names>AF</given-names></name><name><surname>Gallipoli</surname> <given-names>P</given-names></name><name><surname>Teichmann</surname> <given-names>S</given-names></name><name><surname>Ponstingl</surname> <given-names>H</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>Huntly</surname> <given-names>BJP</given-names></name><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Pina</surname> <given-names>C</given-names></name><name><surname>Vassiliou</surname> <given-names>GS</given-names></name><name><surname>Yusa</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia</article-title><source>Cell Reports</source><volume>17</volume><fpage>1193</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.09.079</pub-id><pub-id pub-id-type="pmid">27760321</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vietri Rudan</surname> <given-names>M</given-names></name><name><surname>Barrington</surname> <given-names>C</given-names></name><name><surname>Henderson</surname> <given-names>S</given-names></name><name><surname>Ernst</surname> <given-names>C</given-names></name><name><surname>Odom</surname> <given-names>DT</given-names></name><name><surname>Tanay</surname> <given-names>A</given-names></name><name><surname>Hadjur</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Comparative Hi-C reveals that CTCF underlies evolution of chromosomal domain architecture</article-title><source>Cell Reports</source><volume>10</volume><fpage>1297</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.02.004</pub-id><pub-id pub-id-type="pmid">25732821</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vo</surname> <given-names>BT</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Morgan</surname> <given-names>MA</given-names></name><name><surname>Theurillat</surname> <given-names>I</given-names></name><name><surname>Finkelstein</surname> <given-names>D</given-names></name><name><surname>Wright</surname> <given-names>S</given-names></name><name><surname>Hyle</surname> <given-names>J</given-names></name><name><surname>Smith</surname> <given-names>SMC</given-names></name><name><surname>Fan</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>YD</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Orr</surname> <given-names>BA</given-names></name><name><surname>Northcott</surname> <given-names>PA</given-names></name><name><surname>Shilatifard</surname> <given-names>A</given-names></name><name><surname>Sherr</surname> <given-names>CJ</given-names></name><name><surname>Roussel</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inactivation of Ezh2 upregulates Gfi1 and drives aggressive Myc-Driven group 3 medulloblastoma</article-title><source>Cell Reports</source><volume>18</volume><fpage>2907</fpage><lpage>2917</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.02.073</pub-id><pub-id pub-id-type="pmid">28329683</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Birsoy</surname> <given-names>K</given-names></name><name><surname>Hughes</surname> <given-names>NW</given-names></name><name><surname>Krupczak</surname> <given-names>KM</given-names></name><name><surname>Post</surname> <given-names>Y</given-names></name><name><surname>Wei</surname> <given-names>JJ</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Identification and characterization of essential genes in the human genome</article-title><source>Science</source><volume>350</volume><fpage>1096</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1126/science.aac7041</pub-id><pub-id pub-id-type="pmid">26472758</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Sul</surname> <given-names>HS</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Upstream stimulatory factors bind to insulin response sequence of the fatty acid synthase promoter USF1 is regulated</article-title><source>Journal of Biological Chemistry</source><volume>270</volume><fpage>28716</fpage><lpage>28722</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.48.28716</pub-id><pub-id pub-id-type="pmid">7499393</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Zhao</surname> <given-names>GN</given-names></name><name><surname>Lv</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>LY</given-names></name><name><surname>Hao</surname> <given-names>DL</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>DP</given-names></name><name><surname>Liang</surname> <given-names>CC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CTCF controls HOXA cluster silencing and mediates PRC2-repressive higher-order chromatin structure in NT2/D1 cells</article-title><source>Molecular and Cellular Biology</source><volume>34</volume><fpage>3867</fpage><lpage>3879</lpage><pub-id pub-id-type="doi">10.1128/MCB.00567-14</pub-id><pub-id pub-id-type="pmid">25135475</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Valerio</surname> <given-names>DG</given-names></name><name><surname>Eisold</surname> <given-names>ME</given-names></name><name><surname>Sinha</surname> <given-names>A</given-names></name><name><surname>Koche</surname> <given-names>RP</given-names></name><name><surname>Hu</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>CW</given-names></name><name><surname>Chu</surname> <given-names>SH</given-names></name><name><surname>Brien</surname> <given-names>GL</given-names></name><name><surname>Park</surname> <given-names>CY</given-names></name><name><surname>Hsieh</surname> <given-names>JJ</given-names></name><name><surname>Ernst</surname> <given-names>P</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis</article-title><source>Cancer Cell</source><volume>30</volume><fpage>863</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.10.019</pub-id><pub-id pub-id-type="pmid">27889185</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>W</given-names></name><name><surname>Chory</surname> <given-names>EJ</given-names></name><name><surname>Wernimont</surname> <given-names>AK</given-names></name><name><surname>Tempel</surname> <given-names>W</given-names></name><name><surname>Scopton</surname> <given-names>A</given-names></name><name><surname>Federation</surname> <given-names>A</given-names></name><name><surname>Marineau</surname> <given-names>JJ</given-names></name><name><surname>Qi</surname> <given-names>J</given-names></name><name><surname>Barsyte-Lovejoy</surname> <given-names>D</given-names></name><name><surname>Yi</surname> <given-names>J</given-names></name><name><surname>Marcellus</surname> <given-names>R</given-names></name><name><surname>Iacob</surname> <given-names>RE</given-names></name><name><surname>Engen</surname> <given-names>JR</given-names></name><name><surname>Griffin</surname> <given-names>C</given-names></name><name><surname>Aman</surname> <given-names>A</given-names></name><name><surname>Wienholds</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Pineda</surname> <given-names>J</given-names></name><name><surname>Estiu</surname> <given-names>G</given-names></name><name><surname>Shatseva</surname> <given-names>T</given-names></name><name><surname>Hajian</surname> <given-names>T</given-names></name><name><surname>Al-Awar</surname> <given-names>R</given-names></name><name><surname>Dick</surname> <given-names>JE</given-names></name><name><surname>Vedadi</surname> <given-names>M</given-names></name><name><surname>Brown</surname> <given-names>PJ</given-names></name><name><surname>Arrowsmith</surname> <given-names>CH</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Schapira</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors</article-title><source>Nature Communications</source><volume>3</volume><elocation-id>1288</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms2304</pub-id><pub-id pub-id-type="pmid">23250418</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>LG</given-names></name><name><surname>He</surname> <given-names>QY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization</article-title><source>Bioinformatics</source><volume>31</volume><fpage>2382</fpage><lpage>2383</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv145</pub-id><pub-id pub-id-type="pmid">25765347</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeisig</surname> <given-names>BB</given-names></name><name><surname>Milne</surname> <given-names>T</given-names></name><name><surname>García-Cuéllar</surname> <given-names>MP</given-names></name><name><surname>Schreiner</surname> <given-names>S</given-names></name><name><surname>Martin</surname> <given-names>ME</given-names></name><name><surname>Fuchs</surname> <given-names>U</given-names></name><name><surname>Borkhardt</surname> <given-names>A</given-names></name><name><surname>Chanda</surname> <given-names>SK</given-names></name><name><surname>Walker</surname> <given-names>J</given-names></name><name><surname>Soden</surname> <given-names>R</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name><name><surname>Slany</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>617</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.2.617-628.2004</pub-id><pub-id pub-id-type="pmid">14701735</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Meyer</surname> <given-names>CA</given-names></name><name><surname>Eeckhoute</surname> <given-names>J</given-names></name><name><surname>Johnson</surname> <given-names>DS</given-names></name><name><surname>Bernstein</surname> <given-names>BE</given-names></name><name><surname>Nusbaum</surname> <given-names>C</given-names></name><name><surname>Myers</surname> <given-names>RM</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Model-based analysis of ChIP-Seq (MACS)</article-title><source>Genome Biology</source><volume>9</volume><elocation-id>R137</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id><pub-id pub-id-type="pmid">18798982</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Hyle</surname> <given-names>J</given-names></name><name><surname>Wright</surname> <given-names>S</given-names></name><name><surname>Shao</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A cis-element within the ARF locus mediates repression of p16 INK4A expression via long-range chromatin interactions</article-title><source>PNAS</source><volume>116</volume><fpage>26644</fpage><lpage>26652</lpage><pub-id pub-id-type="doi">10.1073/pnas.1909720116</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zu</surname> <given-names>Y</given-names></name><name><surname>Tong</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>D</given-names></name><name><surname>Pan</surname> <given-names>R</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Luo</surname> <given-names>Z</given-names></name><name><surname>Huang</surname> <given-names>P</given-names></name><name><surname>Wu</surname> <given-names>Q</given-names></name><name><surname>Zhu</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Lin</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TALEN-mediated precise genome modification by homologous recombination in zebrafish</article-title><source>Nature Methods</source><volume>10</volume><fpage>329</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2374</pub-id><pub-id pub-id-type="pmid">23435258</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.57858.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role>Reviewing Editor</role><aff><institution>Van Andel Institute</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>[Editors' note: this paper was reviewed by <ext-link ext-link-type="uri" xlink:href="https://www.reviewcommons.org/">Review Commons</ext-link>.]</p><p><bold>Acceptance summary:</bold></p><p>Aberrant <italic>HOXA9</italic> expression is a hallmark of most aggressive acute leukemias, thus understanding the regulation of <italic>HOXA9</italic> gene in leukemias is important. By utilizing CRISPR/Cas9 mediated screens in a reporter cell line, this study identifies new regulators controlling <italic>HOXA9</italic> expression, which are subsequently validated in multiple cell lines. This study provides the foundation for developing therapeutic strategies, and the <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter is a useful tool to the leukemia and epigenetic fields.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Functional Interrogation of <italic>HOXA9</italic> Regulome in MLLr Leukemia via Reporter-based CRISPR/Cas9 screen&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Maureen Murphy as the Senior Editor. The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is 'in revision at <italic>eLife</italic>'. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>In this manuscript, the authors study the transcriptional regulation of <italic>HOXA9</italic>, a transcription factor that plays a central role in homeostasis of immature hematopoietic cell types and in the development of leukemia. They use the CRISPR/Cas9 technique to introduce a fluorescence reporter cassette into the endogenous <italic>HOXA9</italic> locus of a human MLL/AF4-rearranged B-ALL cell line. After validating this engineered cell line, they perform multiple genetic screens to identify potential transcriptional regulators of <italic>HOXA9</italic> and to delineate essential transcription factors in this cell line. They identify USF2 as new transcription factor that modulates expression of <italic>HOXA9</italic>.</p><p>Major revisions:</p><p>If the authors can commit to adding the following data, as they indicate in their rebuttal, the manuscript would be greatly strengthened and could be considered acceptable:</p><p>1) The authors should include their data on the independent loss-of-function CRISPR transcription factor screen in SEM <italic>HOXA9<sup>P2A-mCherry</sup></italic> MLLr reporter line ectopically expressing HOXA9-MEIS1 to overcome the possibility that key regulators could be missed in the CRISPR/Cas9 screen due to survival dropout.</p><p>2) The authors should include supporting data for the key observations in the manuscript in other cell lines; for example, as indicated by the authors, the data gathered using an additional <italic>HOXA9</italic> MLLr AML reporter cell line established in OCI-AML2 cells to further support findings from the initial in SEM MLLr ALL reporter line.</p><p>3) The authors should perform USF2 knockout experiments in multiple non-MLLr cell lines according to the reviewer's suggestions. As an example, the authors should repeat the competitive proliferation assay to determine the effects of the single knockout of USF1 and USF2 vs the double knockout in SEM cells and other MLLr leukemia cell lines with proper controls.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.57858.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Major revisions:</p><p>If the authors can commit to adding the following data, as they indicate in their rebuttal, the manuscript would be greatly strengthened and could be considered acceptable:</p><p>1) The authors should include their data on the independent loss-of-function CRISPR transcription factor screen in SEM HOXA9-P2A-mCherry MLLr reporter line ectopically expressing HOXA9-MEIS1 to overcome the possibility that key regulators could be missed in the CRISPR/Cas9 screen due to survival dropout.</p></disp-quote><p>Thank you for the reviewer’s positive comments. This reviewer raised an important question that key upstream regulators of <italic>HOXA9</italic> could be missed due to a survival disadvantage. To mitigate this challenge, we have conducted an independent CRISPR/Cas9 TF screen in <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter SEM cells ectopically expressing <italic>HOXA9</italic> together with its functional partner MEIS1. In this regard, exogenously expressed <italic>HOXA9</italic> could rescue the potential cell loss due to decreased <italic>HOXA9</italic> expression in SEM cells, while the level of endogenous <italic>HOXA9</italic> is still monitored by reporter. As a result, we have identified more well-known regulators of <italic>HOXA9</italic> which are also considered as survival essential genes. Among the top 10 hits from this screen, DOT1L and <italic>HOXA9</italic> were enriched. KMT2A, the translocation partner of MLL-AF4 in SEM cells, was identified in the HOXA9-MEIS1 rescue TF screen but not the original screen without ectopic expression of <italic>HOXA9</italic>. Notably, the MYST acetyltransferase HBO1 (also known as KAT7 or MYST2) and several members of the HBO1 protein complex, which were recently shown as critical regulators of leukemia stem cell maintenance, were also identified among the top hits (MacPherson et al., 2020). Most importantly, USF2 was still among the top hits in this screen. Based on these observations, we believe that our reporter-based screen is sensitive to identify <italic>HOXA9</italic> regulators. We have added these new data to Figures 3B, 3D-3F, Figure 3—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>2) The authors should include supporting data for the key observations in the manuscript in other cell lines; for example, as indicated by the authors, the data gathered using an additional HOXA9 MLLr AML reporter cell line established in OCI-AML2 cells to further support findings from the initial in SEM MLLr ALL reporter line.</p></disp-quote><p>Thank you for the reviewer’s comments. First, we successfully established an additional <italic>HOXA9<sup>P2A-mCherry</sup></italic> MLLr reporter line from human AML OCI-AML2 cells using the same CHASE-knock-in protocol. The OCI-AML2<sup>HOXA9-P2A-mCherry</sup> cell line has been fully characterized by <italic>HOXA9</italic> transcriptional response of the reporter allele upon genetic perturbation and pharmaceutical inhibition of known <italic>HOXA9</italic> regulators. This result suggests that our strategy for generating <italic>HOXA9</italic> reporter lines are highly reproducible and can be applied into a broad range of cell lines. Second, we used MLLr AML cell lines OCI-AML2, MOLM13 and NOMO-1 to confirm the effects of USF1 and USF2 single and double knockout on <italic>HOXA9</italic> expression and cell proliferation. We have added these new data to Figure 2—figure supplement 1, Figures 5I-5J and Figure 5—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>3) The authors should perform USF2 knockout experiments in multiple non-MLLr cell lines according to the reviewer's suggestions. As an example, the authors should repeat the competitive proliferation assay to determine the effects of the single knockout of USF1 and USF2 vs the double knockout in SEM cells and other MLLr leukemia cell lines with proper controls.</p></disp-quote><p>Thank you for the reviewer’s comments. We have performed USF2 knockout experiments in two non-MLLr cell lines U937 and OCI-AML3, which also expressed <italic>HOXA9</italic>. USF2 was completely depleted by two sgRNAs in these two cell lines shown by immunoblotting. However, <italic>HOXA9</italic> mRNA expression was not reduced upon USF2 loss. Also, we have conducted competitive proliferation assay in SEM, OCI-AML2 and MOLM13 cells to determine the effects of single knockout of USF1, USF2 and double knockout. As suggested, in the new experiments, we have included two negative controls: (1) a non-targeting control (sgRNA against Luciferase gene, which would not bind to genomic RNA nor induce double strand DNA break); (2) a control guide RNA targeting the human endogenous gene ROSA26. New data are shown as Figure 5G-5J and Figure 5—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Evidence, reproducibility and clarity):</p><p>In this study, the authors make a HOXA9<sup>P2A-mCherry</sup> fusion in the t(4;11) cell line SEM and use this line to perform a CRISPR/Cas9 deletion screen to identify novel regulators of HOXA9 expression. The top ranked candidate was USF2. They used Cut&amp;Run to show USF2 binds directly to the HOXA9 gene and showed that guide RNAs specific for USF2 downregulate HOXA9 expression. They then performed a CRISPR/Cas9 dropout screen in SEM cells and independently verified that USF2 is a key survival target in these cells. They finish by performing a Cas9-KRAB screen using guides across the HOXA9 locus to identify putative new regulatory regions.</p><p>Major points:</p><p>1) The authors start off by making a very good case for better understanding upstream regulators of the HOXA9 gene, as it is overexpressed in a wide range of different leukemias. However, the entire main screen is performed in the MLLAF4 driven cell line SEM. The HOXA9 gene is a direct target of MLL-AF4 regulation, thus it is not clear if this is the best system to identify key HOXA9 regulators that are also applicable to other contexts. Ideally, it would be best to have done the screening in a non-MLL rearranged (MLLr) cell line. At the very least, USF2 knockouts should be performed in multiple non-MLLr cell lines to determine if this is an MLLr-specific TF or a more widely important TF needed for HOXA9 regulation.</p><p>2) Could a more refined deletion analysis of the putative regulatory regions identified in Figure 8 be performed in SEM cells exogenously expressing HOXA9 (so the cells are not killed by the deletion analysis)? It would be interesting to see if any other TF motifs in this region correlate with TFs identified in either the mCherry expression screen (Figure 3B) or the dropout screen (Figure 6D).</p><p>Reviewer #1 (Significance):</p><p>The authors are correct that HOXA9 is a generally important target in leukemia and little is understood about its upstream regulators. With USF2 identified as a key upstream TF, this work represents an important attempt to increase our understanding in that area. I have published multiple papers on gene regulation in MLL leukemias and have a specific focus on MLL-AF4 driven B-ALL.</p></disp-quote><p>We appreciate the positive comments.</p><disp-quote content-type="editor-comment"><p>Referees cross commenting:</p><p>I agree with the points reviewer #2 has raised. I think reviewer #3 in particular has several of the same concerns as I do, and I agree with all of their major comments. They also raise the important point that the way the screen was performed, key upstream regulators of HOXA9 could be missed.</p></disp-quote><p>Thank you for the reviewer’s positive comments. This reviewer raised an important question that key upstream regulators of <italic>HOXA9</italic> could be missed due to a survival disadvantage. To mitigate this challenge, we have conducted an independent CRISPR/Cas9 TF screen in <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter SEM cells ectopically expressing the <italic>HOXA9</italic>, together with its functional partner MEIS1. In this regard, exogenously expressed <italic>HOXA9</italic> could rescue the potential cell loss due to decreased <italic>HOXA9</italic> expression in SEM cells, while the level of endogenous <italic>HOXA9</italic> is still monitored by mCherry reporter. As a result, we have identified more well-known regulators of <italic>HOXA9</italic> which are also considered as survival essential genes. Among the top 10 hits from this screen, DOT1L and <italic>HOXA9</italic> were enriched. KMT2A, the translocation partner of MLL-AF4 in SEM cells, was identified in the HOXA9-MEIS1 rescue TF screen but not the original screen without ectopic expression of <italic>HOXA9</italic>. Notably, the MYST acetyltransferase HBO1 (also known as KAT7 or MYST2) and several members of the HBO1 protein complex, which were recently shown as critical regulators of leukemia stem cell maintenance, were also identified among the top hits (MacPherson et al., 2020). Most importantly, USF2 was still among the top hits in this screen. Based on these observations, we believe that our reporter-based screen is sensitive to identify <italic>HOXA9</italic> regulators. We add these new data to Figures 3B, 3D-3F, Figures 3—figure supplement 1D-F. However, some genes may experience poor sgRNA targeting efficiency leading to the possibility that important regulators could be overlooked, which is a known limitation of all CRISPR/Cas9 library screens.</p><disp-quote content-type="editor-comment"><p>I also just want to clarify something I don't think I made clear enough in my original review. Using an MLL rearranged cell line is not the best way to identify key, specific HOXA9 regulators. Since HOXA9 is commonly an MLL fusion protein (MLL-FP) activated target, MLL-FP activated expression may be dominant in the system, masking the effect of more highly specific transcription factors. This makes it more likely that such a screen would simply identify factors that are part of the general transcription activation machinery (e.g. SP1 or components of the pre-initiation complex). I don't know a lot about USF1 or 2, but I suspect it may fall into this sort of general transcription activation category. Thus, it will be key to know both whether i) this factor is important in other cell types and also ii) how generally required it is for transcriptional activation at other gene targets.</p></disp-quote><p>Thank you for the reviewer’s comments. We agree with the reviewer that <italic>HOXA9</italic> is a direct target of MLL-FP, and MLL-FP plays a key role in <italic>HOXA9</italic> regulation in MLL-rearranged cell lines. In fact, in addition to MLL-FP, a list of other regulators has been identified to be key regulators of <italic>HOXA9</italic> in this particular class of genetic alterations including DOT1L, <italic>ENL</italic>, ASHL1 and recently the HBO1 complex. However, it remains unknown whether additional regulators are involved in regulating <italic>HOXA9</italic>. This study was designed to specifically identify potential regulators of <italic>HOXA9</italic> in an MLLr background, which has not been thoroughly investigated yet. Generally, most human cancer cells do not express elevated levels of <italic>HOXA9</italic>. Significantly high levels of <italic>HOXA9</italic> have been observed in MLLr, NPM1c, and NUP98-HOXA9 fusion leukemia subtypes, among which MLLr is considered a high-risk leukemia with poor diagnosis and outcome. We chose MLLr cell lines because MLL-FP complex is well studied, and many know regulators can serve as positive controls for validating our screening while allowing us to discover possible new hits. In addition, the pipeline described in this manuscript can be easily transferred to other AML lines for studying <italic>HOXA9</italic> regulation in the future. While USF1 and USF2 have been characterized as general transcription factors, we found that they positively regulate transcription levels of <italic>HOXA9</italic> in the MLLr leukemia cell lines SEM, OCI-AML2, NOMO-1 and MOLM13. USF2 knockout in the non-MLLr U937 and OCI-AML3 cell line did not affect <italic>HOXA9</italic> expression nor cell survival, indicating its regulation of <italic>HOXA9</italic> could be exerted in a cell type-specific manner.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Evidence, reproducibility and clarity):</p><p>In this manuscript, Hao Zhang et al. generate a HOXA9-mCherry Knock-in reporter into an MLL-rearranged B-ALL cell line, SEM. By using this new reporter cell line, they apply CRISPR/Cas9 screen to identify a novel transcriptional factor USF2/USF1 which binds at HOXA9 promoter and controls HOXA9 expression at transcriptional level in B-ALL. The major scientific conclusion is convincing. Furthermore, the reliability and reproducibility of the experiments are decent.</p></disp-quote><p>Thank you for the reviewer’s positive comments.</p><disp-quote content-type="editor-comment"><p>However, one of the major claims that USF2 and HOXA9 were positively correlated in MLL-rearranged B-ALL patients is preliminary. The R score is weak especially it is calculated upon separation of HOXA9 high and low expression group.</p></disp-quote><p>Correlation analysis between USF2 and <italic>HOXA9</italic> was unbiasedly conducted in the largest transcriptomic cohort of human B-ALL patients collected in our institution by Dr. Charles Mullighan (Nat Genet. 2019 Feb;51(2):296-307). As a positive control, transcriptional correlation of USF1 and USF2 was consistently detected in all patients. However, significant positive correlation between USF2 and <italic>HOXA9</italic> was specifically identified only in patients with MLLr (136 cases) subtype. Due to the limitation of patient materials, we could not conduct additional experiments on human samples to further extend the study. We have now moved these data to Figure 5—figure supplement 3.</p><disp-quote content-type="editor-comment"><p>Major comments:</p><p>1) Figure 1—figure supplement A and C: the expression of HOXA9 in Pro-B-ALL t(11q23)/MLL in panel A is relatively high. However, the panel C showed contradictory results as no HOXA9 OE is found in Pro-B-ALL t(11q23)/MLL as well as the expression is relatively low. Please discuss why this might be the case.</p></disp-quote><p>We apologize for the mis-labeling of leukemia subtypes. The correct figure (Figure 1—figure supplement 1C) is provided to replace original Figure S1C. It’s clear that Pro-B-ALL t(11q23)/MLL patients demonstrated high levels of <italic>HOXA9</italic>.</p><disp-quote content-type="editor-comment"><p>2) Figure 2 A-D: the results shown in the figure are composed of one sgRNA for each gene and in one cell line per leukemia type. The authors need to add an additional sgRNA and one additional cell line per leukemia type.</p></disp-quote><p>Thank you for the reviewer’s comments. In this figure, we are trying to confirm the response of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> knockin reporter upon known transcriptional or pharmaceutical inhibitors of <italic>HOXA9</italic>. The DOT1L sgRNA and <italic>ENL</italic> sgRNA used in Figures 2A-2D were previously validated and well characterized in other studies. Therefore, we felt confident these controls could be used to faithfully validate the response of the <italic>HOXA9</italic> reporter. In addition, the CRISPR/Cas9 screen, which used seven sgRNAs per target, further confirmed the results observed in Figures 2A-2D. We have also generated an additional <italic>HOXA9<sup>P2A-mCherry</sup></italic> reporter cell line using the MLLr AML cell line OCI-AML2 and comprehensively characterized the knockin allele. We have added these new data to Figure 2—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>3) Figure 3—figure supplement 3B: Please document CTCF expression upon siRNA mediated CTCF. Furthermore, the Y axis description of the figure is missing.</p></disp-quote><p>Thank you for the reviewer’s comments. We have provided the immunoblotting and Q-PCR results showing that CTCF expression was completely inhibited by siRNAs. The Y axis description has been added. See Figure 3—figure supplement 3.</p><disp-quote content-type="editor-comment"><p>4) Figure 5C: Please report expression of HOXA9.</p></disp-quote><p>Thank you for the reviewer’s comments. We have tested four commercial <italic>HOXA9</italic> antibodies to detect <italic>HOXA9</italic> protein levels and failed to distinguish <italic>HOXA9</italic> from other homologs, which is a common problem for the entire field. Therefore, we have removed the <italic>HOXA9</italic> immunoblotting result and provided the mRNA expression level of <italic>HOXA9</italic> in Figure 5C.</p><disp-quote content-type="editor-comment"><p>5) Figure 6D: How/where is HOXA9 expression ranked in this CRISPR screen?</p></disp-quote><p>Thank you for the reviewer’s comments. <italic>HOXA9</italic> was ranked at 197<sup>th</sup> (log<sub>2</sub>FCday12/day0=-0.38; p value=0.069). Although the MeGACK trend suggested <italic>HOXA9</italic> is an essential gene, it’s not among the top 50 essential genes. We reasoned that it may be due to the fact that day12/day0 is not the best timing for investigating the depletion of <italic>HOXA9</italic> sgRNA targeted cells. In addition, compensation from other active <italic>HOXA</italic> genes might play a role upon <italic>HOXA9</italic> loss in our dropout CRISPR screen, which was seen from previous studies (Mol Cell Biol, 26 (10), 3902-3916, 2006; Collins and Hess, 2016). We then designed a sgRNA targeting on TSS of <italic>HOXA9</italic> and delivered the sgRNA to Cas9-expressing SEM cells. Significant reduction of <italic>HOXA9</italic> and proliferation were observed.</p><disp-quote content-type="editor-comment"><p>6) Figure 6E-F: How to define HOXA9 high expression or low expression? What is the criteria and cut-off to separate the high and low expression of HOXA9 group? This piece of data isn't strong enough to claim the correlation between USF2 and HOXA9 in MLL-rearranged B-ALL.</p></disp-quote><p>Thank you for the reviewer’s comments. According to the transcriptome profiling of 136 MLLr B-ALL patients (Gu et al., 2019), two distinct groups of patients were identified and separated by the cutoff of normalized log<sub>2</sub> expression at 6. We observed the higher correlation between USF2 and <italic>HOXA9<sup>high</sup></italic> group (pearson’s <italic>r</italic>=0.40, p=9.9e-09) than the correlation from all of the 136 patients (pearson’s <italic>r</italic>=0.25, p=0.004). Due to the unavailability of additional patient materials, we could not conduct further experiments. Instead, we have moved this piece of data to Figure 5—figure supplement 3.</p><disp-quote content-type="editor-comment"><p>7) Figure 7: Data presented here are not strong enough to claim USF1 and USF2 synthetically regulate HOXA9 expression in MLLr leukemia. Figure A-C please at least use another sg RNA against USF2 to prove HOXA9 expression is downregulated upon CRISPR targeting USF2 in MOLM13 cells. How does USF2 affect cell proliferation in MOML13 cells?</p></disp-quote><p>Thank you for the reviewer’s comments. As suggested by the reviewer, we have repeated this experiment in MOLM13 using single USF1, USF2 knockout along with double knockout. We have also investigated the impact on cell proliferation using a competitive proliferation assay with proper controls. We add these new data to Figure 5—figure supplement 1F-G.</p><disp-quote content-type="editor-comment"><p>8) Supplemental figure legend is missing.</p></disp-quote><p>We apologize for this confusion. The supplemental figure legend was provided at the end of the manuscript text in the initial submission.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Significance):</p><p>Significance for the leukemia and transcription field is high. Overall, Hao Zhang et al. successfully utilize CRISPR/Cas9 technology to study HOXA9 regulation in MLL-rearranged B-ALL. This study helps us understanding the molecular regulation network in HOXA9-driven leukemia.</p></disp-quote><p>Thank you for the reviewer’s positive comments.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Evidence, reproducibility and clarity):</p><p>Summary:</p><p>In this manuscript, Zhang and colleagues study the transcriptional regulation of HOXA9, a transcription factor that plays a central role in homeostasis of immature hematopoietic cell types and in the development of leukemia. They use the CRISPR/Cas9 technique to introduce a fluorescence reporter cassette into the endogenous HOXA9 locus of a human MLL/AF4-rearranged B-ALL cell line. After validating this engineered cell line, they perform multiple genetic screens to identify potential transcriptional regulators of HOXA9 and to delineate essential transcription factors in this cell line. They identify USF2 as new transcription factor that modulates expression of HOXA9 in MLL-rearranged B-ALL.</p><p>Major comments:</p><p>Although the identification of USF2 as a new transcriptional regulator of HOXA9 is interesting, most of the experiments were performed in the SEM cell line, and only few observations were validated in other cell lines. No primary cells/mouse models were used to further validate the role of USF2 in MLLr leukemia. Therefore, the broad validity of the proposed concept is questionable.</p></disp-quote><p>Thank you for the reviewer’s positive comments. We have performed USF2 knockout experiments in two non-MLLr cell lines U937 and OCI-AML3, which also expressed <italic>HOXA9</italic>. USF2 was completely depleted by two sgRNAs in these two cell lines shown by immunoblotting. However, <italic>HOXA9</italic> mRNA expression was not reduced upon USF2 loss. Also, we have conducted the competitive proliferation assay in the MLLr cell lines SEM, OCI-AML2 and MOLM13 to determine the effects of single knockout of USF1, USF2 and double knockout. We have added these new data to Figures 5G-5J and Figure 5—figure supplement 1. We think these additional data helped to extend the broad validity of the proposed concept.</p><disp-quote content-type="editor-comment"><p>Another limitation of the study is inherent to the experimental setup that has been chosen to identify transcriptional regulators of HOXA9. In the screening protocol employed by the authors, transduced cells were flow sorted based on the expression of the fluorescent reporter 10-12 days after transduction of the sgRNA library. With this approach, essential transcription factors that regulate HOXA9 are missed, as cell populations representative in which these factors were mutationally inactivated will most likely be depleted at this timepoint.</p></disp-quote><p>This reviewer raised an important question that key upstream regulators of <italic>HOXA9</italic> could be missed due to a survival disadvantage. To mitigate this challenge, we have conducted an independent CRISPR/Cas9 TF screen in <italic>HOXA9<sup>P2A-mCherry</sup> </italic>reporter SEM cells ectopically expressing the HOXA9-MEIS1 fusion protein. Many of the key well-known regulators of <italic>HOXA9</italic> were among the top 10 hits identified from this screen, including KMT2A, DOT1L and <italic>HOXA9</italic>. Notably, the MYST acetyltransferase HBO1 (also known as KAT7 or MYST2) and several members of the HBO1 protein complex, which are known to be critical regulators of leukemia stem cell maintenance, were also identified among the top hits (MacPherson et al., 2020). Most importantly, USF2 was still among the top hits in this screen. Based on these observations, we believe that our reporter-based screen is sensitive to identify <italic>HOXA9</italic> regulators. However, we could not exclude the possibility that some genes may experience poor sgRNA targeting efficiency leading to the possibility that some important regulators could be overlooked, which is a limitation of all CRISPR/Cas9 library screens.</p><disp-quote content-type="editor-comment"><p>In Figure 2, only one sgRNA for each target was used. The authors should include a second sgRNA targeting DOT1L and ENL, at least in panels A-D. Moreover, HOXA9 expression is only reduced to 40-50% upon knockout of DOT1L or ENL or DOT1L inhibition in Figure 2 B-D. Is this the maximum that can be achieved in this system? If yes, why?</p></disp-quote><p>Thank you for the reviewer’s comments. In this figure, we are trying to confirm the response of the <italic>HOXA9<sup>P2A-mCherry</sup></italic> knockin reporter upon known transcriptional or pharmaceutical inhibitors of <italic>HOXA9</italic>. The DOT1L sgRNA and <italic>ENL</italic> sgRNA used in Figures 2A-2D were previously validated and well characterized in other studies. Therefore, we felt confident these controls could be used to faithfully validate the response of the <italic>HOXA9</italic> reporter. In addition, the CRISPR/Cas9 screen, which used seven sgRNAs per target, further confirmed the results observed in Figures 2A-2D. We have also generated an additional <italic>HOXA9</italic> reporter cell line using the MLLr AML cell line OCI-AML2, which was characterized using the same methods. In our hands, the maximum reduction efficiency of <italic>HOXA9</italic> expression is 40-50% upon sgRNA targeting of DOT1L or <italic>ENL</italic>, or DOT1L inhibition in SEM cells, which is consistent with previous reports. In our second reporter line derived from MLLr AML cell line OCI-AML2, we observed complete repression of <italic>HOXA9</italic> via DOT1L inhibition, indicating the effect of DOT1L inhibition could vary based on cell type by mechanisms that have yet to be identified.</p><disp-quote content-type="editor-comment"><p>Figure 3D: Show the distribution of DOT1L-targeting sgRNAs.</p></disp-quote><p>Thank you for the reviewer’s comments. The distribution of sgRNAs targeting DOT1L was shown along with NT, <italic>HOXA9</italic> and USF2.</p><disp-quote content-type="editor-comment"><p>Figure 4 is not central to main conclusions of this study. In fact, it mainly provides negative data that might distract readers. The authors might consider moving this figure to the supplementary data. Moreover, the Materials and methods section lacks a description of experiments involving auxin-induced CTCF degradation.</p></disp-quote><p>Thank you for the reviewer’s comments. Our data collected from MLLr B-ALL SEM cells targeted by siRNA or CTCF-AID mediated degradation supported the observation from Dr. David Spencer’s lab (Ghasemi et al., 2020), which indicated that <italic>HOXA</italic> gene expression was maintained in the CTCF deletion mutants and transcriptional activity at the <italic>HOXA</italic> locus in NPM1-mutant AML cells does not require long-range CTCF-mediated chromatin interactions. Our CRISPR/screen and degron-mediated CTCF degradation data provided additional insights of CTCF’s function in leukemia cells. We also added detailed description of experiments involving auxin-induced CTCF degradation. We agree with the reviewer that this piece of data might distract readers. Therefore, we move the entire figure to Figure 3—figure supplement 2.</p><disp-quote content-type="editor-comment"><p>Throughout the paper, the authors use sgRNAs targeting Luciferase (sgLuc) and in one experiment the Rosa locus (in human cells) as negative controls. A better control would have been to target the AAVS1 locus in human cells, as this enables proper control for the DNA damage that is induced by sgRNA-induced induction of double strand breaks in the human genome. This would be particularly important for the competitive proliferation assays shown in Figure 6 A-B. Moreover, it is stated in the figure legend that sgRPS19 was used as a positive control for an essential gene, but these dates are not shown in Figure 6A and 6B. Also, as these two panels aim to identify the effect of USF2 as a regulator of SEM cell survival, it would be necessary to compare it to the effect of HOXA9 disruption by including sgRNAs targeting HOXA9. Finally, the authors should show a longer time course for the competitive competition assay than 12 days to determine attenuated effects on cell survival.</p></disp-quote><p>Thank you for the reviewer’s comments. To rule out the possibility that sgRNA-induced induction of double strand breaks may affect <italic>HOXA9</italic> expression and survival, we have checked the enrichment of several well tested sgRNAs in our CRISPR screen. Although double-strand breaks and indels were generated by these sgRNAs, none of them were enriched in our CRISPR screen nor shown to regulate <italic>HOXA9</italic>. We have now also repeated the competitive proliferation assay using sgRNA against ROSA26 endogenous gene, which demonstrated the same result to sgLuc. We apologize about the confusion of sgRPS19. The figure legend has been amended. We agree with the reviewer that comparable disruption of <italic>HOXA9</italic> in the proliferation assay should be included as a control. We have conducted the experiment and include the data in Figures 5C-65. Finally, we have extended the competitive proliferation assay to 23 days to determine attenuated effects on cell survival.</p><disp-quote content-type="editor-comment"><p>Figure 7 claims to validate the synergistic effect of combined inactivation of USF1 and USF2 in HOXA9 regulation. The authors should include a competitive proliferation assay to determine the effects of the single knockout of USF1 and USF2 vs the double knockout in SEM cells. Experiments should be validated in another MLLr human cell line. This assay should also include appropriate positive and negative controls, as mentioned above.</p></disp-quote><p>Thank you for the reviewer’s comments. We have repeated the competitive proliferation assay to determine the effects of the single knockout of USF1 and USF2 vs the double knockout in SEM cells and other MLLr leukemia cell lines (OCI-AML2 and MOLM13 with proper controls. We have added these data to Figures 5I-5J and Figure 5—figure supplement 1G.</p><disp-quote content-type="editor-comment"><p>Also, in Figure 7 D-E, it is necessary to include results from the single USF1 knockout.</p></disp-quote><p>Thank you for the reviewer’s comments. We have repeated these experiments using single knockout targeted with sgUSF1.</p><disp-quote content-type="editor-comment"><p>Legends to all supplementary figures are missing.</p></disp-quote><p>We apologize for the error. The supplemental figure legends are provided now.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Significance):</p><p>The authors have used state-of-the-art technology to generate a novel cell line to study the transcriptional regulation of HOXA9, a transcription factor with important implications in leukemogenesis. They identify USF2 as a new mechanism as to how HOXA9 may be regulated in leukemia cells. If they can address the main issues listed above, this work could be relevant for other scientists studying haematological malignancies. The work might also raise some interest in a broader audience due to the technical aspects of the manuscript.</p></disp-quote><p>Thank you for the reviewer’s positive comments.</p></body></sub-article></article>